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ABSTRACT 
 
BACKGROUND  
Ischaemic heart disease is the leading cause of mortality and morbidity in the developed world. 
Cardiovascular magnetic resonance (CMR) is a non-invasive imaging modality providing in vivo 
myocardial tissue characterisation and quantification. We aimed to validate CMR in the field of 
interventional cardiology as a tool for guiding patient selection and management to the assessment 
of the results of interventions both in the acute and chronic settings.  
 
METHODS AND RESULTS 
We investigated the impact of primary angioplasty delay on the presence and extent of myocardial 
salvage, microvascular obstruction and infarct size. We found that “time is muscle”, and that shorter 
time to reperfusion was associated with smaller infarct size (p=0.05), less microvascular obstruction 
(p=0.04) and a greater amount of salvaged myocardium (p=0.003). Microvascular obstruction was 
then used as an endpoint in a prospective randomised trial assessing the impact of a thrombectomy 
device as adjunctive therapy in primary PCI. The incidence and extent of microvascular damage 
was significantly reduced in the thrombectomy group compared to standard primary PCI 
(p=0.0005). CMR can identify 2 degrees of microvascular damage: early or persistent 
microvascular dysfunction. The latter was the strongest predictor of LV remodelling (p=0.03), it 
was predicted by infarct size (p=0.002), and infarct healing (shrinkage) occurred to a greater extent 
(p<0.006). We validated the clinical use of CMR perfusion in a cohort of patients with chronic 
coronary occlusion whose management is currently controversial. CMR identified myocardial 
viability and inducible myocardial ischaemia in a significant percentage of patients, guided 
revascularisation that reduced ischaemic burden (p<0.0001) with improvements in left ventricular 
function (p<0.0001) and health outcome measures (p<0.0001). Finally, improved CMR perfusion 
image quality was pursued with a new imaging protocol but this demonstrated increased incidence 
of artefacts (p<0.001) and lower diagnostic accuracy compared to the standard technique. 
 
CONCLUSIONS 
Cardiovascular magnetic resonance provides in vivo myocardial tissue characterisation that can 
potentially not only guide treatment but also assess its effects. The result of this work suggests that 
CMR could emerge as a clinical valuable technique in numerous interventional clinical settings 
within acute to chronic myocardial ischaemia, in addition to providing surrogate endpoints for 
clinical trials. 
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CHAPTER 1 
SUMMARY AND OBJECTIVES 
  
Ischaemic heart disease is the leading cause of mortality and morbidity in the developed 
world. Cardiovascular magnetic resonance (CMR) is a non-invasive imaging technique 
providing in vivo myocardial tissue characterisation and quantification. The aim of this work 
is to define the diagnostic role of CMR in the field of interventional cardiology from patient 
selection to assessing the result of intervention, both in the acute and chronic settings.  
 
The research questions in this thesis are:  
 
 Is time to reperfusion an important determinant of infarct size and microvascular 
obstruction? 
 
 Is salvaged myocardium reduced when reperfusion occurs late? 
 
 Does the adjunct use of thrombectomy device in the setting of primary PCI reduce 
microvascular obstruction? 
 
 Is microvascular obstruction related to infarct shrinkage? 
 
 Can CMR detect myocardial viability and inducible perfusion defect in patient with 
chronic total occlusion?  
 
 Can CMR detect the resolution of inducible perfusion defect following successful 
recanalisation of a chronic occluded vessel?  
 
 Is a new stress perfusion protocol using SSFP sequence and half-dose of contrast less 
prone to artefacts compared to standard EPI with full contrast dose? 
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Prompt reperfusion in patients with ST-segment elevation myocardial infarction is associated 
with improved prognosis suggesting that “time is muscle”. Nevertheless, there are 
uncertainties regarding the effects of reperfusion strategies at myocardial level. In particular, 
it is unclear how much salvageable myocardium is present after reperfusion and to how to 
improve its identification in clinical practice. CMR has been validated against histology for 
the identification of infarct size, myocardial salvage and microvascular obstruction. In 
Chapter 5, we investigate the impact of time to reperfusion and delays in revascularisation 
on the presence and extent of myocardial damage. In Chapter 6, microvascular obstruction 
by CMR was then used as an endpoint in a prospective randomised trial assessing the impact 
of a thrombectomy device as adjunctive therapy in primary percutaneous coronary 
intervention. In Chapter 7, two degrees of microvascular damage are identified by CMR and 
their incidence, role on left ventricular remodelling and infarct healing are investigated.   
 
Coronary chronic total occlusions (CTO) are identified in approximately one third of 
diagnostic coronary angiograms. Recanalisation of a CTO is still controversial due to 
inadequate patient selection. Chapter 8 investigates the role of CMR in a selected cohort of 
patients with CTO in identifying those that could benefit from recanalization, and in 
predicting functional improvement after revascularisation and its impact on quality of life.  
 
Myocardial perfusion imaging is not standardised and currently there is no consensus on the 
best sequence to use. Artefacts mimic genuine perfusion defects and improvement in image 
quality is desirable to improve the diagnostic confidence of the technique in the clinical 
setting. Chapter 9 explores the utilisation of a novel perfusion protocol aiming to increase 
image quality while reducing the occurrence of artefacts.  
Chapter 2  CMR in Acute Ischaemia 
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CHAPTER 2 
CMR IN ACUTE MYOCARDIAL ISCHAEMIA 
 
 
2.1 MYOCARDIAL OEDEMA/MYOCARDIUM AT RISK 
2.1.1 Pathophysiology 
In normal myocardium intracellular water represents approximately 77% of the total tissue 
water, and the remaining 23% is intravascular.
1
 Although the physiological mechanisms 
regulating intracellular and interstitial fluid balance are complex and not completely 
understood, prominent aspects of these mechanisms include 1) the Starling filtration principle, 
regulating fluid exchange between the interstitial space and the capillaries, 2) cell membrane 
function and 3) lymphatic drainage (Figure 2.1).  
 
 
Figure 2.1. The hydrostatic forces affecting myocardial fluid balance.  
A= arterial, V=venous, V1=veins leading to coronary sinus, V2=thebesian veins,  
I=interstitial pressure, C=capillaries, P=compressive force in ventricular wall owing  
to contraction, T=transmicrovascular flux, L=lymphatics. Reproduced from Laine
2
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The increase in water content induced by ischaemia has been well documented in vitro
3,4
, in 
the isolated
5
 and in-situ heart.
6
 In particular, a 9.4% increase in the subendocardial water 
content was found after 2 hours of occlusion
7
, where in another study a 16.5% increase in 
tissue water was observed after 50 minutes of occlusion, increasing up to 45% after 75 
minutes. 
5
  
The mechanisms of myocardial oedema, cell swelling and inflammatory response (Figure 
2.2) secondary to ischaemia are not completely elucidated. During ischaemia, the breakdown 
of large molecules leads to intracellular accumulation of metabolic end products of anaerobic 
glycolysis and ATP hydrolysis, increase in tissue osmolality resulting in cell swelling.
3,48
 
During reperfusion, the hyperosmotic intravascular fluid is rapidly replaced by normo-
osmotic blood, creating an osmotic gradient between the intravascular and extravascular 
spaces resulting in myocardial oedema.
4
 Viable reperfused myocytes may restore normal cell 
volume by recovering membrane function and reduction of osmotic load, and myocytes with 
disrupted sarcolemma equilibrate their osmotic pressure with the extracellular space and lose 
their excess in water.
9
 The hypoperfused, ischaemic, but reversibly damaged myocardium is 
defined as myocardium at risk.
10
  
 
 
Figure 2.2 Myocardial oedema, cell swelling and inflammation secondary to ischaemia. 
 
 
 
2.1.2 Other Imaging Modalities 
SPECT  
Currently, the gold standard for determining the area at risk (AAR) is Single Photon Emission 
Tomography (SPECT) with injection of Technnitium-99m (
99
Tc) tracer prior to 
revascularisation.
11
 This technique has been validated extensively against microspheres.
12,13,14
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Radiotracers need to be injected at the time of the occlusion but the imaging is performed 
subsequently, following revascularisation. 
99
Tc MIBI traces blood flow and does not 
redistribute significantly after reperfusion and it is preferably used for imaging AAR 
compared to thallium-201 which has a rapid redistribution that requires early scintigram 
during the occlusion. Myocardial salvage index is usually defined by the initial perfusion 
defect (tracer injected before reperfusion and patient imaged 6-8 hours after) minus the final 
infarct size (at follow-up SPECT scan, 7-14 days after) divided by the initial perfusion defect. 
Salvage index by SPECT has been correlated with TIMI flow grade
15
, TIMI reperfusion 
grade
16
 and ST segment resolution
17
 after reperfusion therapy. SPECT is well clinically 
validated, widely available technique for assessing myocardial salvage. However, the 
requirement of radiotracer administration in the emergency room, the related radiation burden 
and the lower spatial resolution represent limitations of this technique.  
 
AAR assessed by T2w CMR performed at 1 week after reperfusion has been validated against 
SPECT in patients with STEMI (Figure 2.3).
18
  
 
 
 
Figure 2.3 Myocardium at risk by CMR and SPECT, from Carlsson
18
.  
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Echocardiography 
Post-ischaemic oedematous myocardium is associated with both systolic dysfunction and 
increased stiffness, which might then result in higher LV filling pressures. An increased in 
myocardial thickness can be seen in routine 2D echocardiography which is the result of 
myocyte swelling and myofibrillar oedema, which also has some direct effects on myocardial 
contractility (strain) (Figure 2.4)
19
.   
 
 
Figure 2.4 Relationship between myocardial water content (MWC) and mid wall myocardial 
strain Ecc(A) and wall thickness (WT) (B). The open circles represent remote myocardium and 
the filled circles represent stunned myocardium. Adapted from Bragadeesh
19
.  
 
 
 
In vivo determination of the AAR by myocardial contrast echocardiography has also been 
validated against SPECT but limited to the experimental setting.
20
 
 
Invasive Coronary Angiography  
Invasive coronary angiography can also provide an estimate of myocardium at risk using the 
myocardial jeopardy index (Bypass Angioplasty Revascularization Investigation, BARI), as 
recently validated against CMR: salvaged provided in the early hours of reperfusion occurred 
by limiting the transmurality of irreversible myocardial damage.
21
 AAR by T2w CMR has 
been also directly compared and validated by conventional coronary angiography with the 
BARI risk score.
22
 However, the BARI score is simply an anatomical score based on an 
individualised assessment of the length and the calibre of the coronary arteries, and cannot 
distinguish between the benefit provided by residual or collateral flow and that provided by 
reperfusion.  
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2.1.3 CMR Technique and Tissue Validation 
Changes in myocardial water content occurring in the early phase after ischaemia, and 
subsequent increased T2 signal intensity (SI) has been observed in the post-ischaemic 
oedematous myocardium and proposed as a sensitive marker of regional myocardial injury 
since the early 80s.
23,24
 Controversies arose on the extent of elevated T2 signal intensity in 
relation to “true” infarct size, and in particular whether myocardial oedema was matching or 
overestimating infarct size.
25
 Dymarkowski et al. clarified some of these aspects elegantly 
demonstrating that there was a strong correlation between the post-contrast T1-weighted MRI 
imaging and histologically determined infarct size, whilst T2-weighted imaging was 
overestimating infarct size by 10%.
26
 They also noted that the difference between the 
hyperintense areas on T2-weighted and enhanced T1-weighted images were likely to 
represent viable myocardium. Subsequent in vivo experimental studies in a dog model of 
acute myocardial ischaemia validated AAR with T2w against AAR with microspheres 
injected during ischaemia, and identified as myocardial salvage the proportion of myocardium 
at risk (which corresponded to the T2w area) which was not infarcted (the latter assessed by 
LGE imaging) (Figure 2.5).
27
 
 
Figure 2.5 Validation of AAR by T2w CMR against microspheres injected during ischaemia. 
 
 
 
In human studies the increased T2 signal associated with oedema is observed very early in 
acute myocardial infarction (within 1 hour)
28
 and completely resolved few months later
29
, 
allowing a window for the retrospective identification of ischaemia. The increased in the 
myocardial T2 signal is depicted with a T2-weighted sequence, among which the most 
commonly used is the STIR T2 sequence.  
Further studies confirmed the identification of AAR with T2w imaging, which systematically 
exceeded the infarcted area, and the difference between the two representing myocardial 
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salvage.
30
 T2w CMR can also accurately differentiate acute from chronic myocardial 
infarction.
31
 Finally, the prognostic importance of myocardial salvage index by CMR in 
patients with reperfused ST-elevation myocardial infarction (STEMI) has been recently 
demonstrated.
32
  
 
The advantage of CMR over the other imaging modalities is not only the increased spatial 
resolution, but the potential to assess the AAR retrospectively days after revascularisation 
overcoming the logistical complication in SPECT of injecting radiotracer at the time of 
coronary occlusion.
33
   
However, the clinical implications on the presence and extend of myocardial oedema post-
infarction are not entirely established. In particular, it remains uncertain whether myocardial 
oedema should be considered a surrogate endpoint in reperfusion trials.   
 
 
 
2.2 MICROVASCULAR OBSTRUCTION 
2.2.1 Pathophysiology 
The extent of reversible and irreversible myocardial damage is temporally related to the 
duration of myocardial ischaemia. The ischaemic-necrotic wavefront of ischaemic cell death, 
which gradually moves from the subendocardium towards the subepicardium (Figure 
2.6).
34,35
 The mechanism of this subendocardial to subepicardial progression of injury 
probably is multifactorial. It is mostly due to the additional resistance on the endocardial 
vessels due to compression (R3 coronary resistances, see Chapter 3, paragraph 3.1 
pathophysiology of chronic ischeamia), as well as the length of the vessels. Transmural 
distribution of coronary collateral flow is a less well-accepted underlying cause.  
The no-reflow phenomenon, or microvascular obstruction (MVO), reflects severely 
compromised myocardial tissue perfusion (necrotic myocytes with gross microvascular 
damage) despite restoration of the epicardial artery patency.  
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Figure 2.6. Ischaemic-necrotic wavefront phenomenon, diagram and corresponding late 
gadolinium enhancement image.  
 
 
 
No-reflow is a complex process that involves a number of different mechanisms including 
regional and diffuse endothelial swelling, endothelial gaps, fibrin tactoids, microemboli, 
rouleaux formation, neutrophil plugging, and compression of capillaries from adjacent 
swollen myocytes, spasm of the microvasculature at a precapillary level, and the formation of 
platelets plugs, as illustrated in Figure 2.7. 
36
 
 
 
Figure 2.7. Mechanisms of the no-reflow phenomenon. Reproduced from Kloner.
36
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2.2.2 Other Imaging Modalities 
Echocardiography 
Technical developments coupled with new available contrast agents have contributed to 
establish myocardial contrast echocardiography (MCE) as another non-invasive imaging 
technique for assessing myocardial perfusion both visually and quantitatively, and in real 
time.
37,38
 In particular, myocardial blood flow velocity is measured by the rapid destruction of 
echo contrast microbubbles using ultrasound and then determining the rate at which they refill 
the myocardium. The extent of microvascular damage by MCE demonstrated to be superior to 
other known post-infarct reperfusion indexes (ST segment reduction, TIMI flow grade, TIMI 
blush grade) in predicting left ventricular remodelling.
39
 The advantages of the technique are 
easy access and affordability but it is limited by operator dependency, good 
echocardiographic windows and low spatial resolution.
40
 
 
Invasive Coronary Angiography  
The Thrombolysis In Myocardial Infarction (TIMI) study group
 
developed a grading scale for 
an invasive assessment on myocardial perfusion based on visual
 
evaluation of the rate of 
contrast opacification of the infarct
 
artery.
41
 Since then, TIMI flow grade (grading from 0: no 
perfusion to 3: complete perfusion) has become the standard for semiquantitative
 
evaluation 
of myocardial perfusion before and after coronary
 
reperfusion, as well as yielding important 
prognostic information in patients with AMI
42
.  
Just as TIMI flow grade is an important parameter to assess coronary artery flow, the Zwolle 
Myocardial Infarction Study Group suggested that a myocardial blush grade (MBG) (similar 
grading from 0-3) as seen on the coronary angiogram can be used to describe effectively 
myocardial perfusion, with similar prognostic importance.
43
 A TIMI myocardial perfusion 
(TMP) grading system (grading from 0 to 3) was then also established, and based on the 
contrast opacification of the myocardium (“blush”)44,45  
 
 
 
2.2.3 CMR Technique and Tissue Validation 
CMR in the quantification of MVO has been validated against MCE and the histological 
standards of radioactive microspheres and thioflavin-S straining in an experimental model 3 
days after coronary occlusion (Figure 3.8).
46
 Other groups confirmed the good correlation 
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between microvascular damage by CMR using a rest first-pass technique during contrast 
injection against the histological determination of endocardial damage.
47
  
 
 
Figure 2.8. Validation of MVO by first-pass CMR against microsphere. There is good 
correlation between the two techniques. Modified from Wu.
46
  
 
 
 
Studies have shown that the presence and extent of MVO following AMI as measured by 
early gadolinium enhancement CMR is associated with adverse ventricular remodelling
48
 and 
clinical outcome that is independent of the infarct size.
49
 
It is only later that it appeared evident  MVO could persist in the late gadolinium 
enhancement (LGE) images, suggesting the hypothesis of a more severe damage.
50,51
  
Currently, there is no consensus on the best technique to use and a number of clinical studies 
have used irrespectively one or the other
52,53,54,55,56,57,58
 or, in few cases, both 
techniques
59,60,61,62,63
 yielding conflicting results on the significance and extent of 
microvascular obstruction by CMR.  
 
2.3 MYOCARDIAL INFARCTION  
2.3.1 Other imaging modalities 
Assessment of myocardial ischaemia and viability by SPECT offers invaluable diagnostic and 
prognostic information in patients with coronary artery disease. 
Details on the technique are provided in Chapter 4, paragraph 4.3.2 “Single Photon 
Emission Tomography”.   
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2.3.2 CMR Technique and Tissue Validation 
After the contrast injection and the perfusion phase, the distribution of gadolinium in the heart 
is determined by the kinetics of access to different tissue types. Gd is an extracellular contrast 
agent that cannot penetrate in intact cell membrane; however, in the setting of acute 
infarction, the membrane ruptures allowing the penetration of contrast and its increased 
volumes of distribution; similar mechanisms are present in chronic scar, where damaged 
myocytes are replaced by collagen fibres (Figure 2.9).  
 
 
Figure 2.9. Mechanism of Gd distribution in normal and damaged myocardium.  
Adapted from Kim
64
.  
 
 
 
Gd enhancement in infarction was initially noted in limited animal studies
6566
 and 
subsequently in small human studies.
67
  
Different curves of contrast wash-in and wash-out in normal and infarcted myocardium were 
identified, and the technique validated histologically with triphenyltetrazolium chloride (TTC) 
staining in dog model of myocardial infarction.68 LGE correlated closely with the absence of 
TTC staining and electron microscopy changes indicating irreversible cell damage (Figure 
2.10). 
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Figure 2.10. Validation of ex-vivo LGE imaging of infarction against with TTC negative 
staining, adapted from Kim68.   
 
 
 
LGE occurs in both acute and chronic infarction, and correlates with fixed thallium defects. 
The absence of LGE correlates with viability as assessed by radionuclide and stress 
echocardiography.69 
The presence/absence of LGE in dysfunctional segments predicts reversible myocardial 
dysfunction and recovery after revascularisation and thus viability with a good degree of 
confidence (sensitivity 98%, specificity 76%).
70
 In patients with left ventricular dysfunction, 
functional improvement after revascularisation is predicted by the transmural degree of LGE 
with a good of accuracy.
71
 In contrast with nuclear imaging, the detection of hibernation by 
CMR does not rely on the presence of myocardial ischeamia but on the mismatch between 
myocardial viability and contractile function.   
CMR and has been also validated against SPECT for the detection of myocardial infarction 
and found to have an increased sensitivity in detecting subendocardial infarction, given the 
increased spatial resolution of the technique, whereas transmural myocardial infarction were 
detected at similar rate.
72
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CHAPTER 3 
CMR IN CHRONIC ISCHAEMIA: STRESS PERFUSION 
 
 
3.1 INTRODUCTION 
Cardiovascular disease is the main cause of death in most European countries, with a range of 
mortality rates between different countries (<3 per 1,000 inhabitants in the South-Western and 
Northern Europe and 9 per 1,000 inhabitants in Eastern Europe).
1
 
The cascade of events causing myocardial ischaemia and myocardial infarction is a complex 
temporal sequence of hemodynamic, electrocardiographic abnormalities and symptoms
2
, and 
subendocardial and transmural perfusion defects are the first expressions of the imbalance 
between myocardial oxygen supply and demand. Perfusion imaging therefore has a central 
role in investigation and management of patients with possible or actual coronary artery 
disease. In patients with stable angina or suspected coronary artery disease (CAD) exercise or 
pharmacological stress test are indicated for diagnostic work-up, as recommended by the 
recent European
3
 and American Guidelines.
4
 
Exercise electrocardiography (ECG) is the test of choice to identify inducible myocardial 
ischaemia in the majority of patients with suspected stable angina for reasons of availability 
and costs. However, stress imaging techniques (with physical or pharmacological stress) have 
several advantages over the conventional exercise ECG
3
:  
1. superior diagnostic performance for detection of obstructive CAD (Table 3.1);  
2. ability to localize and quantify areas of ischaemia;  
3. ability to provide information in the presence of resting ECG abnormalities (including 
left bundle branch block);  
4. alterative test in patients unable to exercise; 
5. alternative test when exercise testing in inconclusive;  
6. preferred modality in patient with previous percutaneous coronary intervention (PCI) 
or coronary artery bypass graft (CABG) (assess ischaemia after revascularisation);  
7. preferred modality in women (in whom exercise ECG testing has a higher false-
positive rate in women than in men).  
 
As per the ESC guidelines, the use of exercise imaging is preferable where possible, as it 
allows for more physiological reproduction of ischaemia and assessment of symptoms. 
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However, pharmacological stress testing with either perfusion scintigraphy or 
echocardiography might also be used, and it is especially indicated in patients unable to 
exercise adequately.   
 
 
 
Table 3.1 Diagnostic performance of non invasive imaging testing.   
                                                                           Sensitivity (%)               Specificity (%) 
   
Exercise ECG 68 77 
Exercise echocardiography 80-85 84-86 
Exercise myocardial perfusion 85-90 70-75 
Dobutamine stress echocardiography 40-100 62-100 
Vasodilator stress echocardiography 56-62 87-100 
Vasodilators stress myocardial perfusion 83-94 64-90 
Table modified from Fox et al, ESC Guidelines for Stable Angina.3 
Different pre-test likelihoods and post-test referral bias might explain the wide range of results.    
 
 
 
Although there is evidence to support superiority of stress imaging techniques over exercise 
ECG in terms of diagnostic performance, the cost of using a stress imaging test as a first line 
investigation in all comers should be considered.  
 
The recently (March 2010) published guidelines on chest pain of recent onset jointly 
developed by National Institute for Health and Clinical Excellence (NICE) and the National 
Clinical Guidelines Centre for Acute and Chronic Condition in Great Britain represent a 
significant change in practise in some key areas of diagnosing acute coronary syndrome and 
angina.
5
 In particular, exercise ECG is no longer recommended for diagnosing chest pain, and 
it is replaced by imaging testing strategies with better diagnostic accuracy. The NICE 
guidelines on stable angina are illustrated in Figure 3.1. In patients with a low pre-test 
likelihood of CAD, calcium scoring is the recommended first line approach, followed by 
either 64-slice CT angiography or functional imaging test to assess inducible myocardial 
ischaemia (the latter as per the intermediate pre-test likelihood of CAD pathway), depending 
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on the calcium score result. The reason why calcium score is initially preferred to 64-slice CT 
angiography is because of the reduced radiation exposure of the former technique (~1mSv).  
Patients with high pre-test likelihood of CAD should undergo invasive coronary angiography, 
eventually followed by functional imaging testing in case of uncertain significance of 
coronary plaques.  
However, the evidence from the NICE guidelines is not (yet) implemented in the ESC 
Guidelines (last and current edition was in 2006), and it is believed that until then in many 
European countries exercise ECG remains the first line modality to investigate patients with 
chest pain.  
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Figure 3.1. New (March 2010) NICE guidelines in stable chest pain.  
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3.2 PATHOPHYSIOLOGY 
Myocardial ischaemia is created by the imbalance between oxygen supply and oxygen 
demand (Figure 3.2), where MVO2 represents the metabolic needs and coronary blood flow 
(CBF) is determined by the driving pressure across the coronary vascular bed (P)/R (total 
coronary resistances).
6
 Changes in this pressure (within certain limits) are compensated by 
changes in coronary resistances, a mechanism known as coronary autoregulation. 
 
 
Figure 3.2 Balance between oxygen supply and demand.  
Modified from Klocke
6
.  
 
 
 
Coronary resistances are described in Figure 3.3 and include the basal viscous resistance 
(R1, impedence to flow offered during diastole when vascular bed is fully dilated), 
autoregulatory resistance (R2, resulting from tonic contraction of vascular smooth muscle at 
the arteriolar level), and compressive resistance (R3, compression of vascular structures by 
intramyocardial pressure).  
 
 
Figure 3.3 Coronary resistances. Modified from Klocke
6
. 
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In the normal artery, epicardial and microvascular dilatation occur during exercise.  
In the atherosclerotic artery, partial microvascular dilatation is present at rest to compensate 
the drop in pressure across the stenosed epicardial artery (Figure 3.4).  
During exercise, there is additional epicardial artery constriction that results in an increased 
pressure drop across the stenosis with limited additional microvascular vasodilatory capacity. 
As a result, myocardial blood flow is reduced and unable to meet the increased metabolic 
demands of exercise, activating the ischaemic cascade.  
The reason why the subendocardium is more vulnerable to ischaemia than the epicardium is 
illustrated in Figure 3.3. In the presence of a coronary artery stenosis (which create a 
resistance, RS in Figure 3.3), the coronary autoregolatory system responds by reducing R2 to 
facilitate blood flow. R3 however remain the same,  and it is greater in the thesubendocardium 
than in the epicardium. That explains the subendocardial vulnerability to ischaemia, and the 
progression of the ischaemic-necrotic wave front phenomenon from the subendocardium to 
the epicardium.    
 
 
 
3.3 OTHER NON INVASIVE IMAGING MODALITIES 
Different non-invasive imaging modalities can evaluate myocardial perfusion and assess the 
functional significance of epicardial coronary stenoses by demonstrating stress-induced 
ischaemia (perfusion abnormalities) in CAD. When luminal obstruction is <50%, maximal 
flow during exercise can be maintained. Coronary stenosis of >50% may be associated with 
ischaemia as coronary blood flow becomes inadequate to meet cardiac metabolic demand 
during stress
7,8
.  
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Figure 3.4 Regulation of myocardial blood flow.  
Modified fromWilson
9
. 
 
 
 
There are two approaches for pharmacological testing: (i) infusion of dobutamine, a short-
acting sympathomimetic drug which at incremental dose protocol increases myocardial 
oxygen consumption and mimics the effect of physical exercise; (ii) infusion of coronary 
vasodilators which cause maximal coronary hyperemia in normal coronary arteries and a 
reduction in flow in myocardial territories supplied by a stenosed coronary artery (steal 
phenomenon).  
Adenosine is usually used as hyperaemic stimulus due to its potent vasodilator properties. An 
intravenous dose of 140 µg · kg
-1
 · min
-1
 causes maximal or near maximal hyperaemia in 92% 
of patients, with mean coronary flow increasing by 4.4 times the resting value.
10
  
In humans, peak coronary flow occurs approximately after 4 minutes of infusion. 
11
 
The safety profile of adenosine is guarantee by its short half life of adenosine (<10 seconds) 
and limited duration of side effects. 
Dipyridamole causes coronary vasodilatation by increasing interstitial adenosine 
concentration, but its duration of action is quite long (>30 minutes) and consequent longer 
side effects.  
Vasodilators can cause ischaemia through the following mechanisms:  
1. increase flow across a stenosis leads to a fall in distal perfusion pressure with 
preferential shunting to the subepicardium, which is sufficient to cause subendocardial 
ischaemia
12
;  
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2. reduced flow in high-resistance collateral vessels serving an area of diseased artery by 
the generalised vasodilatation and fall in perfusion pressure (exacerbated by the small 
reduction in diastolic blood pressure);  
3. reflex tachycardia from vasodilation raises myocardial oxygen demand. 
 
Current clinically available techniques to evaluate myocardial perfusion are single photon 
emission computed tomography (SPECT), positron emission tomography (PET), 
echocardiography, and more recently cardiovascular magnetic resonance (CMR).  
All these imaging modalities present some advantages and limitations.  
The most validated and established stress imaging techniques are echocardiography and 
perfusion scintigraphy (both may be used in combination with either exercise test or 
pharmacological stress). Indeed, a normal stress myocardial perfusion test is highly predictive 
of a benign prognosis since it is associated with a rate of cardiac death and myocardial 
infarction of <1% per year, which is nearly as low as that of the general population.
3
  Novel 
stress imaging techniques also include stress cardiac magnetic resonance (CMR). Among the 
most important limitations of SPECT and PET include radiation exposure (SPECT and PET), 
high cost and limited availability (PET) and vulnerability to soft tissue attenuation artefacts 
(SPECT), and lower spatial resolution (SPECT is ~10mm, which is inferior to PET (~4mm) 
and CMR (~2mm).  
Overall, the potential advantages of CMR over the other imaging modalities are the increased 
spatial resolution with the ability to detect subendocardial ischaemia, and absent radiation 
exposure.  
 
3.3.1 Echocardiography 
In contrast to myocardial perfusion imaging using radiotracers, most of the echocardiographic 
methods of detection of myocardial ischaemia are based on identifying transient regional left 
ventricular dysfunction. Pharmacological echocardiographic stress testing has a diagnostic 
accuracy similar to SPECT with either coronary vasodilators or dobutamine.
13
  
Dobutamine is a short-acting sympatho-mimetic drug that infused following an incremental 
dose protocol (from 5 to 40µg/kg/min) increases myocardial oxygen consumption mimicking 
the effect of physical exercise. Being a positive inotropic and chronotropic agent, dobutamine 
detects myocardial ischeamia (at high doses) as new regional wall motion abnormalities, as 
opposed to inducible perfusion defects with vasodilators stress.  
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The accuracy of dobutamine echocardiography is limited in patients with pre-excited wall 
motion abnormalities that make it difficult to detect new regional wall motion abnormalities, 
as in acute myocardial infarction and patients with left bundle branch block.
14,15
 
Adenosine and dipyridamole are coronary vasodilators which create different in regional 
blood flow in regions supplied by haemodinamically significant stenotic coronary arteries 
(perfusion defect) versus regions supplied by non diseased coronary arteries (increase 
perfusion). This is the principle of steal phenomenon. Additional details on coronary 
vasodilators are discussed in paragraph 3.4.6.  
Myocardial contrast echocardiography (MCE) can assess myocardial perfusion during 
maximal hyperemia, has the advantages of easier access and affordability but is significantly 
operator dependent, requires good echocardiographic windows and has a low spatial 
resolution.
16
 The combination of echocardiographic myocardial perfusion and wall motion 
abnormalities correlated well with SPECT.
17
   
Myocardial perfusion with three-dimensional echocardiography represents a promising new 
development in ultrasound imaging with the potential to overcome many of the limitations of 
2D imaging.
18
  
 
3.3.2 Single Photon Emission Tomography 
SPECT is a well validated and robust technique for myocardial viability and ischaemia 
with over 7 million scans per year performed in the US. 
SPECT perfusion scintigraphy is performed to produce images of regional tracer uptake that 
reflects regional blood flow. With this technique, myocardial hypoperfusion is characterised 
by reduced tracer uptake during stress in comparison with uptake at rest.  
The regional distribution of coronary myocardial perfusion can be visualised with 
radiopharmaceuticals (thallium-201 or technetium-99m) that accumulate proportional to 
regional myocardial blood flow.  
Thallium-201 (
201
Tl) is a potassium analogue and its uptake into cardiac and skeletal cells is 
both passive and active though an energy-dependent process involving the sodium-potassium 
ATPase enzyme system and intact cell membrane integrity. This compound became available 
in 1974 and has since been used successfully for 25 years.  
However, some of the limitations of 
201
Tl perfusion imaging are:  
1. Relative high radiation exposure to the patient due to its long half-life in the body (the 
dose of 80MBq delivers an effective dose of 14mSv)
19
; 
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2. Low injected dose (to limit radiation exposure) results in low count density of the 
myocardial images;  
3. The low energy emission at 80KeV leads to low resolution images with significant 
attenuation by soft tissues.  
New technetium-99m (
99m
Tc)-labelled compounds with better imaging characteristics and 
novel biological properties do not suffer the first and the third of these problems and this has 
encouraged the introduction of such tracers for visualization of myocardial perfusion since the 
early 1990s. These compounds concentrate mainly in the cytosol (tetrofosmin) or the 
mitochondria (MIBI) of normally perfused and viable myocardium. Presently, 
99m
Tc-
sestamibi and 
99m
Tc-tetrofosfim are widely used in identifying myocardial ischaemia with 
good agreement
20
, although 
99m
Tc-sestamibi may have a better ability than 
99m
Tc-tetrofosfim 
to detect mild-to-moderate ischaemic defects.
21
 In fact, tetrofosmin has a lower first-pass 
extraction fraction compared to sestamibi and therefore during vasodilator stress it is more 
difficult to detect reversibility of defect in the distribution of mild-to-moderate stenoses.  
The advantages of 
99m
Tc-labelled compounds over thallium are:  
1. lower radiation burden to the patient (8mSv for tetrofosmin, and 10mSv for MIBI); 
2. higher energy photon produced (140 keV) that leads to higher resolution images;  
3. higher energy tracers are less affected by attenuation. 
 
AHA/ACC /ASNC guidelines for the use of cardiac nuclide imaging report an overall 87-89% 
sensitivity and 73-75% specificity for the detection of  50% CAD with exercise and 
vasodilator stress perfusion SPECT.
22
 The ranges of sensitivities and specificities associated 
with various protocols and agents used in SPECT are summarised in Table 3.2.  
 
 
3.3.3 Positron Emission Tomography  
PET is emerging as a clinically valuable technique due to its unique ability to image and 
quantify metabolic processes, receptor occupancy, and blood flow.  
18
F-FDG, a marker of glucose utilization, is the most commonly used metabolic radiotracers. 
Viability assessment with FDG is based on the principle that viable myocardium is 
metabolically active and that ischaemic myocardium may in fact have enhanced glucose 
uptake. The most commonly used positron-emitting perfusion tracers include rubidium-82 
(
82
Rb), 
13
N-ammonia and 
15
O-water and they may be used to assess absolute blood flow, flow 
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reserve, or cell membrane integrity. 
15
O-water is freely diffusible and its extraction is 
dependent of the metabolic state, whereas uptake and retention of the other tracers are 
dependent on both perfusion and cell membrane integrity. 
82
Rb is a potassium analogue that, 
like thallium, requires the sodium-potassium pump for uptake.  
Table 3.2. Diagnostic performance of different SPECT protocols. 
                                                                           Sensitivity (%)                 Specificity (%) 
Exercise treadmill test   
     Thallium-201 60-82 65-82 
     Tc-99m sestamibi 82-97 36-90 
     Tc-99m tetrofosmin 60-95 77-89 
Adenosine or dipyridamole   
     Thallium-201 77-92 75-100 
     Tc-99m sestamibi 81-90 67-72 
     Tc-99m tetrofosmin 83-89 55-94 
Dobutamine   
     Thallium-201 86-100 36-100 
     Tc-99m sestamibi 76-100 64-100 
     Tc-99m tetrofosmin 80-95 72-80 
   
 
Modified from Russell RR et al.
23
  
These published figures on sensitivity and specificity do not reflect how an expert centre might operate the 
various tests in a clinical setting. Also, different pre-test likelihood, post-test referral bias and retrospective 
analysis might explain the wide range of results.    
 
 
 
PET perfusion imaging with 
82
Rubidium coupled with CT affords high sensitivity and overall 
accuracy for detecting CAD, including in patients with single-vessel disease, women, obese 
patients and patients with three-vessel CAD.
24,25
 
13
N-ammonia yields excellent image quality for visual and quantitative analysis of absolute 
myocardial blood flow and flow reserve, even at a subendocardial level.
26
  
Its sensitivity and specificity for the detection of CAD is 79% and 85%, respectively
27
. 
Clinical investigations have consistently demonstrated that preserved viability with PET is 
associated with improvement in regional wall motion after revascularisation, particularly in 
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regions demonstrating flow-metabolism mismatch (diminished flow, increased glucose 
uptake).
28,29
 This has been recently confirmed in a randomised controlled trail.
30
 
In contrast to SPECT, PET imaging has the ability to quantify flow in ml/min/g, which is 
particularly useful in identifying “balanced ischaemia” in patients with three-vessel disease by 
showing a failure of flow reserve in all three coronary territories.  
Some limitations of this test include the fact that is: not widely available, expensive, uses 
ionising-radiation exposure, and requires time consuming data analysis. Also, compared with 
CMR, PET lacks spatial resolution which is important for early detection of disease.  
 
3.4 CMR PERFUSION  
After induction of vasodilator stress by adenosine (or dypiridamole), dynamic first-pass 
perfusion imaging is performed during intravenous injection of a gadolinium-based contrast 
agent, aiming to identify areas of inducible perfusion abnormalities (i.e. ischaemic). 
Following intravenous injection, the contrast will first appear in the right ventricular cavity, 
followed by the left ventricular cavity and finally leading to myocardial enhancement, where 
the contrast agent diffuses rapidly from the intravascular to the extravascular compartment. 
This explains why perfusion defects persist very briefly after bolus injection, before 
disappearing due to redistribution in the extravascular space. The pharmacokinetics of 
gadolinium in the blood pool, normal and infarcted myocardium is described in Figure 3.5. 
The corresponding increased image intensity is the result of the shortening of myocardial T1 
relaxation time caused by the contrast agent, and the magnitude of the signal enhancement 
depends on the amount of contrast agent present. 
Whilst Figure 3.5 shows curves of perfusion defect caused by microvascular obstruction and 
myocardial infarction, it does not contemplate a curve indicating inducible perfusion defects 
(as those seen during adenosine/dypiridamole infusion).  
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Figure 3.5 Kinetics and compartments of Gd-chelate contrast agent, from Pennell
31
. 
 
 
 
3.4.1 Contrast Agents 
Gadolinium-based agents are the only clinically approved molecules for MRI imaging. 
Gadolinium is a metal belonging to the lanthanide group of the periodic chart. Due to its 
extreme toxicity, gadolinium is always chelated for in-vivo applications and it is one of the 
most effective paramagnetic agents, enabling to accentuate the difference in tissue relaxation 
characteristics. There are only a few licensed contrast agents for use in humans, and these are 
classified according to their molarity, osmolarity and viscosity (Table 3.3)
32
.  
 
 
Table 3.3 Commonly administered contrast agents for CMR imaging.  
Table reproduced from Caravan et al.
32
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3.4.2 Contrast Dose 
The optimal dose of contrast agent for perfusion CMR has not been determined, but a number 
of studies have helped identify the correct range which is considered to be between 0.05-
0.1mmol/Kg.  
The best dose of gadodiamide for visual assessment of stress-induced regional perfusion 
abnormalities was found to 0.1mmol/kg bodyweight (as opposed to 0.05 and 0.15mmol/kg 
bodyweight) using a GRE-EPI (Gradient Echo-Echo Planar Imaging) sequence.
33
 Superior 
image quality was found with an SSFP (Steady State Free Precession) sequence with both 
dosage regimes of 0.05mmol/kg and 0.025mmol/kg bodyweight for Gd-BOPTA, in 
comparison with T1-GRE or GRE-EPI sequences.
34
 
In a multicentre dose-ranging study it was established that the minimally efficacious dose of 
Gd-DTPA for detecting obstructive coronary artery disease was 0.05mmol/kg (mean 
sensitivity 93±0%, mean specificity 75±7% and mean accuracy 85±3%)
35
 when compared to 
dose of 0.10 and 0.15mmol/kg. In particular, higher doses yielded greater myocardial 
enhancement but did not result in higher diagnostic accuracy. This is most likely due to the 
fact that higher contrast doses are more likely to cause susceptibility artefacts that could be 
misinterpreted as genuine perfusion defects. The same images were assessed using upslope 
analysis and a higher sensitivity and specificity was found at 0.1mmol/kg than at 
0.05mmol/Kg (but again, lower specificity at 0.15mmol/kg).
36
  
 
3.4.3 Contrast Injection Rate 
Another important parameter in perfusion imaging is the injection rate of the contrast agent 
bolus. This has not been standardized yet and it varies between centres from 3ml/s to 7ml/sec. 
In healthy myocardial segments, the myocardial enhancement (upslope) is mainly determined 
by the LV upslope and it is largely independent from the injection rate of the contrast agent 
bolus, as long as the injection speed is not below 3ml/s.
34
 There are no publications of the 
effect of injection rate on perfusion defect visibility. Different opinions exist on this topic, but 
the fundamental tracer-kinetics behind the delayed perfusion of diseased segments implies 
that an abrupt increase of contrast agent concentration is desirable, even if this results in fewer 
MR images during the first-pass. If this aim is accepted, which is not always the case because 
of the reduced number of images, a fast injection rate is believed to assist. For example 
Elkington et al.
37
 demonstrated significantly increased peak Gd concentration in the ascending 
aorta with increased injection rate from 3 to 5ml/s, with non-significant further increase at 
7ml/s injection rate (at rest). The peak myocardial enhancement, however, is dose dependent, 
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but the brief period of image contrast between regions of slower perfusion and normal 
myocardium contains unproven dependence on injection rate. 
 
3.4.4 Pulse Sequences  
Despite many comparison studies
,38,39,40,41,42,43
, the perfusion protocol (pulse sequence, 
contrast agent dose and injection parameters) giving highest diagnostic confidence is not yet 
standardised.
44,45
 Most centres rely on T1-weighted sequences to create images that enhance 
with the passage of Gd contrast agents. The main sequences available are: 1) Fast Single Shot 
Gradient Echo (FLASH), 2) Echo-Planar or Hybrid Echo-Planar (EPI) and 3) Steady-State 
Free Precession (SSFP). The ideal sequence for perfusion imaging should be very rapid, be 
able to “freeze” cardiac motion, have a high SNR, high spatiotemporal resolution and should 
be robust to artefacts. The current available pulse sequences are briefly described as follows. 
 
FLASH is the simplest method of rapid perfusion imaging, the most established and robust 
sequence. It collects one line of raw data per radiofrequency excitation, therefore being 
relatively slow and inefficient. However, it is considered a robust sequence because after each 
data readout the residual signal is discarded and gets a new signal for the next line. This 
sequence has an intrinsic poor SNR due to the low flip angle. The pulse diagram of a gradient 
echo sequence is illustrated in Figure 3.6. 
 
Hybrid EPI requires faster gradients and collects multiple lines of raw data after each 
radiofrequency pulse, and is effectively an accelerated variant of the FLASH technique. 
Compared to FLASH, EPI is a faster sequence, therefore less prone to cardiac motion 
artefacts. However, this sequence is prone to off-resonance artefacts. 
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Figure 3.6. Pulse diagram of a gradient echo sequence  
(modified from Gebker
44
). 
 
 
These can be reduced by running EPI faster, but at the cost of lower SNR, or reducing ETL 
but becomes slower and therefore losing its advantage compared to FLASH and becoming 
more prone to cardiac motion artefacts. The pulse diagram of a gradient echo sequence with 
EPI readout is illustrated in Figure 3.7. 
 
 
 
Figure 3.7. Pulse diagram of a gradient echo sequence with EPI readout 
 (modified from Gebker
44
). 
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SSFP is a promising sequence, but experience is limited.
38,40,42
 It has a higher SNR due to its 
higher flip angle. It is considered an efficient sequence because it re-uses residual 
magnetisation. Compared to EPI, SSFP has superior SNR and CNR but given the longer 
imaging time (125ms) is more prone to motion artefacts. Dark ring artefacts had been noted as 
more prominent with SSFP (visual analysis).
46
 The pulse diagram of an SSFP sequence is 
illustrated in Figure 3.8. 
 
 
Figure 3.8. Pulse diagram of a steady state free precession sequence  
(modified from Gebker
44
). 
 
 
 
Comparing the 3 sequences, hybrid EPI has the shortest time per image (~75ms, compared to 
~180ms for FLASH and ~200ms for SSFP), pivotal for minimizing cardiac motion artefacts. 
However, in the fastest version with minimal off-resonance errors, EPI has lower SNR than 
the other two sequences.  
Increase in cardiac heart rate that often occurs during hyperemic stress may limit the 
acquisition window, resulting in incomplete myocardial coverage. Parallel acquisition 
methods such as sensitivity encoding (SENSE)
47
 and k-t SENSE
48
 are used to shorten data 
acquisition time, with improved image quality, diagnostic accuracy and improved quantitative 
perfusion assessment. 
49,50
 
43
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In our centre and other laboratories hybrid-EPI is the preferred sequence for perfusion 
CMR
51,52
. However, the other sequences are widely used in other institutions. 
 
3.4.5 Arterial Input Function 
Accurate assessment of arterial input function (AIF) is pivotal for quantifying myocardial 
perfusion because it serves as a reference for the analysis. 
In general, lower doses cause lower signal-to-noise (SNR) in the myocardium, whereas higher 
doses determine a non linear signal intensity in the left ventricular cavity (after contrast 
administration) resulting in an inaccurate input function, that influences the quantification of 
myocardial perfusion. In particular, the non linearity (contrast- enhancement saturation) of the 
contrast enhancement in the blood pool increases with the increase of contrast concentration. 
Eventually, the signal intensity would even start to decrease above a certain contrast level, 
due to T2* effects
53
. In order to accurately measure the arterial input of contrast, signal 
saturation effects need to be avoided or corrected.  
Dual contrast sequences or dual contrast bolus protocol are among the methods proposed to 
improve the assessment of the arterial input function. The latter involves giving a low dose of 
contrast bolus to characterize the arterial input function, followed by a second higher bolus to 
image the contrast enhancement in the myocardium.
54
 The dual contrast sequence allows 
during each cardiac cycle the acquisition of a low resolution short axis image with a short 
saturation recovery (10 ms for low T1 weighting) immediately after the R wave in order to 
measure the signal in the LV blood pool, which is then followed by higher resolution multiple 
short axis slices with long saturation-recovery time (in the range of 90-110 ms depending on 
the phase encoding field of view).
55
 This simple high-dose single bolus method has been 
validated against the dual bolus technique with no significant differences in the calculation of 
MPRs.  
In our centre we have adopted the dual sequence approach.  
However, a conflicting report showed that dual-bolus perfusion imaging made no significant 
difference to global perfusion quantification with small improvements in segmental perfusion 
analysis results.
56
 The relevance of dual-bolus or dual-sequence methods depends on the 
contrast-agent dose and any other factors (such as injection rate, choice of saturation-recovery 
delay, etc) that impact upon the linearity of signal response to contrast-agent concentration. If 
lower doses are used, for example 0.04mmol/kg
71
 with a short saturation-recovery delay (e.g. 
50ms), the dual-bolus or dual-sequence methods are probably unnecessary, although 
myocardial SNR is now reduced. 
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3.4.6 Adenosine 
Normal resting flow in the coronary arteries is approximately 1 ml/min/g of myocardium. 
Coronary hyperemia caused by adenosine determines an increase in perfusion in normal 
coronary arteries reaching 3-4 ml/min/g, whereas in myocardial territories supplied by 
stenotic vessels perfusion is restricted to resting values of 1 ml/min/g (the vessel is already 
maximally dilated at rest to overcome the limited blood flow caused by the stenosis).
57
 
Adenosine is infused at the rate of 140 μg Kg-1 min-1 using a syringe pump. CMR first-pass 
perfusion acquisition starts 3-4 minutes after the beginning of adenosine infusion. The safety 
profile of adenosine in the context of stress perfusion imaging was assessed in 9,256 
consecutive patients undergoing radionuclide imaging.
58
. Adenosine infusion is safe, and its 
vasodilator and negative dromotropic effects are generally well tolerated. Serious side effects 
are relatively rare, and they rapidly reverse with termination of the infusion, due to 
adenosine’s ultrashort half-life (<10 seconds). 
 
Dipyridamole is an alternative drug, which increases adenosine through indirect mechanisms. 
It is actively metabolized in the liver and, therefore, its vasodilator capacity is variably 
dependent on individual metabolism rate. Compared to adenosine, dypiridamole has a longer 
half-life (30 minutes), and prolonged side effects. Typically, the infusion dose is 0.56 mg/Kg 
for 4 minutes and the images acquisition starts after 6 minutes. Although the cost of 
dypiridamole is inferior to adenosine, adenosine has been shown to lower costs both for 
patients’ monitoring and adverse events management.59  
Both adenosine and dypiridamole are contraindicated in case of severe conduction 
abnormalities, chronic obstructive pulmonary disease (COPD) and asthma.  
 
3.4.7 Imaging Protocol 
Typically, 3 short-axis slices (basal, mid-cavity and apical) are acquired both during stress 
and at rest, in order to provide complete myocardial segmental coverage, according to the 
recommended 17-segment myocardial model for tomographic cardiac imaging model.
60
 And 
although there is variability in the coronary blood supply to myocardial segments, the 17 
myocardial segments are assigned to one of the three major coronary arteries (Figure 3.9) 
 
The 3 short axis images are acquired throughout the cardiac cycle and triggered to the R wave 
on the ECG tracing; approximately 40-60 images for each slice location. Breathing should be 
suspended for at least the early part of the image acquisition (during the first pass) to 
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minimize breathing motion artefacts and facilitate diagnostic interpretation. The short-axis 
planes can evaluate only 16 myocardial segments, failing to assess the ventricular apex. A 
combined long- and short-axis imaging protocol has been proposed; however, the long-axis 
views were not able to depict inducible perfusion defects in the apex, despite apical ischemia 
being demonstrated with recent SPECT in the same patients. 
61
 
 
 
Figure 3.9. Representative three LV short axis slices, myocardial segmentation and 
corresponding coronary artery supply. Modified from Cerqueria
60
 
 
 
 
The number of short-axis slices is strictly limited by the patient’s heart rate, i.e. in principle 
bradycardia could allow the acquisition of additional slices. Elkington and et. investigated the 
role of adding a long-axis view, but this did not increased the diagnostic accuracy of the test.
37
 
The technique could potentially benefit from a 3D coverage. This is however not currently 
available clinically but indeed under investigation.  
Fifty cardiac cycles are acquired to allow the complete track of the dynamic process of 
contrast bolus from the moment of the peripheral injection to the diffusion in the myocardium 
of the left ventricle. Probably only 30 cardiac cycles are needed, but the exact arrival time of 
the bolus is unpredictable. Resting perfusion images are acquired 20 minutes after the stress 
perfusion images, a time window to allow partial contrast wash-out from the previous 
injection. 
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3.4.8 Qualitative Assessment of Myocardial Perfusion 
Visual assessment is commonly used in routine clinical practise.  
Perfusion defects appear as focal areas of reduced myocardial enhancement (hypointense, 
darker) compared to normal segments (Figure 3.10). The extent of the perfusion defect can be 
either subendocardial or transmural. In contrast with SPECT where the severity of ischemia is 
related to the depth of perfusion abnormality, in CMR defect trasmurality is taken as a 
surrogate. Given the increased spatial resolution of CMR, interpretation of ischemia 
superimposed  upon myocardial damage allows for the  identification of peri-infarct perfusion 
defect, as already described by the nuclear techniques.  
 Qualitative analysis can be challenging in the presence of suboptimal images quality, breath-
holding related artefacts, ECG mistriggering and dark rim artefacts.  
The rest perfusion scan is particularly useful to interpret the presence of artefacts. In CMR, a 
genuine inducible perfusion defect is normally present in the stress but not in the rest images. 
The persistence of a hypointense region in the rest images is indicative of artefacts (provided 
these images are acquired 15-20 minutes after the stress acquisition). In helping to distinguish 
a genuine myocardial perfusion defect from artefact, Klem proposed a visual interpretation 
algorithm that combines the information from stress/rest perfusion with LGE.
62
 Also, the 
duration of the perfusion defect (number of frames), its reoccurrence during the contrast 
recirculation (second-pass) can help guiding image interpretation.  
When qualitative perfusion CMR was compared against angiography, the sensitivity and 
specificity of visual assessment was 93% and 60%, respectively.
63
 Qualitative CMR reporting 
was possible in 98% of cases. As in other imaging techniques, the qualitative approach is 
observer-dependent and potentially less accurate than quantitative analysis. 
 
Whilst higher dose of contrast agents improve normal myocardial SNR for visual assessment, 
lower doses (0.025-0.05mmol/Kg) are usually preferred to measure absolute or relative 
changes in myocardial blood flow and volume to avoid non-linear response to the contrast 
agent.
64
 
 
 
Chapter 3  CMR in Chronic Ischaemia 
 
51 
 
 
Figure 3.10. Stress (A) and rest (B) first pass perfusion imaging. Inducible perfusion defect is 
demonstrated in basal and mid-cavity inferior wall.  
 
 
 
 
3.4.9 Quantification of Myocardial Perfusion 
The aim of quantitative analysis is to remove dependence on observer and on bolus 
dispersion.  
Myocardial perfusion reserve (MPR) was proposed since the early 1970s as an index of 
functional severity of coronary stenosis 
65,66
 and it is calculated as the ratio of hyperemic and 
baseline myocardial blood flow. In humans, PET is the only validated imaging method to 
measure quantitative myocardial blood flow and MPR.
67
 Cullen et al. demonstrated the 
feasibility of performing myocardial perfusion reserve index measurement by first-pass CMR 
in normal volunteers and patients with CAD
68
compared to quantitative angiography and PET 
data. Similar reliable assessment of MPR index by CMR perfusion in a clinical context was 
reported by other groups.
69,70
  
 
A B C 
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Approximately 40% of the intravenously injected (extracellular) contrast agent diffuses from 
the blood into the interstitium during the first pass. Most methods of quantitative analysis are 
based on tracking a bolus and its transit through a region of interest (ROI).  
This procedure requires tracing endo- and epi-cardial contours, as well as placing a ROI in the 
LV cavity, and signal intensities will be then converted into contrast agent concentration in 
order to allow for input correction (Figure 3.11). For the analysis, the left ventricle is divided 
into regions of interest (ROI), according to the 17-segments model.
60
  
Some preliminary steps need to be taken before performing the quantitative analysis: data 
should be corrected for respiratory motion and coil sensitivity.  
Then different models may be applied to calculated perfusion: fully quantitative or semi-
quantitative analysis.
71
  
 
 
Figure 3.11. Tracing ROIs in the LV myocardium and in the LV blood pool. 
 
 
 
For the semi-quantitative analysis the upslope of the signal-intensity curve during contrast 
enhancement is the most widely used parameter, being also the most sensitive parameter to 
differences in myocardial blood flow (Figure 3.12).
72
 Additionally, it correlates closely with 
microspheres (in dogs)
73,74
 and PET measurements (in humans).
75
 An underestimation of 
coronary flow reserve by CMR perfusion measurements compared to PET was reported by 
Ibrahim et al. in patients with angiographically documented CAD.
76
 The upslope index 
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yielded a sensitivity, specificity and diagnostic accuracy of 69%, 89% and 79%, respectively, 
for the localization of coronary artery stenosis (>75%, MPR <1.2) and a sensitivity, 
specificity and diagnostic accuracy of 86%, 84% and 5%, respectively, for detection of 
reduced coronary flow reserve (PET<2.0, MPR<1.3). 
 
The signal intensity (SI) curve is a combination of perfusion and diffusion, both of which are 
influenced by blood flow.
77
 The early phase of SI time curve is mainly influenced by 
perfusion and to a lesser extent by diffusion, and the latter parts are increasingly influenced by 
diffusion. Both the wash-in and wash-out are strongly influenced by the compactness of the 
contrast bolus, and for a reliable calculation it should be small and compact. Ischaemic 
myocardial segments show a slower passage of the contrast agent,
78
 
 
Figure 3.12. Signal intensity curves in the myocardium and in the LV blood pool during first-
pass perfusion. Reproduced from Jerosch-Herold.
71
 
 
 
 
(lower peak myocardial signal intensity, slower rate of signal increase and longer time to peak 
perfusion), resulting in a stronger influence of diffusion and a less pronounced or even 
nonexistent down slope. A linear fit of the upslope of the signal intensity-time curve was 
proposed by Al-Saadi as a new and easy method for the determination of MPR
79
 and to 
minimize the influence of diffusion. This parameter was demonstrated to be highly 
reproducible, with good inter- and intra-observer variability.  
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When the upslope was initially proposed to assess myocardial perfusion, the authors 
normalized it by the up-slope of the LV signal intensity.
70
 These adjustments for difference in 
AIF between hemodynamic states was used to define a perfusion reserve index (stress 
value/rest value) with a similar approach used to calculate coronary flow reserve.   
 
Fully quantitative analysis (quantitative myocardial blood flow, MBF) may be estimated 
using deconvolution (based on a mathematical model of contrast agent kinetics).
72
  
 
In order to quantify perfusion, it is necessary to achieve an accurate estimate of the AIF, as 
described in paragraph 4.3.5. In most work, the contrast agent kinetics are based on the Fick’s 
principle that the rate at which a substance accumulates in a tissue ROI is given by the 
difference of the concentration of the tracer flowing into and leaving the region. Essentially 
this corresponds to the principle of mass balance: tracer that has entered and not exited has 
remained in the region of interest. Additional complexity could be added if the vascular 
compartment were to be considered in its spatial extent (with concentration of the tracer 
higher at the arterial inlet than further downstream), rather than a lumped compartment that 
would instead only consider contrast concentration as a function of time. In principle, a 
spatially lumped model has a significant positive effect on the accuracy of MBF 
estimations
71
; however such models are not widely used.  
 
The term “model” is used as above for the different tissue compartments. However, and 
somewhat confusingly, it is also used for some approaches to the deconvolution. The 
approaches that can be used for quantifying MBF by deconvolution of the AIF from the 
myocardial signal can be divided into two categories: 1) model based and 2) model 
independent analysis.
71
 Category 1 tends to use a “Fermi function model” to constrain the 
shape of the deconvolution result, which is otherwise very noisy. Category 2 avoids any fixed 
shape model but instead applies a series of slowly-varying curves to constrain the 
deconvolution. 
The work in this thesis is based on the Fermi function constrained deconvolution, reviewed 
very clearly by Lee and Johnson (ADD ref). The main limitations of this approach are: 1- the 
tracer bolus re-circulates and the Fermi model does not account for the second pass of contrast 
agent; 2-the Fermi function does not model the interstitial contrast agent as it leaks into the 
extravascular compartment.     
 
Chapter 3  CMR in Chronic Ischaemia 
 
55 
 
Despite the limitations described above, this method has been validated against microspheres 
showing an improved response to higher myocardial blood flow compared to the semi-
quantitative analysis.
73
  
 
“Fully quantitative” analysis of myocardial perfusion reserve is based on the ratio of 
stress/rest MBFs with one important modification, that calibrations for surface-coil response 
etc may be assumed to cancel between stress and rest if the surface-coil did not move. With 
this assumption, myocardial perfusion reserve may be derived from uncalibrated “indices” of 
myocardial blood flow. This approach was used to derive the “myocardial perfusion reserve 
index” referred to in other chapters. However, the perfusion protocol used for this work was 
not suitable for calculation of absolute rest or stress MBF. Firstly, the myocardial signal 
would require corrections for surface-coil response, which would otherwise make the septum 
have apparently higher MBF than lateral myocardium. This correction cannot be done with 
simple image normalisation and requires separate “proton-density” weighted prescans.51 
Secondly, this high-dose protocol would have some non-linear response to contrast-agent 
concentration in myocardium. The high-dose was required for visual analysis and the effect of 
non-linearity in myocardium was accepted as probably reasonably small (around 20% 
underestimate of stress MBF).
80
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CHAPTER 4 
GENERAL METHODS USED IN THIS THESIS  
 
 
4.1 CARDIOVASCULAR MAGNETIC RESONANCE 
4.1.1 Scanner  
With the exception of the study presented in Chapter 7, the equipment used for this thesis was 
a 1.5 Tesla Avanto CMR scanner (Siemens Medical Solutions, Erlangen, Germany) with a 
cardiac dedicated 12-channel phase array receiver surface coil (6 anterior and 6 posterior coils 
elements). All studies were gated with a multichannel ECG (vector ECG) and acquired during 
breath-hold in end-expiration.  
The sites of recruitment and imaging were: 1) University “La Sapienza” in Rome, Italy for 
studies in Chapter 5 and Chapter 6; 2) S.Donato Hospital in Arezzo, Italy for study in Chapter 
7 and 3) the Royal Brompton Hospital in London for the studies presented in Chapter 8 and 
Chapter 9.  
 
4.1.2 Patient Preparation and Monitoring 
Pacemaker, implantable cardiac defibrillator (ICD) and metallic cerebral clips were absolute 
contraindication to CMR. There was no specific preparation for patients undergoing a CMR 
scan, unless they were undergoing a stress perfusion scan.  
 
In preparation for CMR perfusion, patients were asked to abstain from coffee, tea, chocolate 
and other substances containing caffeine at least 24 hours prior to the test. Aminophyline and 
nitrates were also discontinued the day before. A 12-lead ECG was performed prior to the 
test. Severe conduction abnormalities (atrio ventricular block> IIa), severe chronic obstructive 
pulmonary disease (COPD) and asthma, unstable angina represented contraindication for the 
test. Nevertheless, patients with a history of mild to moderate asthma were clinically 
evaluated, including review of medications in consideration for perfusion imaging with a 
modified titrated adenosine protocol, as in practice in the Nuclear Medicine Department, 
Royal Brompton Hospital.
1
  
Two venous accesses (normally the right and the left anterocubital veins) were secured using 
18G (for Gd injection) and 20G (for adenosine infusion) cannulae.  
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Heart rate, rhythm and symptoms were continuously monitored throughout the duration of the 
scan. Blood pressure was measured before adenosine infusion (baseline), at 3 minutes of 
infusion (stress) and 20 minutes after completing the infusion (rest). The blood pressure cuff 
was positioned on the arm receiving the injection of contrast.  
 
Criteria for termination of adenosine included a drop in systolic blood pressure >20mHg, 
persistent or symptomatic hypotension, severe respiratory difficulty, and 
persistent/symptomatic II-III degree atrio-ventricular (AV) blocks. Caution was adopted in 
presence of stenosis valvular disease, particularly aortic.  
 
4.1.3 Imaging Protocol  
The complete imaging protocol used in this work is described in Figure 4.1. It started with 
the acquisition of long and short-axis cines, followed by long and short-axis oedema imaging 
(T2 STIR). Upon completion of a 4-minute adenosine infusion, stress perfusion images were 
acquired during Gd injection. Adenosine infusion was then stopped and long and short-axis 
late gadolinium enhancement (LGE) images were acquired. Approximately 20 minutes after 
the first contrast administration, a second dose of Gd was injected and rest perfusion images 
were acquired. Cine, T2 STIR, and LGE images were acquired at the same long- and short-
axis slice position. The total duration of the scan was approximately 50-60 minutes.  
 
 
Figure 4.1. Complete imaging protocol used in this thesis  
 
Cine and LGE imaging were carried out in all scans for all studies. Additional oedema, first-
pass stress/rest perfusion to assess for inducible perfusion defect or first-pass rest perfusion 
Chapter 4  General Methods 
 
63 
 
imaging to assess for microvascular obstruction were performed according to the specific 
study designs and aim.  
Details on the pulse sequence and imaging protocol used in each of the above steps are 
provided in the next paragraphs.   
 
4.1.4 Software for Image Analysis 
Image analysis was performed using a semi-automated customised software (CMRtools, 
Cardiovascular Imaging Solutions, London, United Kingdom) with dedicated plug-ins (LV 
tools, Perfusion tools) for the assessment of LV function, infarct size, myocardial oedema, 
and myocardial perfusion (Figure 4.2). 
 
 
Figure 4.2. CMRtools and plug-ins. 
 
 
 
4.2 ASSESSMENT OF LEFT VENTRICULAR FUNCTION 
CMR is considered the gold standard imaging technique for the assessment of ventricular 
dimensions and function, with a greater interstudy reproducibility compared to two-
dimensional echocardiography.
2,3
 Given the increased spatial and temporal resolution soft 
tissues can be clearly visualised without the need for contrast agent and a full three 
dimensional dataset acquired. Also, as a tomographic technique, any desired image plane can 
be acquired by CMR and it is not limited by body habitus or acoustic window, or by 
geometrical assumptions in reconstructing three dimensional data from two dimensional 
measurements, as with standard 2D echocardiography.  
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4.2.1 Pulse Sequence 
Cine images were acquired using a steady state free precession (SSFP) sequence. Typical 
parameters were TE= 1.6ms, TR=3.2ms, inplane resolution 1.4 x 1.8mm, slice thickness 
8mm, temporal resolution 50ms, 25 phases, flip angle 60 degrees and matrix 256x256. 
All cines were ECG gated, and to ensure full coverage of the cardiac cycle, retrospective 
gating was used. Images were acquired during breath hold (at end-expiration) over multiple 
cardiac cycles (typically 12-15 heart beats). The final image was the average from the data 
acquired across these various cardiac cycles. In the presence of arrhythmia or limited breath 
hold, image parameters were optimised on a per subject case.   
 
4.2.2 Image Acquisition 
Following the acquisition of the initial localisers in the three orthogonal planes (transverse, 
coronal and sagittal), a free breathing multislice Half Fourier Single shot Turbo Spin Echo 
(HASTE) sequence was used to cover the entire thorax in the transverse plane. Breath-hold 
Steady State Free Precession (SSPP) vertical long axis (VLA) and basal short axis (SA) 
scouts were then acquired (Figure 4.3 step 1) and used to pilot he acquisition of the 
subsequent horizontal long axis (HLA) (Figure 4.3, steps 2 and 3). Multiple contiguous SA 
cines were acquired encompassing the left ventricle from base (AV ring) to the apex (Figure 
4.4).  
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Figure 4.3. Piloting and acquisition of horizontal and vertical long axis views. 
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Figure 4.4. Piloting and acquisition of short axis slices. 
 
 
 
4.2.3 Image Analysis  
Image analysis was performed using a semi-automated software (CMRtools, Cardiovascular 
Imaging Solutions, London, United Kingdom) with a dedicated plug-in (LVtools) for the 
assessment of the left ventricle. With a step-by-step workflow the endocardial and epicardial 
borders were contoured in end-diastole and end-systole, and an intensity-based threshold 
applied to delineate individual voxels as blood or myocardium generating a 3D model of the 
myocardium and blood pool (Figure 4.5). Papillary muscles and trabeculae were included in 
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the calculation of LV mass. The motion of the mitral and aortic valve is taken into account for 
calculating 3D LV volumes and LV mass. The position and the orientation of the valve planes 
were identified in end-diastole and end-systole, and then automatically interpolated to exclude 
regions belonging to the left atrium (Figure 4.6).  
The images were assessed according to the AHA/ACC 17-segment model
4
 (Figure 4.7). Wall 
motion score was calculate assigning to the all the segments the following score: 0 (normal), 1 
(mildly hypokinetic), 2 (severely hypokinetic), 3 (akinetic), or 4 (dyskinetic). Wall thickening 
is an aspect of wall motion often taken in consideration in CMR for a more accurate 
assessment of regional function. This is an advantage of CMR over echocardiography since 
the former technique clearly defines the endocardial border as opposed to echocardiography 
where this is often blurred.    
 
 
 
Figure 4.5. Three-dimensional semi-automated LV assessment. 
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Figure 4.6. Valve plane tracking . 
 
Figure 4.7. Myocardial segmentation, 17-segment model
4
. 
 
 
 
4.3 ASSESSMENT OF MYOCARDIAL OEDEMA 
4.3.1 Pulse Sequence 
The T2-weighted (T2w) sequence used to assess myocardial oedema was a breath-hold black-
blood segmented turbo spin echo (TSE) technique with triple inversion recovery preparation 
(short time (tau) inversion recovery). More specifically, this is a fast spin echo pulse sequence 
that uses radio frequency pulses for spin inversion of the blood pool and inversion recovery 
preparation for fat saturation (STIR), as described by Simonetti.
5
  
The STIR sequence is designed to suppress signal from fat but also enhance the signal from 
tissues with long T1- and T2-relaxation times, such as inflammatory/oedematous tissues.  
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Sequence parameters were: TR 2 R-to-R intervals, TE 75 ms, flip angle 180°, TI 170 ms, slice 
thickness 8 mm, no interslice gap, field of view 340 to 400 mm, matrix 256 × 256, and a 
voxel size of 2.3 × 1.3 × 8 mm.  
 
4.3.2 Image Acquisition  
The images were acquired on the short axis planes covering the entire left ventricle, in 
addition to long-axis slices, during 6 to 8 consecutive breath holds (Figure 4.8). Each slice 
was obtained during an end-expiratory breath-hold of 12 to 15 s, depending on the patient's 
heart rate. All T2 STIR images were acquired at the same long- and short-axis position as the 
cine and LGE images. Surface coil normalisation algorithm was used as provided by the 
vendor.   
 
 
Figure4.8. T2-STIR short- and long-axis images.  
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4.3.3 Image Analysis   
Region of interest were drawn in the areas of increased signal intensity using a threshold 
approach: signal intensity of the affected region >2 SD of remote myocardium
6
. The level 
setting was set at the mean signal intensity of the unaffected area.  
Salvaged myocardium was then quantified as the difference between the area of increased 
signal on T2w-STIR (area at risk) and the area of LGE (infarct size) as previously described.
6
 
All measurements were expressed as a percentage of total LV mass.  
 
4.4 ASSESSMENT OF MYOCARDIAL PERFUSION  
4.4.1 Pulse Sequence 
First-pass stress perfusion imaging was performed using a 3-slice (basal, mid-cavity and 
apical views) hybrid-EPI sequence with T-SENSE (TR 5.8ms, TI 110-140ms, FOV 
360x270mm, voxel size 2.8 x 2.8 x 10mm, EPI factor 4) over 50 consecutive cardiac cycles. 
The images were acquired after 4 minutes of 140µg/kg/min adenosine infusion and following 
the injection of 0.1mmol/kg of Gd. Rest perfusion images were acquired >20 minutes after 
stress perfusion imaging.  
Arterial input function was assessed using the dual sequence method (for additional details, 
please refer to Chapter 4, paragraph 3.4.5 “Arterial Input Function”).  
 
4.4.2 Image Acquisition 
The 3 basal, mid-cavity and apical slices were piloted using the horizontal and vertical long-
axis cine images. Images were put in their end-systolic frames in order to avoid imaging the 
LV outflow tract (Figure 4.9). In the absence of contrast injection, the endocardial border was 
not clearly visualised, but these images were indeed used to check slice positioning, and 
presence of artefacts/wrap.  
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Figure 4.9.Piloting perfusion images.  
 
 
 
4.4.3 Image Analysis   
Visual assessment of regional myocardial perfusion was performed in all studies. With the use 
of the display tool of the software, perfusion images were played continuously, and 
subsequently frame by frame to assess the signal intensity pattern and location, as well as the 
dynamic filling pattern (Figure 4.10).  
 
 
Figure 4.10 Dynamic contrast filling pattern with progressive contrast arrival.  
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Images were then displayed in two panels (stress images on the top and corresponding rest 
images on the lower panel) and inducible perfusion defects appeared as missing enhancement 
(white arrow) over a few frames (typically 5-7 frames) with consecutive signal increase in the 
stress images, but not in the rest scan (Figure 4.11). Perfusion images were also compared 
against the corresponding late gadolinium (LGE) images.
7
   
Presence of artefact was considered when 1) filling myocardial defect was present at the time 
of contrast arrival in LV cavity before myocardial enhancement; 2) filling myocardial defect 
was present both in the stress and rest scans; 3) filling myocardial defect was very short-lived 
(2-3 frames).  
The extension of perfusion defects were reported with their transmurality (transmural vs 
subendocardial) but was also scored visually in each segment as 0 (normal), 1 (defect <25% 
wall thickness), 2 (defect 25-50%), 3 (defect 50-75%), 4 (>75%), and its sum identified the 
visual perfusion score. 
 
Myocardial perfusion reserve (MPR) was also calculated with Perfusion tools® 
(Cardiovascular Imaging Solutions London, UK), based on uncalibrated perfusion analysis as 
described in Chapter 3. Endocardial and epicardial contours were semi-automatically drawn 
in each frame of the 3 short axis slices before applying an automated motion correction 
algorithm to remove registration errors particularly during respiratory motion. If through-
plane motion was still evident, individual frames of image series were disabled. A ROI was 
then drawn in the blood pool (attentively avoiding the papillary muscles or trabeculations) and 
its average signal intensity used to calculate AIF. ECG timing was then imported, and 
myocardial segmentation applied. 
Finally, the software used a model-based deconvolution (i.e. constrained to fit a Fermi-
function shape of tissue impulse response) to fit a smooth curve from which derived 
segmental stress and rest myocardial perfusion indexes, as well as the final MPR for each 
segment (Figure 4.12 and 4.13). The uncalibrated nature of these indices is explained further 
in Chapter 3. 
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Figure 4.11 Visual assessment of regional myocardial perfusion. Inducible perfusion defects 
appear as filling defect (hypointense areas) (white arrows).  Perfusion images were then 
compared against the corresponding late myocardial enhancement slices. 
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Figure 4.12. Myocardial perfusion reserve in an ischaemic segment. 
 
 
 
Figure 4.13. Myocardial perfusion reserve in a non ischaemic segment. 
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4.5 ASSESSMENT OF MYOCARDIAL INFARCTION 
4.5.1 Pulse Sequence 
Late gadolinium enhancement (LGE) images were acquired 10-15 minutes after the injection 
of 0.1mmol/Kg of Gd in the long and short-axis planes, using a segmented inversion recovery 
gradient echo sequence (TR 600ms, TE 3.8ms,  25 degrees, slice thickness 8mm, gap 2mm, 
typical pixel size 1.7 x1.4mm.
8
  
The inversion time was progressively optimised and adjusted to adequately null normal 
myocardium (typical values 320-440ms).
9
 
 Cine and LGE images were acquired at the same long- and short-axis slice position. 
 
4.5.2 Image Acquisition 
The images were acquired on the short axis planes covering the entire left ventricle, in 
addition to long-axis slices, during 6 to 8 consecutive breath holds (Figure 4.14). Each slice 
was obtained during an end-expiratory breath-hold of 15 to 20 s, depending on the patient's 
heart rate. All LGE images were acquired at the same long- and short-axis position as the cine 
and STIR images. 
 
 
Figure 4.14 LGE short- and long-axis images.  
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4.5.3 Image Analysis   
Infarcted myocardial mass and microvascular obstruction were manually traced and 
calculated from the LGE short-axis images Region of interest were drawn in the areas of 
increased signal intensity using a threshold approach: signal intensity of the affected region 
>5 SD of remote myocardium.
10
  
 
 
Figure 4.15.Quantification of infarct size and microvascular obstruction  
 
Microvascular obstruction was defined as a dark zone within the infarcted segments, usually 
located in the subendocardium. Areas of microvascular obstruction were assessed separately 
but incorporated in the infarct size analysis (Figure 4.15). All measurements were expressed 
as a percentage of total LV mass.  
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CHAPTER 5 
IMPACT OF PRIMARY PCI DELAY ON MYOCARDIAL SALVAGE, MICROVASCULAR 
OBSTRUCTION AND INFARCT SIZE  
 
 
5.1 INTRODUCTION 
Current therapeutic strategies in patients with ST-segment elevation myocardial infarction 
(STEMI) aim for a timely recanalization of the infarct-related artery (IRA) to reduce the 
progression of the ischemic-necrotic wavefront of myocardial injury and salvage the damaged 
but still viable myocardium within the area at risk
1,2
. In some patients microvascular 
obstruction (MVO) may occur within the ischemic region in addition to myocardial necrosis, 
and it is usually associated with greater left ventricular (LV) remodeling and a worse clinical 
outcome
3,45
. Delays in recanalizing the occluded artery in patients with STEMI influence the 
presence and extent of infarct size (IS) and of MVO
5,6,7
, with a strong impact on the rate of 
cardiac mortality and morbidity
8
. Cardiovascular magnetic resonance (CMR) with late 
gadolinium enhancement (LGE) imaging represents a well-established and reproducible 
diagnostic tool to assess irreversible ischemic injury and to visualize the location and 
transmural extent of IS and MVO within the infarcted region
5,6,9
. 
T2-weighted short tau inversion recovery (T2w-STIR) imaging is a sequence sensitive to 
increased myocardial water content, allowing the delineation of myocardial oedema after an 
acute ischemic insult, thus representative of the myocardium at risk. The T2w-STIR 
hyperintense areas usually include both reversible and irreversible injured myocardium
10,11,12
. 
However, by the use of a combined T2w-STIR and LGE CMR imaging protocol, salvaged 
myocardium can be quantified as the difference between the area of increased T2w-STIR 
signal (myocardium at risk) and the area of LGE (IS), as previously reported
10,11,12,13,14
. The 
authors of previous studies
1,2,6,7,15,16,17,18
 evaluating the influence of primary percutaneous 
coronary intervention (PPCI) delays on IS and myocardial salvage in patients with STEMI 
reported conflicting results. The present study was designed to determine the influence of 
time to reperfusion on myocardial damage assessed by CMR in patients with STEMI 
undergoing PPCI. 
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5.2 METHODS 
5.2.1 Patients 
Between October 2007 and May 2008, 75 consecutive patients with first STEMI undergoing 
PPCI within 12 h after the onset of symptoms were prospectively enrolled in the study. 
Creatine kinase and troponin I measurements were systematically performed at hospital 
admission, every 3 h for the subsequent 24 h, and then every 12 h for the following 2 days. 
The CMR study was carried out within 5 days from PPCI. A follow-up CMR study to assess 
LV remodelling was performed at 6 months. Exclusion criteria were unsuccessful PPCI, 
rescue percutaneous coronary intervention (PCI), facilitated PCI, contraindication to 
glycoprotein IIb/IIIa inhibitors, non-STEMI, previous MI, previous coronary artery bypass 
grafting, and contraindications to CMR. Patients with hemodynamic instability at the time of 
CMR also were excluded. All participants gave written informed consent to the protocol, and 
the study was approved by the local ethics committee. 
 
5.2.2.Percutaneous Coronary Intervention 
We performed PPCI and stenting of the IRA in all patients according to the clinical protocol 
used at our institution
3,19
. Thrombolysis In Myocardial Infarction (TIMI) flow grade was 
semiquantitatively scored as previously described
2,19
. The number of coronary vessels 
demonstrating significant coronary artery disease was reported. Collateral flow to the infarct 
zone was assessed on the initial angiogram before PPCI and graded on a scale of 0 to 3 by use 
of Rentrop classification
20
. A successful angioplasty was defined a combination of post-
procedural TIMI flow grade 3 and residual stenosis <30%. Time to reperfusion was defined as 
the interval from the onset of symptoms to the first balloon inflation. 
 
5.2.3. CMR Protocol  
We performed CMR imaging in all patients by using a 1.5-T system (Magnetom Avanto, 
Siemens Medical Systems, Erlangen, Germany) equipped with SQ-engine gradients 
(amplitude: 45 mT/m; slew rate: 200 mT/m/ms) and a 12-channel phased-array cardiac coil. 
After obtaining scout images, cine steady-state free precession (SSFP) CMR images were 
acquired from patients during short breath holds in the short-axis, 2-chamber, and 4-chamber 
planes; on short-axis images, the left ventricle was completely encompassed from the base to 
the apex, from which we acquired a total of 10 to 12 images. Cine SSFP images were 
obtained by use of the following parameters: time per frame 51.3 ms, echo time (TE) 1.21 ms, 
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flip angle 80°, 8-mm slice thickness, no interslice gap, matrix of 256 × 256, field of view 
ranging from 340 to 400 mm, and a voxel size of 1.7 × 1.7 × 8.0 mm. 
For T2w-STIR imaging, a breath-hold black-blood segmented turbo spin echo technique was 
adopted by the use of a triple inversion recovery preparation module (TR 2 R-to-R intervals, 
TE 75 ms, flip angle 180°, TI 170 ms, slice thickness 8 mm, no interslice gap, field of view 
340 to 400 mm, matrix 256 × 256, and a voxel size of 2.3 × 1.3 × 8 mm). Technical details of 
this sequence are described elsewhere
21
. The T2w-STIR images were acquired on short axis 
planes covering the entire left ventricle during 6 to 8 consecutive breath holds. Each slice was 
obtained during an end-expiratory breath-hold of 12 to 15 s, depending on the patient's heart 
rate. 
Finally, short-axis LGE images were obtained by use of a segmented inversion recovery 
technique and acquired 10 to 15 min after injection (Gd-BOPTA, Multihance, Bracco, Milan, 
Italy; 0.1 mmol/kg body weight at 2 ml/s). Sequence parameters were the following: image 
data acquisition in 100 ms in diastole (adapted per patient), 23 raw data lines per alternate 
cycle, TE 4.33 ms, matrix 256 × 256, flip angle 30°, slice thickness 8.0 mm, no interslice gap, 
and voxel size 1.7 × 1.4 × 8 mm. The inversion time was progressively optimized to null the 
signal in the normal myocardium (typical values, 250 to 300 ms) to ensure matching slice 
position between T2w-STIR and LGE images, same acquisition planes were adopted. Cine, 
T2w-STIR, and LGE images were acquired at the same short-axis slice position. 
 
5.2.4 Image Analysis 
All CMR studies were analyzed off-line by the use of a dedicated workstation (Siemens 
Argus, Erlangen, Germany). Left ventricular volumes, systolic function, and mass were 
calculated from the short-axis SSFP cines. Infarcted myocardial mass and MVO were 
manually traced and calculated from the LGE short-axis images. As reported in Bondarenko 
et al.
22
, myocardial regions was considered infarcted if the IS signal intensity was >5 SDs 
above the remote myocardium. The MVO was defined as a dark zone within the infarcted 
segments, usually located in the subendocardium. The mass of myocardial oedema was traced 
and calculated from the T2w-STIR images by the use of a similar threshold-based approach 
(signal intensity >2 SDs of remote myocardium)
23
. Salvaged myocardium was quantified as 
the difference between the area of increased T2w-STIR signal (area at risk) and the area of 
LGE (IS) as previously described
10,11,12,13,14
. All measurements were normalized to LV mass. 
 
 
Chapter 5  CMR in STEMI 
 
81 
 
 
5.2.5. Statistical Analysis 
Data were analyzed with SPSS software version 15.0 (SPSS Inc., Chicago, Illinois). The 
continuous variables were calculated as the average value considering the standard deviation, 
whereas those that were categorical were calculated as percentages. The differences between 
means of continuous variables at different times to reperfusion were analyzed by 1-way 
analysis of variance by the use of a linear trend analysis, and a post-hoc analysis with 
Bonferroni correction was made for differences between groups. The differences between 
categorical variables were analyzed with the chi-square test of Pearson. A Student t test for 
independent groups was used to assess differences in continuous variables between anterior 
versus non anterior infarction, whereas a Student paired-samples t test was used to highlight 
differences in LV parameters after primary PCI and at 6-month follow-up; these tests were 
made without correction for multiple comparisons. A linear regression analysis was used to 
evaluate the relationship between time to treatment and CMR extent of MVO, IS, and 
salvaged myocardium. Differences were considered statistically significant at a 2-sided p 
value ≤0.05. 
 
5.3 RESULTS 
5.3.1 Clinical and Angiographic Data 
Seventy patients (89% men, mean age 58 ± 9 years) were studied with CMR 3 ± 2 days after 
PPCI. There were no differences between the 4 groups. Seventy-five patients were initially 
recruited, but 5 patients were excluded because of claustrophobia (n = 3) or clinical instability 
(n = 2). A follow-up CMR was performed in 58 patients; the remaining 12 patients declined. 
We performed PPCI in left anterior descending artery (LAD) in 43 patients, in the right 
coronary artery (RCA) in 26 patients, and in the left circumflex artery (LCx) in 1 patient. 
Mean time to reperfusion was 4.4 ± 4.7 h. No events suggesting reocclusion/stenosis were 
observed between PPCI and CMR examinations. 
For the purpose of the study, patients were subcategorized into 4 quartiles on the basis of time 
from symptom onset to reperfusion: ≤90 min (group I, n = 19), >90 to 150 min (group II, n = 
17), >150 to 360 min (group III, n = 17), and >360 min (group IV, n = 17). No differences on 
baseline clinical (Table 5.1) and angiographic characteristics were observed in the 4 groups 
(Table 5.2). In particular, no statistical differences between groups were observed in relation 
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to incidence of LAD disease, TIMI flow grade 3 before PPCI, and significant collateral 
circulation. 
 
 
Table 5.1 Baseline clinical characteristics of the population. 
 
Variables  
 
Groups (n = 70 Patients)  
 
p Value  
 
 
≤90 Min  
(n = 19) 
>90–150 Min  
(n = 17) 
>150–360 Min 
 (n = 17) 
>360 Min  
(n = 17) 
 
Risk factors      
Age, yrs 58 ± 7.3 57 ± 10 57 ± 13 58 ± 11 0.75 
Sex, male 15 (78) 13 (76) 10 (58) 9 (53) 0.42 
Hypertension 5 (26) 4 (23) 7 (41) 3 (18) 0.15 
Diabetes 1 (5) 3 (18) 0 (0) 1 (6) 0.34 
Smoking 12 (63) 12 (70) 8 (47) 9 (53) 0.54 
Dyslipidemia 4 (21) 6 (35) 4 (23) 2 (12) 0.61 
Family history of CAD 5 (26) 6 (35) 3 (18) 3 (18) 0.45 
      
Time to treatment, h 1.0 ± 0.1 2.4 ± 0.4 5.0 ± 0.9 9.0 ± 3.5 0.001 
CK, UI/l 1,806 ± 934 2,012 ± 1,871 2,264 ± 1,544 2,562 ± 1,134 0.34 
CK-MB, UI/l 284 ± 218 302 ± 243 311 ± 234 483 ± 486 0.33 
Troponin I, ng/ml 8.7 ± 9.9 10.6 ± 11.4 10.9 ± 10.1 11.8 ± 9.2 0.28 
      
Concomitant  Medications    0.89 
ACE inhibitors/ARBs 18 (95) 15 (88) 16 (94) 17 (100)  
Beta-blockers 17 (89) 16 (94) 16 (94) 16 (94)  
Statins 19 (100) 17 (100) 17 (100) 16 (94)  
Values are mean ± SD or n (%). 
ACE = angiotensin-converting enzyme; ARB = angiotensin receptor blocker; CAD = 
coronary artery disease; CK = creatine kinase; CK-MB = creatine kinase-myocardial band;  
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Table 5.2 Angiographic characteristics of the population.  
Variables  
 
Groups (n = 70 Patients)  
 
p Value  
 
 
≤90 min 
(n = 19) 
>90–150 min 
(n = 17) 
>150–360 min 
(n = 17) 
>360 Min 
(n = 17) 
 
Infarct-related artery     0.44 
  LAD 14 (74) 10 (59) 9 (53) 10 (59)  
  LCx 0 (0) 0 (0) 1 (6) 0 (0)  
  RCA 5 (26) 7 (41) 7 (41) 7 (41)  
Number of vessels     0.26 
  1 10 (53) 7 (41) 8 (47) 8 (47)  
  2 6 (31) 8 (47) 6 (35) 8 (47)  
  3 1 (5) 2 (12) 3 (17) 1 (6)  
TIMI flow grade 3 before PCI 3 (15) 2 (11) 3 (17) 3 (17) 0.84 
Collateral flow grade 2 to 3 2 (10) 3 (17) 2 (11) 3 (17) 0.51 
 
Values are mean ± SD or n (%). 
LAD = left anterior descending coronary artery; LCx = left circumflex coronary artery; PCI = 
percutaneous coronary intervention; RCA = right coronary artery; TIMI = Thrombolysis In 
Myocardial Infarction. 
 
 
 
5.3.2. Time to Reperfusion and Infarct Size 
An infarcted region on LGE images was visualized in all patients and corresponded to the 
territory distribution of the IRA. Mean IS among 4 groups was 12 ± 8% of LV mass. A 
significant increase of IS over time was found (8%, 11%, 12%, and 18%, respectively, p = 
0.05) (Figure 5.1 A). The largest increase in IS was observed in patients with the longest time 
to reperfusion (group IV vs. I, p = 0.002). Time to reperfusion expressed as a continuous 
variable significantly correlated with IS (r = 0.60, p = 0.0001) (Figure 5.2). On a separate 
analysis on LAD versus non-LAD infarcts, we observed that anterior infarcts were 
significantly larger than inferior ones. This phenomenon was consistently observed across the 
4 reperfusion groups (Table 5.3). 
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Figure 5.1. Time to reperfusion and cardiovascular magnetic resonance parameters. Bar 
graphs show the influence of time to reperfusion on infarct size (A), myocardial oedema (B), 
myocardial salvage (C), and microvascular obstruction (MVO) (D).  
Data are expressed as % left ventricular mass. 
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Figure 5.2. Relationship between time to reperfusion and infarct size. 
Triangles represent anterior infarct location and circlesnon-anterior infarct location. 
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Table 5.3. Relationship among infarct location (LAD vs. Non-LAD) and time to treatment, 
infarct size, and LVEF. 
Variables  
 
Groups  
 
 
≤90 
Min 
p 
Value 
>90–150 
Min 
p 
Value 
>150–360 
Min 
p 
Value 
>360 
Min 
p 
Value 
LAD time  
to treatment, h 
1.0 ± 0.2 0.710 2.5 ± 0.5 0.984 5.2 ± 0.9 0.335 11.5 ± 1.1 0.359 
Non-LAD time 
to treatment, h 
1.1 ± 0.2  2.4 ± 0.5  4.5 ± 0.8  10.2 ± 3.1  
         
LAD 
infarct size, % 
12 ± 3.1 0.050 14 ± 10.1 0.041 16 ± 7.9 0.038 20 ± 9.8 0.002 
Non-LAD 
infarct size, % 
6.8 ± 1.5  8.9 ± 3.2  9.7 ± 6.8  10 ± 1.3  
         
LAD  
LVEF, % 
47 ± 12.4 0.427 44 ± 10.1 0.220 44 ± 5.7 0.147 34 ± 6.0 0.378 
Non-LAD 
LVEF, % 
50 ± 10.7  51 ± 9.4  51 ± 7.2  39 ± 7.6  
 
LAD = left anterior descending artery; LVEF = left ventricular ejection fraction. 
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5.3.3. Time to Reperfusion and Myocardial Salvage 
Increased signal intensity on T2w-STIR imaging (myocardial oedema) was observed in 62 of 
70 patients (89%); in the remaining 8 (11%) patients, T2w signal intensity was not 
homogeneous throughout segments because of the presence of a central hypointense core with 
peripheral hyperintense rim related to underlying microvascular damage. The mean size of 
oedema among 4 groups was 16 ± 8% of LV mass. In all patients the location of T2w-STIR 
increased signal intensity corresponded to the territory of distribution of the IRA. The extent 
of myocardial oedema did not changed significantly as time to reperfusion progressed (16%, 
15%, 15%, and 19%, respectively, p = 0.37) (Figure 5.1 B). Conversely, the extent of 
salvaged myocardium (oedematous but not necrotic myocardium) was significantly reduced 
overtime (8.5%, 3.2%, 2.4%, and 2.1%, respectively, p = 0.003) (Figure 5.1 C). In particular, 
a marked reduction in salvaged myocardium was observed when reperfusion occurred area 
after 90 min of coronary occlusion (group I vs. II, p = 0.0001; group I vs. III, p = 0.0001; 
group I vs. IV, p = 0.0001), whereas no significant changes were observed between groups II, 
III, and IV. In late reperfused patients (group IV), an almost complete absence of salvaged 
myocardium was observed (Figure 5.1.C). A significant inverse correlation was found 
between time and salvaged myocardium by linear regression analysis (r = −0.53, p = 0.005). 
5.3.4. Time to Reperfusion and Microvascular Obstruction 
Mean size of MVO was 2.1 ± 3.4% of LV mass. The incidence and extent of MVO 
progressively increased as time to reperfusion increased (0.5%, 1.5%, 3.7%, and 6.6%, 
respectively, p = 0.039) (Figure 5.1 D). In particular, the larger MVO area was observed in 
the latest reperfused group (group IV vs. I, p = 0.034); a weak but statistically significant 
correlation was observed between time to reperfusion and MVO (r = 0.39, p = 0.005). 
Furthermore, in patients with MVO, IS was significantly greater than in patients without 
MVO (16 ± 9.8% vs. 10 ± 6.9%, respectively, p = 0.012). 
5.3.5. Time to Reperfusion and LV function 
Significant increase in LV volumes and reduction in ejection fraction over time was observed 
(Table 5.4). However, these changes were not homogeneous because both left ventricular 
end-diastolic volume (LVEDV) and left ventricular end-systolic volume (LVESV) increased 
and left ventricular ejection fraction (LVEF) reduced only in the group reperfused the latest 
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(group IV). There were no differences in LVEF across the 4 reperfusion groups between 
anterior and non anterior infarcts (Table 5.3). 
 
Table 5.4. Influence of time to reperfusion on left ventricular function assessed by CMR. 
Variables  
 
Groups  
 
p Value  
 
 
≤90 Min 
(n = 19) 
>90–150 Min 
(n = 17) 
>150–360 Min 
(n = 17) 
>360 Min 
(n = 17) 
 
LVEDV, ml 128 ± 32 131 ± 37 130 ± 41 153 ± 22 0.03 
LVESV, ml 62 ± 22 69 ± 30 68 ± 24 94 ± 21 0.02 
LVEF, % 47 ± 10 46 ± 9 47 ± 6 38 ± 7 0.06 
CMR = cardiovascular magnetic resonance; LVEDV = left ventricular end-diastolic volume; 
LVEF = left ventricular ejection fraction; LVESV = left ventricular end-systolic volume. 
 
 
5.4 DISCUSSION 
In this study we describe the benefits associated with early coronary reperfusion as assessed 
by CMR in patients with STEMI treated with PPCI. Noninvasive myocardial tissue 
characterization provided by CMR enabled us to differentiate reversible and irreversible 
myocardial injury (myocardium at risk and myocardial infarction, respectively) and 
consequently to determine the presence and extent of salvaged myocardium. 
The main findings of this study are that: 1) patients reperfused early (≤90 min) demonstrated 
smaller IS and microvascular damage and larger salvaged myocardium, whereas patients 
reperfused later (time to reperfusion >360 min) presented larger IS and MVO and very 
limited, if any, salvaged myocardium; and 2) the presence and extent of salvaged myocardium 
markedly decreased when reperfusion occurred after >90 min of coronary occlusion. To the 
best of our knowledge, this is the first in vivo, clinical, and non-invasive evaluation of the 
impact of time to refeperfusion on infarct size, microvascular obstruction and myocardial 
salvage in patients with STEMI undergoing PPCI.   
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5.4.1. Time to Reperfusion and Myocardial Damage 
Reimer and Jennings
1
 have demonstrated that approximately one-half of the ischemic 
myocardium progresses towards necrosis within 40 min of coronary occlusion, one-third of 
the ischemic myocardium is still salvageable at 3 h, and that the process of myocardial 
necrosis is complete about 6 h after the onset of coronary occlusion. After this time, the 
potential for salvage myocardium is considered minimal or absent
1,2
. The benefits of 
reperfusion persist up to 12 h, but these are of decreasing magnitude over time
5,7,9
. According 
to the “open artery hypothesis,” most of the clinical benefits of late recanalization (>6 h) are 
independent from myocardial salvage and are mostly related to attenuation of LV remodeling 
processes and reduction of clinical instability
2,7,24
. 
Multiple randomized clinical trials
6,7,8
 showed a significantly lower rate of mortality among 
patients achieving TIMI flow grade 3 within 90 min after the onset of STEMI (golden hour). 
For these reasons, the European Society of Cardiology and American College of 
Cardiology/American Heart Association clinical guidelines on STEMI recommend PCI 
within 90 min from first medical contact. Our CMR data confirm this experimental and 
clinical evidence by demonstrating a progressive increase over time in IS and MVO extent. 
However, by using CMR we were able to observe, for the first time, that salvaged 
myocardium consistently reduces after 90 min of coronary occlusion, both in the LAD and 
non LAD infarctions. (Figure 5.3). As time to reperfusion progresses, infarct size (thin 
arrows) and microvascular obstruction (MVO) (*) both increase. Of note, in group I (patients 
early reperfused) the area of myocardial oedema (open arrows) largely exceeds the area of 
infarct size, demonstrating presence of myocardial salvage; conversely in group IV 
(reperfused the latest), the area of myocardial oedema almost corresponds to the infarcted 
area, suggesting limited myocardial salvage. 
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Figure 5.3. Influence of time-to-reperfusion on myocardial salvage, infarct size and 
microvascular obstruction in two patients with inferior (A) and anterior (B) STEMI.  
Top panels: T2-weighted short tau inversion recovery (T2w-STIR) images; the arrows identify 
the extension of myocardium at risk; the asterisks identifies microvascular obstruction.   
Lower panels: corresponding late gadolinium enhancement (LGE) images; the arrows 
identify the extension of necrotic myocardium (infarct size); the asterisks identifies 
microvascular obstruction.   
 
 
 
Previous studies 
1,2,5,6,7,15,1617,18
 in which the authors evaluated the influence of time to 
reperfusion on IS and salvaged myocardium yielded conflicting results. As previously 
underlined, Reimer and Jennings
1
 demonstrated in dogs a substantial reduction of salvaged 
myocardium in the first hours after coronary ligation. Whereas a reduced efficacy of lytic 
treatment overtime has been well documented, a recent meta-analysis by Boersma
18
 suggests 
that time delays are largely unimportant in primary PCI. In particular, with clinical data 
obtained by the use of myocardial scintigraphy, Schomig et al.
16
 found no significant relation 
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between time to reperfusion and IS and a constantly high myocardial salvage index in patients 
treated with PCI even after 12 h from symptom onset. Conversely, by analyzing the T2W-
STIR and LGE images, our CMR data support the hypothesis that myocardium potentially 
salvaged by reperfusion significantly reduces after 90 min of coronary occlusion even in 
patients treated with PPCI. 
The main determinants of MVO are still unclear
3,4,5,15,24
. In agreement with Tarantini et al.
15
, 
we observed a progressive MVO increase over time. In particular MVO was detected only in 
6 of 19 patients (31%) treated within 90 min and in 14 of 17 patients (82%) treated after 6 h. 
Thus, both incidence and extent of MVO are time-dependent phenomenon, as observed for IS. 
These results are consistent with previous experimental data hypothesizing that the extent of 
microvascular injury is also driven by the extent of IS
14,15,25
. 
Finally, the impact of time to reperfusion on LV volumes and LVEF was significantly more 
pronounced in patients reperfused late (group IV) compared with the other groups (I, II, and 
III). This finding was confirmed also in the CMR at 6 months, demonstrating a significant 
increase in LVEDV and LVESV in the later reperfused groups (group III, >150 to 360 min 
and group IV, >360 min); LVEF significantly decreased only in group IV. 
5.4.2. Myocardium at Risk and Salvaged Myocardium 
Increased signal intensity in the T2w-STIR images is related to increased water content. In 
patients with STEMI this phenomenon is likely to represent post-ischemic intracellular edema 
either related to altered transmembrane sodium gradients or to the inflammatory response to 
the acute ischemic insult. The authors of recent CMR studies 
10,11,12,13,14,24
 demonstrated that 
the increased signal intensity on T2w-STIR images corresponds indeed to the area of 
myocardium at risk determined histologically. Aletras et al.
10
 demonstrated in animal model 
of 90-min coronary occlusion followed by reperfusion that the area at risk measured by 
microspheres was comparable with the area of increased signal in the T2w images 2 days 
later. The increased signal intensity on T2w-STIR images consist of both reversibly and 
irreversibly injured myocardium. In addition, areas of LGE identified IS with detailed 
precision compared with histology
10
, confirming that IS acutely is not overestimated because 
of the contribution of oedematous areas, which are indeed characterized and quantified only 
by the T2w images. Therefore, on the basis of the histological evidence that myocardium at 
risk is identified by the T2w areas and IS by LGE areas, the amount of salvaged myocardium 
can be derived by subtracting the area of LGE from the T2w area. 
Cury et al.
26
 recently applied T2w imaging by using a double inversion-recovery with 
chemical fat saturation and LGE protocol to improve the accuracy in the diagnosis of acute 
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coronary syndrome in the emergency department. The authors of previous studies 
11,12,13,14,15
 
showed that areas of increased T2 signal intensity are consistently larger than the LGE areas 
of the irreversible injury. Similarly, in our study, the oedematous zone is consistently larger 
than the infarcted zone but only in patients treated early and progressively reduces with delays 
on reperfusion evolving in irreversible myocardial damage. The amount of myocardium 
successfully salvaged dramatically reduces after 90 min of coronary occlusion; thus, clinical 
benefits of IRA reopening are after this period
2,7,18
 are largely not attributable to myocardial 
salvage. 
Milavetz et al.
27
 reported the influence of time to reperfusion on myocardial salvage assessed 
by technetium-99m sestamibi demonstrating that in patients with first anterior MI undergoing 
successful reperfusion therapy (PPCI or thrombolysis) the greatest degree of myocardial 
salvage was achieved with an early reperfusion therapy (<2 h). Our data confirm these 
findings by the use of CMR as an alternative noninvasive imaging modality. The retrospective 
determination of myocardium at risk, IS—and consequently myocardial salvage—by CMR up 
to 5 days after reperfusion appears logistically very attractive as compared with the tracer 
injection before reperfusion therapy required by technetium-99m sestamibi
28
. Finally, our 
study provides additional insight on the association of 4 different time-to-reperfusion intervals 
and the extent of reversible and irreversible damage. 
5.4.3. Clinical Implications 
The results of our study suggest that any strategy
293031
 to shorten the delay in the reperfusion 
of patients with STEMI (i.e., pre-hospital lysis or a direct catheter laboratory notification 
bypassing the emergency department) is crucial. Although Boersma
18
 hypothesizes that that 
time delays are less important for primary PCI, the present study demonstrated the amount of 
myocardial salvage reduces significantly already after 90 min of coronary occlusion. Our data 
might explain the unsatisfactory clinical results of myocardial protection therapy
32
. Agents 
directed toward improving the myocardial reperfusion itself are time-limited to the period 
when myocardial salvage occurs. Thus, possibly only patients presenting very early after 
symptom onset may take advantages from cardioprotective drugs. 
Finally, this work confirms and emphasizes the important diagnostic role of CMR with LGE 
and T2w-STIR techniques in providing in vivo characterization of myocardial tissue damage 
at different temporal stages of coronary reperfusion. The use of CMR can identify and 
quantify areas of salvaged myocardium in patients with STEMI treated with PPCI, 
representing a potentially valuable tool to be used in large clinical trials assessing the efficacy 
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of different reperfusion strategies. Large clinical trials are needed to assess the role of CMR in 
the risk stratification after acute myocardial infarction and possibly improve patient 
management. 
 
5.4.4. Study Limitations 
Despite the limited study population, a relatively high percentage of our patients were treated 
very early (24% of patients ≤90 min from the symptom onset, 51% within 150 min), which 
was made possible by an integrated hospital network system activated in our city and region. 
For the same reason the mean IS detected in our study population was slightly smaller than 
previously reported. The influence of time to reperfusion on the extent of myocardial salvage 
IS and MVO needs to be confirmed in larger longitudinal studies. 
Currently, there is no consensus on which technique can be used to perform the best MVO 
quantification
33
. With first-pass myocardial perfusion imaging, the area of MVO is larger than 
using LGE imaging. In our study MVO was assessed in LGE images. Although the size of 
MVO may be underestimated by use of the LGE sequences, the persistence of MVO in these 
images is likely to reflect a more severe form of MVO
15
. Finally, in this study CMR was 
performed as part of a research protocol and did not contribute to the care of patients. 
 
5.4.5. Conclusion 
According to previous prognostic data, in patients with STEMI “time is muscle”.  
Using state-of-the-art CMR technology, this study has assessed in a novel (imaging) way that 
in fact “time is muscle”. It has identified that in patients reperfused early (<90 minutes) 
infarct size is limited and the extent of myocardial salvage is significantly larger than in 
patient reperfused later (>360 minutes). Conversely, patients reperfused later present much 
larger infarct size and reduced myocardial salvage. Of note, the presence of microvascular 
obstruction was identified only in patients reperfused later.  
Infarct size, myocardial salvage and microvascular obstruction by CMR can represent 
surrogate endpoints to be used in prospective clinical trials comparing different reperfusion 
strategies or cardioprotective agents.  
 
Chapter 5  CMR in STEMI 
 
94 
 
References 
 
1
  Reimer KA, Jennings RB. The “wavefront phenomenon” of myocardial ischemic cell death. II. Transmural 
progression of necrosis within the framework of ischemic bed size (myocardium at risk) and collateral ﬂow. Lab 
Invest 1979;40:633– 44. 
 
2
  Gerber BL. Risk area, infarct size, and the exposure of the wavefront phenomenon of myocardial necrosis in 
humans. Eur Heart J 2007;28:1670 –2.  
 
3
 Agati L, Voci P, Bilotta F, et al. Inﬂuence of residual perfusion within  the  infarct  zone  on  the  natural  
history  of  left  ventricular dysfunction after acute myocardial infarction. J Am Coll Cardiol 1994;24:336 – 42.  
4
Chaitman BR, Lim MJ. No reﬂow and the quest to achieve optimal perfusion during the acute phase of 
myocardial infarction. J Am Coll Cardiol 2004;44:313–5. 
 
5
Bogaert  J,  Kalantzi  M,  Rademakers  FE,  et  al.  Determinants  and impact  of  microvascular  obstruction  in  
successfully  reperfused  ST- segment  elevation  myocardial  infarction.  Assessment  by  magnetic resonance 
imaging. Eur Radiol 2007;17:2572– 80. 
 
6Thiele H, Kappl MJ, Linke A, et al. Inﬂuence of time-to-treatment, TIMI-ﬂow grades, and  ST-segment  
resolution on infarct size and infarct transmurality as assessed by delayed enhancement magnetic resonance 
imaging. Eur Heart J 2007;28:1433–9. 
 
7
Brodie B, Webb J, Cox D, et al. Impact of time to treatment on myocardial reperfusion and infarct size with 
primary percutaneous coronary intervention for acute myocardial infarction (from the EMERALD Trial). Am J 
Cardiol 2007;99:1680 – 6. 
 
8
De Luca G, Suryapranata H, Ottervanger JP, Antman EM. Time delay to treatment and mortality in primary 
angioplasty for  cute myocardial infarction: every minute of delay counts. Circulation 2004;109:1223–5. 
 
9
 Kim RJ, Wu E, Rafael A, et al. The use of contrast-enhanced magnetic resonance imaging to identify reversible 
myocardial dysfunction. N Engl J Med 2000;343:1488 –90. 
 
10
 Aletras, Tilak GS, Natanzon A, et al. Retrospective determination of the area at risk for  reperfused  acute  
myocardial infarction with T2-weighted cardiac magnetic resonance imaging: histopathological and 
displacement encoding with stimulated echoes (DENSE) functional validations. Circulation 2006;113:1865–70. 
 
11
 Abdel-Aty H, Simonetti O, Friedrich MG. T2-weighted cardiovascular magnetic resonance imaging. J Magn 
Reson Imaging 2007;26: 452–9. 
 
12
 Friedrich MG, Abdel-Aty H, Taylor A, et al. The salvaged area at riskin reperfused acute myocardial 
infarction as visualized by cardiovascular magnetic resonance. J Am Coll Cardiol 2008;51:1581–7. 
 
13
 Stork A, Lund  GK, Muellerleile K, et al. Characterization of the peri-infarction zone  using T2-weighted MRI 
and delayed enhancement MRI in patients with acute myocardial infarction. Eur Radiol 2006;16:2350 –7. 
 
14
 Dymarkowski S, Ni Y, Miao Y, et al. Value of T2-weighted magnetic resonance imaging early after 
myocardial infarction in dogs: comparison with bis-gadolinium-mesoporphyrin enhanced  T1-weighted magnetic 
resonance imaging and functional data from cine magnetic resonance imaging. Invest Radiol 2002;37:77– 85. 
 
15
  Tarantini G, Cacciavillani L, Corbetti F, et al. Duration of ischemia is a major determinant of transmurality 
and severe microvascular obstruction after primary angioplasty: a study performed with contrast-enhanced 
magnetic resonance. J Am Coll Cardiol 2005;46:1229 –35. 
 
16
 Schomig A, Ndrepepa G, Mehilli J, et al. Therapy-dependent inﬂuence of time-to-treatment interval on 
myocardial salvage in patients with acute myocardial infarction treated with coronary artery stenting or 
thrombolysis. Circulation 2003;108:1084 – 8. 
 
17
 Bates ER, Nallamothu BK. Commentary: the role of percutaneous coronary intervention in ST-segment-
elevation myocardial infarction. Circulation 2008;118;567–73. 
Chapter 5  CMR in STEMI 
 
95 
 
 
 
18
 Boersma  E. Does time matter? A pooled analysis of randomized clinical trials comparing primary 
percutaneous coronary intervention and in-hospital ﬁbrinolysis in acute myocardial infarction patients. EurHeart 
J 2006;27:779 – 88. 
 
19
  Galiuto L, Garramone B, Scarà A, et al. The extent of microvascular damage at myocardial contrast 
echocardiography is superior to other known indexes of post-infarct reperfusion in predicting left ventricular 
remodeling. Results of the multicenter study “Acute  Myocardial Infarction Contrast Imaging” (AMICI). J Am 
Coll Cardiol 2008;51:552–9. 
 
20
 Rentrop KP, Cohen M, Blanke H, et al. Changes in collateral channel ﬁlling immediately after controlled 
coronary  artery occlusion  y an angioplasty balloon in human subjects. J Am Coll Cardiol 1985;5:587–92. 
 
21
 Simonetti OP, Finn JP, White RD, et al. “Black blood” T2-weighted inversion-recovery MR imaging of the 
heart. Radiology 1996;199:49–57. 
 
22
 Bondarenko  O,  Beek  AM,  Hofman  MB, et al. Standardizing the deﬁnition of hyperenhancement in the 
quantitative assessment of infarct size and myocardial viability using delayed contrast-enhanced CMR. J 
Cardiovasc Magn Reson 2005;7:481–5. 
 
23
 Abdel-Aty H, Zagrosek A, Schulz-Menger J, et al. Delayed enhance ment and T2-weighted cardiovascular 
magnetic resonance imaging differentiate acute from chronic myocardial infarction. Circulation 2004;109:2411– 
6. 
 
24
 Bucciarelli-Ducci C, Ng FS, Symmonds K, et al. The complex pathophysiology of acute myocardial infarction 
imaged by cardiovascular magnetic resonance infarction, edema, microvascular obstruction, and inducible 
ischemia. Circulation 2008;118:e89 –92. 
 
25
 Reffelmann T, Hale SL, Li G, et al. Relationship between no reﬂow and infarct size as inﬂuenced by  the  
duration  of  ischemia and reperfusion. Am J Physiol Heart Circ Physiol 2002;282:H766 –72. 
 
26
 Cury RC, Shash K, Nagurney JT, et al. Cardiac magnetic resonance with T2-weighted imaging improves 
detection of patients with acute coronary syndrome in the emergency department. Circulation 2008; 118:837– 
44. 
27
 Milavetz JJ, Giebel DW, Christian TF, et al. Time to reperfusion and salvage in myocardial infarction. J Am 
Coll Cardiol 1998;31:1246 –51. 28.  
 
28
 Pennell DJ. Myocardial salvage. Retrospection, resolution, and radiowaves. Circulation 2006;113:1821–3. 
 
29
 Antman EM. Time is muscle. Translation into practice. J Am Coll Cardiol 2008;52:1216 –21. 
 
30
 Stone GW. Angioplasty strategies in ST-segment elevation myocardial infarction: part I: primary percutaneous  
coronary intervention. Circulation 2008;118:538 –51. 
 
31
 Stone GW. Angioplasty strategies in ST-segment elevation myocardial infarction: part II: intervention after 
ﬁbrinolytic therapy, integrated treatment recommendations, and future directions. Circulation 2008;118:552– 66. 
 
32
 Granger CB, Patel MR. The search for myocardial protection is there still hope? J Am Coll Cardiol 
2007;50:406 – 8. 
33
 Rochitte CE. Microvascular obstruction the ﬁnal frontier for a complete myocardial reperfusion. J Am Coll 
Cardiol 2008;23:2239–40. 
 
Chapter 6  EXPIRA Trial 
 
96 
 
CHAPTER 6 
THROMBUS ASPIRATION DURING PRIMARY PCI IMPROVES MYOCARDIAL 
PERFUSION AND REDUCES INFARCT SIZE.  
THE EXPIRA PROSPECTIVE RANDOMIZED TRIAL  
(THROMBECTOMY WITH EXPORT CATHETER IN INFARCT-RELATED ARTERY DURING PRIMARY 
PERCUTANEOUS CORONARY INTERVENTION)  
 
6.1 INTRODUCTION 
Primary percutaneous coronary intervention (PPCI) is the standard treatment in patients 
with STEMI achieving a Thrombolysis In Myocardial Infarction (TIMI)-3 in >90% of 
patients.
1
 However, despite a “brisk” epicardial coronary flow in the infarct-related artery, 
microvascular damage frequently limits the efficacy of PPCI. Recent studies suggest that 
thrombectomy improves myocardial perfusion and reduces left ventricular remodeling by 
reducing microvascular damage.
2,3,4
 Cardiovascular magnetic resonance (CMR) represents 
the gold-standard technique to identify and quantify microvascular obstruction (MVO) and 
infarct size (IS)
5,6
 and to date this imaging technique has not been applied to assess the 
efficacy of thrombectomy. The aim of this trial was to evaluate the impact of a manual 
intracoronary aspiration thrombectomy device (Export®,Medtronic) as adjunctive therapy 
in emergency PPCI (EM-PCI) on traditional procedural outcomes as myocardial blush 
grade (MBG) and ST-segment resolution (ST-R) but also on imaging outcomes as MVO 
and IS by CMR in patients with an anterior ST elevation myocardial infarction (STEMI).  
 
6.2 METHODS 
6.2.1 Study Design and Population 
One-hundred-and seventy-five consecutive patients admitted with STEMI and candidates 
to undergo PPCI were enrolled. Patients were randomly assigned in a 1:1 manner to EM-
PCI or standard-PCI (S-PCI). In the CMR substudy, a second randomization (1:1) was 
performed within anterior STEMI patients only (Figure 6.1). All patients were pre-treated 
immediately before the revascularization with aspirin 300 mg, intravenous heparin, 
abciximab at a standard dose (weight proportional) and clopidogrel 300 mg. Following a 
wire being passed across the lesion thrombectomy was performed by more than two 
Chapter 6  EXPIRA Trial 
 
97 
 
passages of the aspiration catheter across the lesion. Subsequently patients received aspirin, 
Clopidogrel (12 months), nitrates, beta-blockers, ACE inhibitors and statins. 
The protocol was accepted by the institutional ethical board, and was performed in 
accordance with the Declaration of Helsinki. All patients provided written informed 
consent. The inclusion criteria were: STEMI within 9 hours from symptoms onset, infarct 
related artery 2.5 mm in diameter, TIMI≤1, and age >18 years. 
Exclusion criteria were: previous PCI on infarct-related artery, previous myocardial 
infarction, previous coronary artery bypass grafting, cardiogenic shock, three vessel 
disease, left main stem disease, severe valvular heart disease, thrombolysis, 
contraindication to GP IIb/IIIa inhibitors.. 
 
 
Figure 6.1. EXPIRA study design, comprehensive of the CMR substudy.  
 
 
 
6.2.2 Angiographic and ECG Analysis  
TIMI flow grade and MBG were estimated visually by two experienced observers, as 
previously described.
7,8
 Thrombus burden at lesion site was graded from 0 to 5 according 
to the Thrombus Score.
9
 Inter- and intraobserver coefficients of variation assessed in 20 
randomly selected patients were 8% and 5% for MBG, 5% and 3% for TIMI. All patients 
underwent a 12-lead ECG at baseline and 90 minutes after revascularization. ST-segment 
resolution (ST-r) was measured as previously described.
10
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6.2.3 CMR Protocol 
CMRI was performed at day 3 to 5 after PPCI and at 3 months using a 1.5-T scanner 
(Avanto Siemens, Germany). Left ventricular function was assessed by standard steady-
state free precession technique. Consecutive short-axis views were obtained by 
encompassing the left ventricle from base to apex; vertical and horizontal long-axis views 
were acquired. Typical image parameters were: TE=1.6ms, TR=3.2ms, =60 degrees, 
matrix=256x256, slice thickness 8mm, gap 2mm.  
Rest myocardial perfusion was evaluated with a first-pass technique using a T1-weighted 
multishot gradient-echo echo planar inversion-recovery sequence (TR=6.6ms, TE=1.3ms, 
TI=240ms, 25° flip angle, slice thickness 10mm). Three short-axis slices (basal, mid-cavity 
and apical levels) were obtained injecting 0.1 mmol/kg of gadolinium-BOPTA (Multihance, 
Bracco, Italy) at 2mL/sec followed by 20mL saline flush in the right anterocubital vein. CMR 
images were acquired in long- and short-axis views with a segmented inversion-recovery fast 
gradient echo sequence 15 minutes after contrast injection. Sequence parameters were: TR= 
~9 ms,  23 raw data lines per alternate cycle, TE=3.8ms, =25 degrees, slice thickness 8mm, 
gap 2mm. The inversion time was progressively optimized to null normal myocardium. 
 
6.2.4 CMR Image Analysis 
All measurements were performed by two fully blinded operators using an off-line 
dedicated workstation (Siemens Argus). Left ventricular ejection fraction, end-diastolic 
and end-systolic volumes and LV mass were calculated from the short-axis views. 
MVO and IS were quantified by manual drawing the regions of hypointensity on the first-
pass perfusion images and the regions of hyperintensity on the CMR short-axis slices, 
respectively. MVO was included in the infarcted area. MVO and IS are expressed in grams 
(assuming 1.05 g/ml the specific gravity of the myocardium) and as a percentage of the LV 
mass. Inter- and intraobserver coefficients of variation, assessed in 20 randomly selected 
patients, were 3% and 1% for MVO, 3% and 2% for IS, respectively.  
 
6.2.5 Clinical Follow-up and End-Points  
Clinical follow-up was performed at 9 months in all patients to assess the occurrence of the 
following major adverse coronary events (MACE): cardiac death, non fatal reinfarction, 
target vessel revascularization. The incidence of stent thrombosis was also evaluated. 
Primary study end-points were the occurrence of final MBG ≥2 and the rate of ST-r.  
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End-points of the CMR substudy were the presence and extent of MVO in the acute phase 
and IS extent at 3 months.  
 
6.2.6 Statistical Analysis 
We estimated that 45 patients would be required in each study group to have a power of 
80% to detect an absolute difference in the occurrence of MBG ≥2 of 30% with a two-
sided alpha value of 0.05. Categorical variables were analyzed by the chi-square or Fisher 
exact test, as appropriate. All continuous variables were expressed as mean ± SD and 
analyzed by Student t test. Event-free survival curve for MACE was constructed using 
Kaplan-Meier method, and statistical differences between curves were assessed by log-
rank test. Statistical analysis was performed with StatView, version 5.0 (SAS Institute, 
Cary, North Carolina). 
 
6.3 RESULTS 
6.3.1 Baseline Characteristics 
Two-hundred-fifty-six consecutive STEMI patients were recruited and 81 patients were 
excluded (Figure 6.1). Clinical and angiographic characteristics of EM-PCI and S-PCI are 
shown in Table 6.1 and Table 6.2. 
 
6.3.2 Angiographic and Periprocedural Findings 
EM-PCI showed a significant reduction of the thrombus burden (TS 0-1: EM-PCI, 63% vs. 
S-PCI, 42% vs., p=0.006). The rate of post-thrombectomy TIMI ≥2 was higher in EM-PCI 
(92% vs. 77%, p=.006) with a similar final rate (EM-PCI 100% vs. S-PCI 98% p=0.9) 
(Table 6.3). Primary end-points occurred more frequently in EM-PCI (MBG≥2: 88% vs. 
59%, p<0.0001; ST-r: 63% vs. 39%, p=0.001) (Table 6.3, Figure 6.2).  
 
6.3.3 Clinical Outcomes 
At 9 months no differences were observed in terms of cumulative MACE (log-rank test p= 
0.14) (Figure 6.2). However, S-PCI had a higher incidence of cardiac death (log-rank test 
p = 0.02) than EM-PCI (Figure 6.3). No stent thrombosis occurred in both groups. 
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Table 6.1 Baseline clinical and demographic characteristics of all study patients. 
 Total 
(n=175) 
S-PCI 
(n=87) 
EM-PCI 
(n=88) 
P value 
Age, yrs 65.311.2 64.612.5 66.714.1 0.298 
Males, (%) 105 (60.0) 48 (55.1) 57 (64.7) 0.218 
Risk factors 
Hypertension, (%) 
Diabetes, (%) 
Smoking, (%) 
Obesity, (%) 
Familiar history of CAD, (%) 
Cholesterol, mg/dl  SD 
Triglycerides, mg/dl  SD 
 
102 (58.3) 
37 (21.1) 
66 (37.7) 
7 (4.0) 
58 (33.1) 
16327 
12237 
 
43 (49.4) 
16 (18.4) 
23 (26.4) 
2 (2.3) 
32 (36.8) 
16715 
12526 
 
59 (67.0) 
21 (23.8) 
43 (48.8) 
5 (5.7) 
26 (29.5) 
16111 
12431 
 
0.021 
0.459 
0.003 
0.443 
0.338 
0.002 
0.817 
Renal Failure, % 14 (8.0) 7 (8.0) 7 (7.9) 1.00 
Killip class III, % 42 (24.0) 25 (28.7) 17 (19.3) 0.160 
Symptoms to balloon, hrs  SD 6.11.3 6.11.8 6.20.9 0.7 
LVEF, %  SD 4113 40.79.3 4210.5 0.192 
ST-segment elevation (mV) 22.913.5 22.39.3 23.610.5 0.384 
 
Table 6.2 Baseline procedural characteristics of all study population. 
 Total 
(n=175) 
S-PCI 
(n=87) 
EM-PCI 
(n=88) 
p value 
Location of IRA, (%) 
LAD 
LCX 
RCA 
BARI score  % 
 
76 (43.4) 
42(24.0) 
57 (32.6) 
28.9±10.3 
 
38 (43.7) 
20 (23.0) 
29 (33.3) 
28.1±9.2 
 
38 (43.2) 
22 (25.0) 
28 (31.8) 
29.7±6.1 
 
1.00 
0.859 
0.872 
0.17 
Multivessel disease, (%) 37 (26.8) 16 (18.4) 21 (23.8) 0.459 
Bifurcation, (%) 23 (13.1) 11 (12.7) 12 (13.6) 1.00 
Lesion length, mm  SD 14.55.3 14.46.6 14.7 3.9 0.714 
Vessel reference diameter, mm  SD 2.90.6 2.90.5 2.90.6 1.00 
MLD before thrombectomy, mm  SD 0.850.4 0.860.2 0.830.3 0.438 
Pre-thrombectomy Thrombus Score, (%) 
3 
4 
5 
 
18 (10.3) 
62 (35.4) 
95 (54.3) 
 
9 (10.3) 
32 (36.8) 
47 (54.0) 
 
9 (10.6) 
30 (34.1) 
48 (54.5) 
 
1.00 
0.753 
1.00 
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Table 6.3. Post-procedural angiographic characteristics of all study population. 
 Total   
(n=175) 
S-PCI 
 (n=87) 
EM-PCI 
 (n=88) 
 
p value 
       “Direct” stenting  69 (39.4) 2 (2.3) 67 (76.2) 0.0001  
Stent Type, (%) 
        Bare-Metal Stent 
        Drug-Eluting Stent 
 
73 (41.7) 
102 (58.3) 
 
34 (39.1) 
53 (60.9) 
 
39 (44.3) 
49 (55.7) 
 
0.540 
0.540 
Post-stenting MLD, mm  SD 2.90.8 2.90.7 2.90.1 1.00 
CK-MB peak, ng/ml 105125 108111 109119 0.605 
90 min ST-segment resolution, (%) 90 (51.4) 34 (39.1) 56 (63.6) 0.001 
ST-segment elevation (mV) 10.215.3 12.812.3 7.69.7 0.002 
Post-stenting TIMI flow grade, (%) 
       ≥ 2  
       0-1 
 
174(99.4) 
1  (0.6) 
 
86 (98.9) 
1 (1.1) 
 
88 (100) 
0 (0.0) 
 
0.975 
0.997 
Post-stenting MBG, (%) 
       ≥ 2  
       0-1 
 
130 (74.3) 
45 (25.7) 
 
52 (59.8) 
35 (40.2) 
 
78 (88.6) 
10 (11.4) 
 
<0.0001 
<0.0001 
 
Table 6.4.Clinical and angiographic characteristics of patients in CMR substudy. 
 S-PCI 
(n=37) 
EM-PCI 
(n=38) 
P value 
Age, yrs 55.213.7 60.79.6 0.288 
Males, (%) 81.8 90 0.593 
Risk factors 
Hypertension, (%) 
Diabetes, (%) 
Smoking, (%) 
Familiar history of CAD, (%) 
Time to balloon, (min) 
TnT levels, (ng/ml) 
Location of IRA, (%) 
LAD 
LCX 
RCA 
Other 
TIMI 3 post, (%) 
 
28.2 
9.2 
72.7 
78.9 
306108 
11245 
 
56 
0.5 
18.1 
25.4 
98 
 
59  
10.1 
60.2 
65.4 
372105 
13450 
 
42 
6 
30 
22 
97.5 
 
0.071 
0.943 
0.537 
0.269 
0.570 
0.458 
 
0.125 
0.217 
0.091 
0.875 
0.901 
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Figure 6.2 Kaplan-Meier 9-month cumulative event-free survival (cardiac death, non fatal 
MI, and revascularization).  
 
 
Figure 6.3 Kaplan-Meier 9-month event free survival for end point of death.  
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6.3.4 CMR Evaluation 
Seventy-five patients underwent CMR. One patient was excluded from the analysis due to 
incomplete image acquisition (due to claustrophobia) and 2 patients declined the follow-
up scan at 3 months.  
No differences on the baseline ejection fraction, volumes and IS were observed between 
the two groups. Post-procedural rate of MBG2 and ST-r >70% was higher in EM-PCI 
(89% vs 59% and 84% vs 40%, p=0.0001, respectively). In the acute phase greater 
incidence and extent of MVO was observed in the S-PCI vs EM-PCI (72.9% vs 31.5%, 
p=0.0005 and 3.72.6g vs 1.71.9g, p=0.0003, respectively); no differences were observed 
in IS (Table 6.4) (Figure 6.4).  
 
 
 
Table 6.5. CMR Results. 
 
 
S-PCI 
(n=37) 
EM-PCI 
 (n=38) 
P value S-PCI 
(n=37) 
EM-PCI 
(n=36) 
P value 
                              Acute Phase         3-Month Follow-up 
 
EDV (ml) 
ESV (ml) 
EF (%) 
IS (%) 
IS (g) 
MVO(n) 
MVO (g) 
 
137.5±18.6 
77.4±15.4 
44.3±9.5 
13 6.7 
147.5 
27 (72.9%) 
3.7±2.6 
 
131.5±14.4 
71.3±17.3 
46.3±8.6 # 
14±12 § 
17±15* 
9 (31.5%) 
1.7±1.9 
 
0.1 
0.1 
0.3 
0.6 
0.2 
0.0005 
0.0003 
 
144.5±20.3 
76.1±16.5 
46.7±10.6 
11 8.7 
13 12 
- 
- 
 
136.2±19.9 
69.3±17.7 
49.0±9.3 # 
9 4.5§ 
118.7* 
- 
- 
 
0.08 
0.09 
0.3 
0.2 
0.4 
- 
- 
#0.08; § p=0.001;*p=0.004. 
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Figure 6.4. Infarct size and MVO by CMR in the two groups. 
 
 
 
At 3 months a reduction in final IS was detected in EM-PCI (IS mass from 1715g to 
118.7g; p=0.004; IS% from 1412% to 94.5%, p=0.001) whereas no changes were 
observed in S-PCI. MVO was not observed in either group at follow-up. 
However, when comparing infarct size between the 2 groups, a non significant difference was 
found both at baseline, and at follow-up.  
 
6.4 DISCUSSION  
In accordance with previous data
2,3,4
 manual thrombectomy improves MBG and increases 
ST-segment resolution in selected STEMI patients with angiographically visible 
thrombus. The present study showed a lower incidence and extent of MVO after 
recanalization and a reduced IS at 3 months in patients undergoing thrombectomy as 
compared to standard-treated group. To our knowledge this is the first study evaluating 
the effects of thrombectomy on MVO and IS using CMR.  
CMR is a non-invasive and high resolution imaging modality that identifies myocyte 
necrosis (IS) and microvascular damage (MVO) providing in-vivo tissue characterization 
in patients with myocardial infarction.
5,6,11
 Poor contrast penetration due to microvascular 
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damage reflects the complex pathophysiological mechanisms of no-reflow, from 
endothelial cell swelling and contracture to microvascular plugging and microemboli of 
atherosclerotic debris.  
Restoration of epicardial coronary blood flow by PPCI is highly successful in patients 
with acute myocardial infarction; however, this is not always followed by restoration of 
microvascular perfusion. Mechanical thrombus removal followed by direct stenting may 
explain the better results obtained in EM-PCI group. Conversely, mechanical damage 
occurring during pre-dilatation may explain the higher incidence and extent of MVO and 
IS detected in standard-treated patients.  
Infarct shrinkage at five months was reported by Ingkanisorn
12
 and Baks
5
 (34% and 31% 
decrease in infarct size, respectively). In our study infarct size decreased at 3 months by 
35% in the EM-PCI group and by 7% in the S-PCI group. In this latter group, impaired 
restoration of normal blood flow may have lead to inadequate scar healing. The smaller 
definitive IS may explain the lower incidence of MACE and the higher survival observed 
in EM-PCI group. Recently the TAPAS trial showed a surprisingly low rate of death in 
thromboaspiration group at 30 days and at 1 year follow-up.
13
 Improved myocardial 
reperfusion and higher infarct shrinkage achieved in EM-PCI group is likely related to a 
protective effect of thrombus aspiration on microvascular flow and might explain the 
significant lower incidence of cardiac death in the Export pre-treated patients. These 
findings are valuable despite the fact that the study was not powered to assess MACE.  
In this cohort of patients we did not observed significant LV remodeling at 3 months. In 
agreement with Galiuto
14
, there was a trend toward higher increase in end-diastolic 
volumes in S-PCI group. However, in our study population IS was relatively small; prompt 
revascularization and use of state-of-the-art pharmacological therapy could partially 
account for this. In conclusion, the most interesting findings of the study are a lower 
incidence of microvascular obstruction, and greater infarct shrinkage in the thrombectomy 
group compared to standard PCI suggesting a role of the microcirculation in infarct healing 
and particularly in infarct shrinkage. This latter aspect is further investigated in Chapter 7.  
 
6.4.1 Study Limitations  
This study represents a single-centre experience in a limited number of patients. 
Assessing MVO only on the 3 short-axis rest perfusion slices (basal, mid and apical) is 
likely to underestimate size of MVO. Some Authors have recently observed the presence 
of MVO in the delayed enhancement images.
15
 However, the classical definition of MVO 
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by CMR is based on the images acquired early after contrast injection (either first-pass 
imaging, as used in this study, or images acquired 1-3 minutes after contrast injection
6
, 
MVO represents areas of poor contrast penetration but these areas usually ‘fill-in’ with 
time. Therefore assessing MVO in the late images could also potentially underestimate the 
areas of MVO. In fact, in the time frame of 15 minutes (as opposed to 1-3 minutes), these 
areas of poor contrast penetration could ‘fill-in’ with contrast. In conclusion, both methods 
(first pass perfusion with 3 representative short-axis slices or complete short-axis stack 
acquired at 15minutes after contrast injection) present some advantages and limitations.  
Also, the limited number of patients recruited in the study and the relative small infarct size 
observed at baseline could account for the detection of a non-significant difference in infarct 
size between the 2 groups. Only patients with LAD infarcts were recruited in the CMR 
substudy and the results of the study should be therefore confined to this patients’ population, 
and not necessarily applicable to patients with infarcts in other coronary territories.  
  
 
6.4.2 Conclusions  
Manual aspiration thrombectomy preserves microvascular integrity and reduces final 
infarct size (greater infarct shrinkage) after STEMI, thus it may represent a useful adjunct 
to pharmacotherapy. Based on these findings, CMR could provide a very useful tool for 
large clinical trials on adjunctive therapies in PPCI. 
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CHAPTER 7 
MICROVASCULAR DYSFUNCTION AFTER PCI BY CMR PERFUSION AND LATE 
GADOLINIUM ENHANCEMENT IMAGING.  
IMPACT ON INFARCT HEALING AND LEFT VENTRICULAR REMODELLING 
 
7.1 INTRODUCTION 
Timely restoration of normal antegrade flow and tissue-level perfusion are both key factors in 
the reduction of mortality in ST-segment elevation myocardial infarction (STEMI). Despite 
restoration of epicardial blood flow with primary percutaneous
 
coronary intervention (PCI), 
microvascular obstruction with reduced myocardial perfusion occurs in a large proportion of 
patients, contributing to increased infarct size, left ventricular (LV) remodelling and reduced
 
survival.
1,2,3
 Cardiovascular magnetic resonance (CMR) can  delineate with high resolution 
the presence and extent of infarct size and microvascular injury, both in patients with acute 
and chronic ischemic heart disease.
4
 The ability of CMR to identify infarcted and viable 
myocardium, microvascular damage and to perform sequential measurements of ventricular 
volumes, suggests that a great potential of this imaging technique to provide important 
insights into the pathophysiology of infarct healing and LV remodeling. Two methods have 
been described for the detection of microvascular obstruction using gadolinium-enhanced 
CMR: first-pass perfusion
5,6
 and late gadolinium enhancement (LGE)
7
. Currently, there is no 
consensus on the best technique to use and a number of clinical studies have used one or 
other
3,8,9,10,11,12,13
 or, in few cases, both techniques,
14,15,16,17,18
 yielding conflicting results on 
the significance and extent of microvascular obstruction by CMR.  
Furthermore, the time course of microvascular damage, infarct size, infarct healing and LV 
remodelling after acute myocardial infarction (AMI) has not yet been completely clarified. 
Understanding the natural course of infarct healing and the effect of early reperfusion on 
ischemic myocardium might contribute to the understanding and development of new 
therapies for ischemic heart disease. 
The purpose of the present study was to evaluate the predictive value of CMR characteristics 
of microvascular injury on recovery of global and regional LV function, and LV remodeling 
after primary PCI followed by optimal pharmacological treatment. In addition we sought to 
investigate the time-dependent complex relationship between microvascular dysfunction, 
infarct healing, and LV remodelling.  
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7.2 METHODS 
7.2.1 Study Design and Population 
This is a single-centre, prospective study on the impact of microvascular dysfunction on 
infarct healing and left ventricular remodelling.  
From February 2008 to March 2009 we prospectively enrolled forty-one consecutive patients 
presenting with a first STEMI undergoing primary PCI presenting at S.Donato Hospital in 
Arezzo, Italy. Inclusion criteria were: (1) confirmed first AMI and (2) successful primary 
coronary angioplasty, defined as Thrombolysis in Myocardial Infarction trial [TIMI] flow 
grade 3 and residual stenosis (<30%) within 6 hours of the onset of symptoms or between 6 
and 24 hours if there was evidence of continuing ischaemia.  
Exclusion criteria were (1) IRA diameter stenosis <70% with TIMI grade 3 flow, or inability 
to identify IRA, (2) unsuccessful primary PCI, (3) rescue or facilitated PCI, (4) previous 
myocardial infarction, (5) significant other cardiac disease, (6) life-limiting non-cardiac 
disease, (7) contraindications to CMR (claustrophobia, pacemaker, implantable cardioverter 
defibrillator, cerebral clips). Other exclusion criteria were the absence of an optimal 
echocardiographic apical view and the presence of hemodynamic instability at the time of 
CMR. No upper age limit was used. Echocardiographic acoustic window was assessed in the 
emergency department or in the cath-lab by a cardiologist before the procedure. Patients with 
a poor image quality were not enrolled in the study. All participants gave written informed 
consent to the protocol and the study was approved by the local Ethics Committee.  
Angiographic markers of epicardial flow and tissue-level perfusion were assessed on 
completion of diagnostic coronary angiography and shortly after PCI. Blood samples for 
cardiac troponin (TnI), creatine kinase (CK), and CK-MB levels were obtained on admission 
and every 6 hours thereafter up to 48 hours and at 6, 12, 18, and 24 hours after PCI.  
Serial 2-dimensional echocardiographic and CMR studies were performed in each patient at 
baseline after PCI, at 1 month and at 6 months after the index infarction 
 
7.2.2 CMR Protocol 
CMR was performed 5 ± 2 days after primary PCI, at 1 month and at 6 months using a 1.5 
Tesla scanner (Signa CV/I, GE Medical Systems, Milwaukee, Wisconsin) with a cardiac 
dedicated 4-channel phased array receiver surface coil. 
A breath-hold steady-state free-precession (SSFP) pulse sequence with standard parameters 
was used to evaluate regional and global left ventricular function. A stack of short-axis 
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images were obtained encompassing the left ventricle from base to apex (typically 9-12 
images), in addition to 2 long-axis views (vertical and horizontal long-axis views). Slice 
thickness was 8 mm with a slice gap of 2 mm. The matrix and field of view were 256 × 160 
and 360 to 400 mm, respectively.  
Rest myocardial perfusion was evaluated with a first pass technique using a single shot 
spoiled gradient echo pulse sequence (slice thickness 10 mm) during 40-50 consecutive 
heartbeats. Three short-axis slices (basal, mid cavity, and apical levels) were acquired 
injecting 0.1 mmol/kg of gadolinium-BOPTA (Multihance, Bracco, Milan, Italy) at 3 ml/s 
followed by 20 ml saline flush in the right anterocubital vein. 
Late gadolinium enhancement (LGE) images were obtained using an inversion recovery 
prepared breath-hold gradient-echo technique 15 minutes after contrast injection. Typical 
image parameters were flip angle 25°; slice thickness 8 mm; slice gap 2 mm; number of 
excitations 1; matrix 256 × 192, field of view ranging from 340 to 400 mm.  The inversion 
time was progressively optimized to null normal myocardium. Cine and LGE images were 
acquired at the same long- and short-axis slice position.  
 
7.2.3 CMR Image Analysis 
All measurements were performed by an expert operator blinded to clinical, angiographic, and 
echocardiographic data. Quantitative analysis was performed using a semi-automated 
software program (CMRtools, Cardiovascular Solutions, London, UK). Quantitative LV 
volumes, LVEF and LV mass were calculated from the short axis views excluding the 
papillary muscles. Regional wall motion and infarct-zone wall motion score index (IZ-WMSI) 
was assessed as described for echocardiography.  
Infarct size and microvascular damage were calculated as previously described.
12,13
 
Transmural segments were defined as myocardial segments with nearly transmural (>75% 
wall thickness) myocardial infarction; infarcted segments as myocardial segments with any 
degree of myocardial infarction (from 1% to 100% wall transmurality).   
Microvascular damage was calculated in the rest first-pass perfusion images (microvascular 
obstruction, MVO) and on the LGE short-axis images (persistent microvascular obstruction, 
PMO). PMO was included in the infarcted area. MVO, PMO and IS are expressed in grams 
(assuming 1.05 g/ml as the specific gravity of the myocardium) and as a percentage of the LV 
mass. Presence and absence of MVO or PMO will be expressed as MVO+/PMO+ and MVO-
/PMO-, respectively.  
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7.2.4 Echocardiography Image Analysis   
Only one patient was excluded because of poor echocardiographic window at baseline.  
Two-dimensional echocardiographic images were analyzed by 2 readers who had no 
knowledge of the clinical, angiographic, and CMR data. Images were saved for off-line 
analysis. Regional wall motion was assessed according to the 16-segment model.
19
 For each 
segment, wall motion was scored as 1 (normal), 2 (hypokinetic), 3 (akinetic), or 4 
(dyskinetic). In each patient, an infarct-zone wall motion score index (IZ-WMSI) was derived 
by averaging the scores from each segment within the area at risk, as previously described.
20
 
LV volumes and LV ejection fraction (LVEF) were measured with the modified Simpsons 
rule algorithm.
21
 Intraobserver and interobserver variability values in the evaluation of end-
diastolic volumes were <5%, as previously reported.
20
 The definition used for LV remodelling 
was an increase of end-diastolic volume 20% at 6 months compared to baseline.1  
 
7.2.5 Statistical Analysis 
Continuous data are expressed as a mean ± SD. Baseline data were compared by means of the 
chi-squared test for categorical variables and unpaired t test for continuous variables. 
Changes in LV volumes, LVEF and IZ-WMSI (both by echocardiography and CMR) were 
analyzed by the analysis of variance (ANOVA) for repeated measurements, followed by a 
post-hoc analysis with a Bonferroni correction for differences between groups. A Student t-
test for independent groups was used to assess differences in continuous variables, while a 
Student paired-samples t-test was used to highlight differences in left ventricular parameters 
at baseline, 1 month and at 6-months. A multivariate logistic regression analysis was 
conducted in all patients considering as dependent variable the occurrence of remodelling at 
follow-up (assessed by CMR) and, on a separate analysis, the occurrence of PMO. All the 
variables presenting a significance value <0.25 at univariate analysis were included in the 
model. A linear regression analysis was used to evaluate the relationship between CMR and 
echocardiographic parameters and between the AUC CK-MB and infarct size by CMR.  
Differences were considered statistically significant at 2-sided p-value of ≤ 0.05. 
Statistical analyses were performed with SPSS software v. 15.0. 
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7.3 RESULTS 
7.3.1 Baseline Characteristics 
Of the 41 patients initially recruited, 37 patients completed the study protocol (31 men, mean 
age: 60±12 years; range: 35 to 82 years). Four patients were excluded due to incomplete 
imaging follow-up (CMR, n=2: echocardiography, n=2). 
Clinical and angiographic characteristics of patients are showed in Table 7.1. Mean ST-
segment elevation at baseline electrocardiogram was 11.8±7.5mV; time from symptoms-to 
first medical contact was 163±144min, with a door-to-balloon time of 74±37min.  
Medical therapy at discharge included beta-blockers and ACE-inhibitors (in 89% and 86% of 
patients, respectively).  
 
7.3.2 Angiographic Characteristics 
All patients included in the study had successful PCI of the infarct related artery. All patients 
had single vessel disease. In 19 patients (51%) the culprit vessel was the left anterior 
descending artery (LAD), in 16 patients (43%) the right coronary artery (RCA), and the left 
circumflex artery (LCx) in 6% (n=2) of patients (Table 7.1). TIMI flow 0 pre-PCI was 
observed in 78% of the cases and TIMI flow 3 post-PCI was achieved in 97% of patients. 
Glycoproteins IIb/IIIa inhibitors were administered in 95% of the patients. The number of 
coronary lesions was 1.3±0.5 with a mean length of 14.4±4.7mm. Complex coronary lesions 
(tandem lesions, calcification and bifurcations) were observed in 10% of patients.  
 
7.3.3 Microvascular Damage and Infarct Size by CMR  
MVO was more frequently observed than PMO (92% vs. 43% of patients, p=0.004) and 
involved a larger but non-significant myocardial extent (4.2±3.9g vs. 3.0±5.2g, respectively 
p=ns). Seventeen patients (46%) had MVO without PMO and 16 patients (43%) had MVO 
and PMO. MVO was always present in all patients with PMO. Only in four patients (11%) 
there was no MVO or PMO.  
All patients had LGE in the territory of the culprit artery representing myocardial infarction. 
At baseline mean infarct size in all patients population was 28.4±20.7g (15±10%). Infarct size 
was significantly larger in the PMO+ than in the PMO- group (42.5±22.6g vs. 17.7±10.5g, 
p<0.0001), with more total infarcted segments (n=6.6 ± 1.7 vs n=4.6 ± 2.1, p=0.005) and 
transmural infarcted segments than PMO- (n=5.3 ± 2.3 vs n=2.7 ± 2.4 p=0.002) (Table 7.2). 
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Table 7.1. Baseline demographics, clinical and angiographic characterists. 
 
 All Patients 
  
Age, y 60 ± 12 
Males 31 (84) 
Diabetes 7 (19) 
Hypertension 18 (49) 
Dyslipidemia 14 (38) 
Smokers 20 (54) 
Family history 12 (32) 
Previous CAD 3 (8) 
Previous PCI 0 
Previous CABG 2 (5) 
Killip at presentation  
           I 34 (92) 
          II 2 (5) 
          III 1 (3) 
          IV 0 (0) 
Symptom-to-balloon time, min 236 ± 155 
Symptom-first medical contact, min 163 ± 144 
Door-to-balloon, min 74 ± 37 
Peak MB, ng/ml  301 ± 265 
AUC MB   5462 ± 4562 
ST-segment elevation at baseline, mV 11.8 ± 7.5 
ST-segment elevation at 90min, mV  5 ± 4.7  
TIMI pre PCI  
          0 29 (78) 
          1  4 (11) 
          2 4 (11) 
          3 0 
Glycoprotein IIb/IIIa 35 (95) 
Culprit vessel, n  
        LAD 19 (51) 
        LCx  2 (6) 
        RCA 16 (43) 
Angiographic no-reflow 8 (22) 
TIMI post PCI  
          0 0 
          1 0 
          2 1 (3) 
          3 36 (97) 
Beta-blockers at discharge 33 (89) 
ACE inhibitors at discharge 32 (86) 
  
Data are expressed as mean ± SD or numbers and percentage (%). 
CAD= coronary artery disease; PCI= percutaneous coronary intervention; CABG= coronary artery bypass 
surgery; AUC MB= area under the curve CK-MB; TIMI= Thrombolysis in Myocardial Infarction; LAD=left 
anterior descending coronary artery; LCx= left circumflex coronary artery; RCA= right coronary artery 
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Table 7.2. CMR characteristics of patients with and without persistent microvascular 
obstruction.  
 
 PMO-  PMO+ P value 
 n=21 
 
n=16  
    
Patients with transmural infarct (>51%), n 13 (62) 15 (94) 0.06 
Infarcted segments, n 4.6 ± 2.1 6.6 ± 1.7 0.005 
Transmural segments (>51%), n 2.7 ± 2.4 5.3 ± 2.3  0.002 
Segments with PMO, n 0 3.1 ± 1.8 0.0001 
MVO size, g 1.7 ± 1.4 5.6 ± 3.8 0.0003 
PMO size, g 0 6.9 ± 6.1 0.0001 
    
Baseline CMR    
EDV, mL 136 ± 34 146 ± 23 ns 
ESV, mL 58 ± 22 68 ± 16 ns 
EF, % 58 ± 9 53 ± 8 ns 
IZ-WMSI   1.8 ± 0.6 2.3 ± 0.7 0.008 
IS, g 16.9 ± 10.4 42.5 ± 22.6 0.0001 
IS, % LV 10.0 ± 6.2 22.3 ± 11.0 0.0001 
    
 CMR at 1 month    
EDV, mL 132 ± 36 155 ± 24 0.01 
ESV, mL 51 ± 23 75 ± 23 0.001 
EF, % 62 ± 10 52 ± 11 0.005 
IZ-WMSI 1.5 ± 0.6 2.2 ± 0.6 0.006 
IS, g 12.7 ±8.0 31.7 ± 18.0 0.001 
IS, % 8.6 ± 5.7 18.4 ± 10.6 0.001 
    
CMR at 6 months     
EDV, mL 128 ± 41 159 ± 34 0.01 
ESV, mL 50 ± 23 76 ± 33 0.006 
EF, % 63 ± 9 53 ± 10 0.008 
IZ-WMSI 1.4 ± 0.4 1.9 ± 0.8 0.008 
IS, g 12.5 ± 9.8 28.1 ± 14.8 0.001 
IS,  % 8.2 ± 6.0 16.0 ± 7.7 0.003 
 
Data are mean ± SD or number (%) of patients.  
PMO= persistent microvascular obstruction; CMR= cardiovascular magnetic resonance; IS=infarct size; EDV= end-diastolic 
volume; ESV= end-systolic volume; EF= ejection fraction; WMS= wall motion score; WMSI= wall motion score index; IZ-
WMSI= infarct zone wall motion score index.  
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7.3.4 Microvascular Damage and Infarct Size by CMR versus Biomarker, 
Electrocardiographic and Angiographic Measures  
Infarct size by CMR correlated with peak serum creatine kinase level (r=0.7, p<0.0001). 
There was a moderate correlation between the presence of PMO and baseline infarct size 
(Spearman ρ=0.64, p<0.001); a weaker correlation was observed with MVO (Spearman 
ρ=0.48, p=0.002). There was a statistically significant relation between MVO and PMO and 
TIMI frame count (p=0.03 and p=0.03, respectively), but not with TIMI flow grade. Infarct 
size by CMR correlated with baseline ST-elevation (r=0.49, p=0.002), ST-elevation at 90min 
(r=0.45, p=0.005) and ST-elevation at 180min (r=0.59, p<0.001). The presence of PMO was 
related to incomplete ST segment resolution (p=0.03), whereas no significant correlation was 
found with MVO.   
 
Table 7.3. Clinical, angiographic characteristics of patients with and without persistent 
microvascular obstruction.  
 
 PMO-  PMO+ P value 
 n=21 
 
n=16  
    
Symptoms-to-balloon, min 209.4 ± 127.3 270.0 ± 185.0 ns 
Door-to-balloon, min 69.0 ± 33.0 78.0 ± 42.0 ns 
Symptoms-FMC, min 140 ± 118 192 ± 171 ns 
Killip Class, n 
            1 
            2         
 
20 (95) 
1 (5) 
 
14 (88) 
2 (12) 
 
ns 
ns 
TIMI pre PCI, n 
            0    
            1   
            2   
 
14 (67) 
3 (14) 
4 (19) 
 
15 (94) 
1 (6) 
0 
 
0.01 
ns 
0.03 
TIMI post PCI, n 
            3 
            2       
 
21 (100) 
0 
 
15 (94) 
1 (6) 
 
ns 
ns 
TFC, frames 14.6 ± 5.2 16.8 ± 7.4    ns 
cTFC, frames 11.0 ± 2.7   12.6 ± 4.7   ns 
AUC CK-MB 3904 ± 1223         7409 ± 2321     0.02 
Patients with >75% ST elevation at 180min, n 13 (62) 8 (50) ns 
 
Data are mean ± SD or number (%) of patients.  
FMC= first medical contact; TIMI= Thrombolysis in Myocardial Infarction; PCI= Primary Coronary Intervention;  
TFC= TIMI Frame Count; AUC MB= Area under the Curve MB;  
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When grouping patients based on the presence and absence of PMO (PMO+ and PMO-, 
respectively), patients PMO+ presented more frequently with TIMI 0 flow pre-PCI, larger 
AUC of CK-MB. Symptom-to-balloon and door-to-balloon time were not different between 
patients PMO+ and PMO- (Table 7.3).  
 
7.3.5 LV Function and LV Remodelling by Echocardiography 
At baseline, patients PMO+ showed an increased end-systolic volume (ESV) (59±13 ml vs. 
49±15 ml, p=0.03) and more impaired systolic function compared to PMO- (LVEF 50±5 % 
vs. 55±7%, p=0.03). No differences in EDV and IZ-WMSI between the two groups were 
detected at baseline (Table 7.4). LV remodelling was observed in 20% of the overall patient 
population. At 1- and at 6-month follow-up, LV volumes were consistently larger in the 
PMO+ group.  
 
Table 7.4. Baseline, 1 month and 6 months echocardiography in patients with and 
without persistent microvascular obstruction.  
 
 PMO-  PMO+ P value 
 n=21 
 
n=16  
Echo at Baseline     
EDV, mL 109 ± 28 119 ± 20 ns 
ESV, mL 49 ± 15 59 ± 13 0.03 
EF, % 55 ± 7 49 ± 5 0.03 
IZ-WMSI   2.0 ± 0.3 2.1 ± 0.4 ns 
    
 Echo at 1 month    
EDV, mL 108 ± 31 134 ± 25 0.01 
ESV, mL 47 ± 21 67 ± 21 0.01 
EF, % 57 ± 9 51 ± 8 0.03 
IZ-WMSI 1.5 ± 0.6 1.9 ± 0.6 0.03 
    
Echo at 6 months     
EDV, mL 108 ± 35 137 ± 28 0.008 
ESV, mL 47 ± 22 71± 24 0.005 
EF, % 57 ± 8 50 ± 9 0.01 
IZ-WMSI 1.4 ± 0.5 1.7 ± 0.7 ns 
    
EDV= end-diastolic volume; ESV= end-systolic volume; EF= ejection fraction; IZ-WMSI= infarct zone wall motion score 
index.  
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From baseline to 1-month and 6-month follow-up, a greater improvement in LVEF was 
observed in the PMO- group compared with patients PMO+ (from 55±7% to 57±9% to 
57±7% vs 50±5% to 51±8 to 50±9%, p=0.009 by ANOVA) (Figure 7.1). Accordingly, a 
significant increase in EDV (119±20mL to 134±25mL to 137±28mL vs 109±28mL to 
108±31mL to 108±35mL, p=0.02 by ANOVA) and a significant increase in ESV (59±13mL 
to 67±21mL to 71±24mL vs 49±15mL to 47±21mL to 47±22mL, p= 0.006 by ANOVA) were 
observed in the PMO+ group compared to PMO-. No significant changes in IZ-WMSI were 
detected.  
 
 
Figure 7.1 Serial LV volumetric evaluation by echocardiography.  
 
 
7.3.6 LV Function and LV Remodelling by CMR 
At baseline, there was no significant difference in LV function between the PMO+ and PMO- 
group, except for a lower IZ-WMSI in the PMO+ group (p=0.008) (Table 7.2).  
From baseline to 1-month and 6-month follow-up, a greater improvement in LVEF was 
observed in the PMO- group compared with patients PMO+ (from 58±9% to 62±10% to 
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63±9% vs 53±8% to 52±11 to 53±10%, p=0.01 by ANOVA). Accordingly, a significant 
increase in EDV (146±23mL to 155±24mL to 159±34mL vs 136±34mL to 132±36mL to 
128±41mL, p=0.03 by ANOVA) and a significant increase in ESV (68±16mL to 75±23mL to 
76±33mL vs 58±22mL to 51±23mL to 50±23mL, p= 0.007 by ANOVA) (Figure 7.2) were 
observed in the PMO+ group compared to PMO-. IZ-WMSI progressively improved over 
time in the 2 groups. However, in PMO- the improvement started to occur at 1 month (from 
1.8±0.6 baseline to 1.5±0.6 1 month, p=0.03), and continuing to improve significantly at 6 
months (1.5±0.6 1 month to 1.4±0.4 6 months, p=0.02).   
In PMO+ improvement of IZ-WMSI was observed only later at 6 months (from 2.3±0.7 
baseline to1.9±0.8 6 months, p=0.04). No significant improvements were seen between 
baseline-1 month and 1 month-6 months follow-up.   
 
 
Figure 7.2 Serial LV volumetric evaluation by CMR. 
 
 
A significant strong correlation between CMR and echocardiography in the assessment of 
EDV (r=0.8, p<0.0001), ESV (r=0.9, p<0.0001), LVEF (r=0.9, p<0.0001) and wall motion 
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score index (WMSI) (r=0.8, p<0.0001) was demonstrated (Figure 7.3). A good agreement 
between the two techniques was also observed in the Bland-Altman analysis (Figure 7.4)  
 
 
Figure 7.3. Echocardiography vs CMR on the evaluation of LV volumes, systolic function and 
regional wall motion abnormalities. There is a good correlation between the two techniques 
in assessing global and regional left ventricular function.  
 
 
7.3.7 Predictors of LV Functional Recovery and Remodeling 
The predictors of LV remodeling at the univariate analysis were baseline CMR ESV and 
EDV, baseline infarct size (%), presence of PMO, presence of diabetes and ST deviation at 
baseline. PMO+ was the strongest predictor of LV remodeling (p=0.032) followed by ST 
deviation at baseline (p=0.037) (Table 7.5).   
Among all the parameters considered the presence of microvascular obstruction (MVO) at 
first-pass perfusion, TIMI pre and TIMI post were not predictive of LV remodeling. In fact, 
MVO was observed in the majority of patients (92%), and TIMI 3 post-PCI achieved in 97% 
of the cases.  
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Figure 7.4. Bland-Altman analysis of echocardiography vs CMR.  
 
 
 
Table 7.5. Multivariate baseline predictors of LV remodeling. 
 
Variable Odds Ratio* 
(95% CI) 
p Value 
CMR EDV1, mL 0.950 (0.865-1.043) 0.2838 
CMR ESV1, mL 1.004 (0.882-1.144) 0.9469 
Infarct size, % 0.918 (0.772-1.092) 0.3339 
PMO+ 1010.03 (1.808- 564218.4) 0.0321 
Diabetes 7.736 (0.370-161.719) 0.1871 
ST deviation baseline 1.248 (1.013-1.537) 0.0374 
   
In bold statistical significant values.  
CMR= cardiovascular magnetic resonance; EDV1= baseline end-diastolic volume; ESV1= 
baseline end-systolic volume; PMO+= presence of persistent microvascular obstruction 
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7.3.8 Predictors of Persistent Microvascular Damage 
The parameters predicting the presence of PMO at the univariate analysis were time 
symptoms-first medical contact, baseline ESV and EF, number of infarcted segments, number 
of transmural segments and infarct size (Table 7.6). Among all these variables the only 
independent predictor of PMO at the multivariate analysis was infarct size (g) (p=0.002).  
7.3.9 Time Course of Microvascular Damage by CMR 
Although angiographic no-reflow was observed only in 8 patients (22%), microvascular 
damage by CMR (MVO or PMO) was identified in a larger percent of patients: MVO by first-
pass perfusion imaging was present in almost all patients (34/37patients, 92%) and it was 
localized in the subendocardium with a variable degree of transmural extension. This 
perfusion defect was superimposed to the infarcted area (as assessed in the subsequent LGE 
imaging), and its calculated size was 4.2±3.9g. PMO on LGE images was observed in 16 
patients (43%), located predominantly within the infarcted area and appearing as a dark inner 
core; in patients PMO+ its calculated size was 3.0±5.2g.  
MVO was larger in patients PMO+ than PMO- (5.6±3.8g vs 1.7±1.4g, p<0.0003). 
The presence of PMO was always associated with MVO at first-pass perfusion (100% of 
patients). However, not all patients with MVO showed PMO in the late images (seen in only 
53% of patients). PMO appears to be a better index of microvascular damage than MVO to 
predict LV remodelling, as demonstrated by the uni- and multi-variate analysis and with 
ANOVA.   
There was no evidence of MVO and PMO on the CMR scans at 1 month and 6 months and 
these areas of hypoperfusion were replaced by myocardial scar.  
 
 
7.3.10 Time Course of Infarct Healing by CMR 
In all patients population baseline infarct size was 28.4±20.7g and decreased significantly by 
34% at 6 months (18.8±13.3g) (p<0.0001).  
Infarct size reduction (from baseline to 1-month and 6-month follow-up) was significantly 
greater in patients PMO+ (22.3±11.0% to 18.4±10.6% to 16.0±7.7%) than in PMO- 
(10.5±6.1% to 8.6±5.7% to 8.2±6.0%) (p< 0.006 by ANOVA). Shrinkage of infarct size 
occurred mainly between baseline and 1-month follow-up (p<0.0001 in both groups), 
followed by non-significant additional changes between 1- and 6-months (p=ns in both 
groups).     
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Table 7.6. Univariate and multivariate baseline predictors of PMO.  
 
Variable Odds Ratio* 
(95% CI) 
p Value Odds Ratio† 
(95% CI) 
 
p Value 
Symptoms-FMC 1.003 (0.999-1.007) 0.173   
Door-to-balloon 0.999 (0.993-1.005) 0.677   
TIMI pre 0.774 (0.353-1.699) 0.523   
TIMI post 0.846 (0.069-10.327) 0.896   
CMR EDV1, mL 1.012 (0.989-1.035) 0.312   
CMR ESV1, mL 1.029 (0.992-1.067) 0.121   
CMR EF1, % 0.932 (0.856-1.014) 0.103   
Infarcted segments, n 1.512 (0.973-2.351) 0.066   
Transmural segments, n 1.419 (0.991-2.031) 0.056   
Infarct size, g 1.105 (1.022-1.195) 0.013 1.130 (1.047-1.220) 0.002 
Infarct size, % 1.140 (1.028-1.265) 0.013   
ST elevation at baseline 1.044 (0.953-1.144) 0.350   
>50% 90min ST resolution 1.650 (0.421-6.464) 0.472   
>75% 90min ST resolution 0.500 (0.128-1.949) 0.318   
 
*Univariate analysis; † multivariate analysis. In italics parameters that entered the multivariate analysis and in bold statistical significant values. 
FMC= First Medical Contact; TIMI= Thombolysis in Myocardial Infarction; EDV1= baseline end-diastolic volume; ESV1= baseline end-
systolic volume; EF1= baseline ejection fraction. 
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7.4 DISCUSSION  
To the best of our knowledge, this is the first in vivo, clinical and non-invasive serial 
evaluation (at baseline, 1 month, 6 months) of microvascular dysfunction and infarct size, 
their time course and impact on LV remodelling after successful primary PCI and optimal 
pharmacological treatment to prevent LV remodelling.  
The main findings of this study are that (1) CMR can detect two degrees of microvascular 
dysfunction: PMO is the most severe form, associated with larger infarct size and strongly 
related to LV remodelling; MVO of less clinical relevance because highly prevalent; (2) 
microvascular dysfunction is a dynamic process with a peculiar time course, (3) infarct 
shrinkage is a phenomenon occurring early (within the first month after the acute event) in the 
evolving phase of myocardial infarction, mirroring the resolution of microvascular 
dysfunction (4) echocardiography and CMR are equally valuable in serial LV volumetric 
evaluation but CMR, giving its unique non-invasive tissue characterization, can delineate the 
nature and extent of myocardial/microvascular damage  which play a pivotal role in LV 
remodelling.  
 
7.4.1 Patterns and Time Course of Microvascular Dysfunction 
In our patient cohort we identified 2 patterns of microvascular dysfunction: MVO at first-pass 
perfusion imaging and PMO at LGE imaging. This is the first study that analyzed both these 
aspects in 3 serial CMR scans. Other authors recently promoted the serial evaluation of 
microvascular obstruction at three different intervals (baseline, 3- and 6-months), but the 
results for the evaluation at 3 months were actually not formally presented and discussed.
22
  
The main findings of our study on microvascular dysfunction are: 1) the size of MVO was 
consistently larger than PMO; 2) all patients that had PMO, necessarily presented MVO; 3) 
the presence of MVO does not necessarily imply the presence of PMO. All these observations 
have not been completely reported previously and demonstrate that microvascular obstruction 
is a dynamic process. In fact, as time progresses (minutes) the contrast agent ultimately ‘fills 
in’ the areas of microvascular dysfunction that present reduced contrast penetration. This 
explains why the areas of PMO are smaller than MVO, but also why not all patients with 
MVO present with PMO.  
PMO was associated with larger infarct size, more transmural and infarcted segments by 
CMR, but also by clinical electrocardiographic, angiographic and biomarker measurements 
compared to MVO. This suggests that although MVO in first-pass perfusion was more 
sensitive in detecting microvascular damage, PMO had a greater clinical relevance.  
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Both MVO and PMO were detected only in the acute scan (Figure 7.4). Although this 
phenomenon was previously reported, its time course has not been completely clarified. The 
serial CMR evaluation performed in this patient cohort, demonstrated that at 1 month MVO 
and PMO were no longer present and replaced by myocardial scarring. This finding was also 
confirmed in the 6-month scan.    
Interestingly, although angiographic no-reflow was present only in 22% of the patients, 
microvascular dysfunction at a myocardial tissue level defined by imaging was identified in 
92% of the patients (when using MVO) or in 43% of the patients when considering PMO. 
This suggests that TIMI 3 flow post PCI alone it not an adequate parameter for assessing 
microvascular perfusion.   
Studies using myocardial contrast echocardiography, similarly demonstrated that among 
patients with TIMI 3 flow, the extent of microvascular damage is the most powerful 
independent predictor of LV remodelling.
23
 However, compared to CMR, this imaging 
technique is limited in the accurate delineation of complementary aspect of myocardial 
damage such as infarct size and infarct shrinkage.   
 
In the majority of previous studies MVO or PMO have been assessed qualitatively by using a 
semi-quantitative approach (score)
15,16,18,16
.
 
In this  study MVO and PMO were assessed both 
qualitatively (presence/absence) and quantitatively (planimetry, g). Whether a precise 
quantitative approach, although provides insights on the extent of microvascular damage 
within the infarcted area, has an additional value over the qualitative evaluation remains 
unclear. However, similarly to infarct size, the accurate quantification of the extent of 
microvascular damage has been previously used by our group as a useful endpoint in clinical 
trials assessing reperfusion strategies.
12,13
  
 
7.4.2 Infarct Size, Microvascular Dysfunction and LV Remodelling  
PMO was strongly associated with worse regional and global recovery, as demonstrated both 
by CMR and echocardiography. Whilst LV volumes were consistently larger, and systolic 
function more impaired, in patients with PMO+, IZ-WMSI progressively improved in both 
patients. Interestingly, a significant improvement was achieved earlier (1 month) in patients 
PMO-, whereas in PMO+ was observed later (6 months), suggesting more myocardial 
stunning in the latter group.  
Bolognese et al reported that LV remodelling occurred in a relevant proportion (30%) of 
patients with AMI successfully treated with primary PCI.
1
 In our patients cohort the percent  
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Figure 7.5 Cine and late gadolinium enhancement (LGE) CMR at baseline, 1 month and 6 
months in patient with PMO+. The area of persistent microvascular dysfunction is within the 
infarcted area (white arrows). In the follow-up scans LV volumes increased and PMO was 
not longer present and replaced by myocardial scarring.  
 
 
of LV remodelling was 20% despite the large majority of patients were treated with beta-
blockers and ACE-I. 
In our study, infarct size was the strongest predictor of persistent microvascular damage 
(PMO), which in turn predicted LV remodelling. Also, larger and more transmural infarcts are 
more likely to present microvascular damage. These findings confirm the important 
relationship between infarct size, microvascular dysfunction and LV remodelling previously 
observed with CMR.
11,11,18
  
Echocardiography and CMR were equally valuable techniques to assess LV volumes and LV 
remodelling. Whilst echocardiographic is a widely available and can be performed at the 
Chapter 7  MVO, Healing and Remodelling  
 
126 
 
bedside, CMR has the intrinsic advantage of proving high resolution delineation of infarct 
size and microvascular dysfunction which are important determinants of LV remodelling.  
 
7.4.3 Infarct Healing  
Infarct healing is a dynamic process during which the necrotic tissue is replaced by 
collagenous contracted scar. Some of the underlying mechanisms are represented by the 
retraction of the collagen fibres, along with the “overestimation” of acute infarct size due to 
the myocardial oedema/inflammation and microvascular damage within the infarct zone, as 
earlier suggested by Reimer and Jennings.
24
 Although infarct healing is a complex process, 
infarct shrinkage (infarct remodelling) could be considering a surrogate.   
In our study group, infarct size decreased by 34%. This is in agreement with previous reports:  
Hombach reported an infarct size reduction of 31%
7
, Baks 31% reduction at 5 months
9
; 
Inkangison and Choi found a reduction of 31% and 27%, respectively.
25,26
 
However, two novel aspects of our study are that 1) we investigated the time course of infarct 
healing at two different points in time (1 month, 6 months), 2) we studied the impact of 
microvascular dysfunction on infarct healing. The time frame of infarct healing was similar 
between the two groups, occurring at 1 month. However, the percentage of infarct size 
reduction was greater in patients with PMO+. No additional significant changes in infarct 
healing were observed between 1 and 6 months. Interestingly, 1 month after the acute event 
also coincides with the resolution of microvascular obstruction and its evolution into 
myocardial scarring was also completed.  
Our results complement previous findings that in patients PMO+ a significant reduction of 
infarct size was only observed between 1 week and 2 months.
18
 This study is the first to 
demonstrate that infarct size reduction was greater in patients PMO+ than in patients without 
microvascular obstruction. This finding is consistent with the overestimation of infarct size in 
the acute phase, followed by the repair of microvascular damage and evolution in myocardial 
scarring.  
 
7.4.4 Clinical Implications 
CMR can identify and quantify areas of microvascular and myocardial damage in patients 
with STEMI treated with primary PCI. LV remodelling occurs in a significant percentage of 
patients despite successful recanalization of the IRA, restoration of perfusion at myocardial 
tissue level and optimal pharmacological treatment.  
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Microvascular damage as assessed by CMR is an important determinant of LV remodelling 
and infarct shrinkage, which occur at specific time frames. CMR could therefore provide 
potentially valuable endpoints for clinical trials that aim to assess the efficacy of different 
reperfusion strategies. 
 
7.4.5 Study Limitation 
The study was a single centre with limited patient population and the results should be 
confirmed in larger clinical studies. Due to the small sample size, we did not have adequate 
power to examine clinical endpoints and to directly compare the prognostic value of PMO and 
MVO. However, serial CMR examinations allowed us to assess the temporal course of 
microvascular dysfunction and the relative role of PMO and MVO in predicting functional 
recovery and LV remodeling.  
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CHAPTER 8 
CARDIOVASCULAR MAGNETIC RESONANCE GUIDANCE FOR RECANALIZATION OF 
CORONARY CHRONIC TOTAL OCCLUSION  
 
 
8.1 INTRODUCTION 
One or more coronary chronic total occlusions (CTO) are identified in approximately one 
third of diagnostic coronary angiograms in patients with known or suspected coronary artery 
disease (CAD).
1,2
 The benefits of percutaneous coronary intervention (PCI) of a CTO are 
controversial for three main reasons: first, PCI of a CTO is technically challenging for the 
interventional cardiologist, with a lower success rate than achieved in other coronary lesions; 
secondly, the OAT trial demonstrated a lack of benefit of PCI versus medical therapy in 
patients with an occluded infarct-related artery.
3
 However, these results cannot be widely 
applied to patients with CTO (occlusion duration  3 months) because the OAT patient cohort 
presented with an occluded infarct-related coronary artery 3 to 28 days after acute myocardial 
infarction, and PCI was not guided by the presence of residual myocardial viability and 
ischemia; thirdly, the procedure can last several hours with significant radiation exposure, 
contrast dose and cost. Selection criteria aimed at identifying patients who can benefit from 
PCI of CTO have not yet been proposed. Cardiovascular magnetic resonance (CMR) is a high 
resolution non-invasive imaging technique that can assess regional and global left ventricular 
(LV) function, and detect the presence and the extent of infarction and ischemic burden. We 
therefore hypothesised that CMR could improve the selection of patients suitable for PCI of 
CTO. 
 
 
8.2 METHODS 
8.2.1 Study Design and Population 
This was a single-centre, prospective study of patients with a CTO considered suitable for 
recanalization following coronary angiography. CTO was defined as the presence of TIMI 0 
flow within the occluded artery with an estimated occlusion duration of  3 months, as 
suggested in the EuroCTO Club consensus document.
4
 CMR was performed 1 month before 
intervention and 3 months after recanalization. The CMR criteria for proceeding to 
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revascularization were: 1) a majority of the segments in the CTO territory had <75% 
transmural extent of infarction by late gadolinium enhancement (LGE) and 2) inducible 
myocardial ischemia was present in the CTO territory. Myocardial segments were assigned to 
coronary arteries as described in the American Heart Association 17 segment model, with 7 
segments for the left anterior descending artery (LAD), 5 for the right coronary artery (RCA) 
and 5 for the left circumflex artery (LCx).
5
 If the LCx was dominant, 2 inferior segments were 
reassigned from the RCA to the LCx. Of the 52 patients initially recruited, 32 completed the 
study. The patient flow in the study is summarized in Figure 8.1. Exclusion criteria were: 1) 
significant other cardiac disease, 2) eGFR <30mL/min, 3) contraindications to CMR (eg; 
claustrophobia, pacemaker, implantable cardioverter defibrillator, cerebral clips), 4) 
contraindication to adenosine (eg; severe asthma, >first degree heart block). All participants 
gave written informed consent and the study was approved by the local Ethics Committee.  
 
 
 
Figure 8.1. Patients flow in the study. 
 
 
 
Chapter 8  CMR in CTO 
 
132 
 
8.2.2. CMR Image Acquisition 
CMR was performed in a 1.5T scanner (Avanto, Siemens) with a dedicated cardiac 8-channel 
phased array receiver surface coil. Cine images were obtained with a steady-state free-
precession (SSFP) sequence in 2 long-axis and multiple contiguous short-axis views 
encompassing the left ventricle (LV) from base to apex.  Typical image parameters were: TE 
1.6ms, TR 3.2ms, time per cine frame 51ms,  60 degrees, matrix 256x256, slice thickness 
8mm, gap 2mm. First-pass stress perfusion imaging was performed using a 3-slice (basal, 
mid-cavity and apical views) hybrid-EPI sequence with T-SENSE (TR 5.8ms, TI 110-140ms, 
FOV 360x270mm, voxel size 2.8 x 2.8 x 10mm) over 50 consecutive cardiac cycles. The 
images were acquired after 4 minutes of 140µg/kg/min adenosine infusion and following the 
injection of 0.1mmol/kg of Gd-DTPA. Late gadolinium enhancement (LGE) images were 
acquired 10-15 minutes after gadolinium injection in long and short-axis planes, using a 
segmented inversion recovery gradient echo sequence (TR 600ms, TE 3.8ms,  25 degrees, 
slice thickness 8mm, gap 2mm, typical pixel size 1.7 x1.4mm).
6
 The inversion time was 
progressively optimised and adjusted to adequately null normal myocardium (typical values 
320-440ms). Cine and LGE images were acquired at the same long- and short-axis slice 
position. Finally, first-pass rest perfusion images were acquired >20 minutes after stress 
perfusion imaging.  
 
8.2.3. CMR Image Analysis   
Image analysis was performed by an experienced operator blinded to the clinical and 
angiographic data, using semi-automated software (CMRtools, Cardiovascular Imaging 
Solutions, London, United Kingdom). Quantitative LV volumes, LV ejection fraction (EF) 
and LV mass were calculated from the short axis views excluding the papillary muscles. The 
images were assessed according to the AHA/ACC 17 segment model.
5
 For each segment, 
wall motion was scored as 0 (normal), 1 (mildly hypokinetic), 2 (severely hypokinetic), 3 
(akinetic), or 4 (dyskinetic). Infarcted myocardial mass was calculated from the LGE images. 
Myocardial regions were considered infarcted if the signal intensity was >5 SD above the 
remote myocardium.
7
  Myocardial perfusion reserve (MPR) was calculated in all CTO and 
remote myocardial territories as previously described.
8
  The extension of the perfusion defect 
was also scored visually in each segment as 0 (normal), 1 (defect <25% wall thickness), 2 
(defect 25-50%), 3 (defect 50-75%), 4 (>75%), and its sum identified the visual perfusion 
score.  
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8.2.4 CTO Revascularization  
In the majority of cases (>70%) patients were treated using a bilateral anterograde approach 
(right and left femoral artery puncture). This approach was attempted using microcatheters or 
OTW balloon for support and wire exchange, wires used included the Miracle, Confianza and 
Fielder XT (Asihi Intecc, Japan). Retrograde coronary approach was mainly attempted in 25% 
of the patients after 1 or more unsuccessful anterograde attempts. 
 
8.2.5. Seattle Angina Questionnaire 
The Seattle Angina Questionnaire (SAQ) is a widely used questionnaire to assess health 
outcome measures in patients with CAD.
9,10
 In our study, we used the UK version of the 
SAQ
11
 which consists of 14 items that measure three different aspects of quality of life: a 
seven-item scale of physical limitations (how daily activities are limited by angina), a four-
item angina frequency and perception scale (frequency of symptoms and use of medications, 
and effect of angina on quality of life), a three-item treatment satisfaction scale. All items use 
five-point descriptive scales and scores are calculated by summing all the single scores within 
each group and transforming them to a 0-100 scale, where 0 is the worst and 100 is the best. 
The questionnaire was given to the patients at the time of their CMR scans (baseline and 
follow-up).  
 
8.2.6. Statistical Analysis 
Continuous normal data are expressed as mean ± SD. Wilcoxon paired-sample test or Student 
paired-sample t test respectively were used to compare paired non-parametric and parametric 
data before and after revascularization. Chi-squared test was used to compare categorical 
variables. Differences were considered statistically significant with a 2-sided p-value of ≤ 
0.05. Statistical analyses were performed with SPSS software v12. 
 
 
8.3 RESULTS 
8.3.1 Clinical and Angiographic Data 
Thirty-two patients completed the study (94% men, mean age 65±9 years). Sixteen patients 
were excluded due to: absent myocardial viability in a majority of segments (n=6), absence of 
inducible myocardial ischaemia (n=7), and failed PCI to CTO at the second attempt (n=3) 
(Figure 8.1). Baseline characteristic are shown in Table 8.1. There was a high incidence of 
cardiovascular risk factors, and the majority of patients had previous myocardial infarction 
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(MI, n=21, 66%), previous PCI (n=13, 41%) and multi-vessel disease (n =21, 66%). Some 
patients had previous PCI to a CTO artery (n=3, 9%). There was a 28% incidence of previous 
failed PCI to CTO. Collaterals were present in 70% of the patients. There was a low incidence 
of symptoms: the majority of patients had limited or no angina (CCS class I and II) (n=26, 
81%) and NYHA functional class I and II (n=21, 66%). The angiographic characteristics of 
the CTO are summarized in Table 8.2. The majority of the vessels recanalized were right 
coronary artery (62%) with the remainder being left anterior descending artery (38%). 
 
8.3.2. LV Function 
From baseline to follow-up, there was significant decreased of end-systolic volume (ESV) 
from 65 ±38mL to 56 ±38mL (p<0.001) with no significant change in end-diastolic volume 
(EDV) (166 ±42mL to 161 ±42mL, p=0.18) (Figure 8.2). LVEF increased from 62 ±13% to 
67 ±12% (p<0.0001). Baseline regional wall motion was abnormal in 19 patients (58%) and 
improved after revascularization in 47% of the patients. Visual wall motion score improved 
from 5.9 to 4.5 (p=0.003).  
 
8.3.3. Presence and Extent of Myocardial Ischaemia  
The presence of reversible perfusion defect was identified in all 32 patients, and was limited 
to the subendocardium in 12 (37%) patients, transmural or near transmural in 4 (13%) 
patients, and peri-infarct ischemia in the subepicardial viable rim was detected in 16 (50%) 
patients (Figure 8.3). A complete or near-complete resolution of ischemia after PCI was seen 
in 90% of patients (p<0.0001) (Figure 8.4). Visual perfusion score improved from 10.9 to 1.6 
(p< 0.0001).  
 
8.3.4. Myocardial Perfusion Reserve  
At baseline, MPR in the CTO territory was reduced compared to remote territory (1.8 ±0.7 vs 
2.2 ±0.7; p=0.01; Figure 8.5), and improved significantly after recanalization (to 2.3 ±0.9; 
p=0.02) and was similar to the remote territory (2.5 ±1.2; p=ns). There were no differences of 
MPR in the remote territory before and after PCI.      
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Table 8.1. Baseline demographics, clinical and angiographic characteristics  
 
 
Age, [years] 
 
65 ± 9 
Males 30 (94%) 
Family history of CAD 24 (75%) 
Hypertension 21 (66%) 
Dyslipidemia 23 (72%) 
Diabetes 7 (22%) 
Smokers 22 (69%) 
Previous MI 21 (66%) 
Previous PCI to CTO 3 (9%) 
Previous PCI, other vessel 13 (41%) 
Previous CABG 6 (19%) 
Multivessel disease 21 (66%) 
CCS class at presentation  
           I 11 (34%) 
          II 15 (47%) 
          III 5 (16%) 
          IV 1 (3%) 
NYHA class at presentation  
           I 12 (38%) 
          II 9 (28%) 
          III 10 (31%) 
          IV 1 (3%) 
Medication at presentation*  
          Aspirin 31 (97%) 
          Clopidogrel 24 (75%) 
          Statin 32 (100%) 
          ß-blockers 21 (66%) 
          ACE-inhibitors 20 (62%) 
Data are mean ± SD or number (%) of patients. CAD= coronary artery disease; MI= myocardial infarction, 
CABG= coronary artery bypass surgery, PCI= percutaneous coronary intervention; CTO=chronic total 
occlusion, CCS= Canadian Cardiovascular Society, NYHA= New York Heart Association. 
*Medications post-recanalisation did not change significantly. 
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Table 8.2. Angiographic and revascularization characteristics   
 
CTO vessel  
          RCA 20 (62%) 
          LAD 12 (38%) 
          LCx 0  
           
Presence of collaterals      70% 
Previous failed PCI to CTO 9 (28%) 
Retrograde approach 8 (25%) 
Tapered stump 27 (66%) 
Total stent length [mm] 64 ± 34 
Maximum balloon size [mm] 3.2 ± 1.1 
Maximal balloon pressure [atm] 17 ± 6 
Number of wires 3 ± 1.3 
Final TIMI 3 flow 34 (83%) 
Fluoroscopy time [min] 55 ± 25 
Contrast volume [mL] 382 ±115 
Data are mean ± SD or number (%) of patients. CTO= chronic total occlusion; RCA= right coronary artery; 
LAD=left anterior descending coronary artery; LCx= left circumflex coronary artery; PCI= percutaneous 
coronary intervention.  
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Figure 8.2. Left ventricular volumes and ejection fraction assessed by cine CMR before and 3 
months after CTO recanalization. 
 
 
 
 
 
 
Figure 8.3. Stress perfusion and LGE in a patient with CTO of the RCA. Adenosine stress 
perfusion images (top panel) show the presence of subendocardial inducible defect in the 
basal and mid-cavity inferior wall (white arrows), not present at rest (middle panel). Late 
gadolinium enhancement (LGE) images demonstrate a viable inferior wall with absent 
myocardial enhancement (=no infarction) (bottom panel). 
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Figure 8.4. Stress perfusion and LGE in patient with CTO of the LAD. The LAD is proximally 
occluded (top panel, white arrowhead) and adenosine stress perfusion demonstrated 
inducible perfusion defect in the mid-cavity and apical septum (top panel, white arrow). After 
recanalization, adenosine stress perfusion showed complete resolution of the inducible 
perfusion defect previously observed (bottom panel). 
 
 
 
 
 
Figure 8.5. Myocardial perfusion reserve (MPR) before and  
after revascularization in the CTO and remote coronary artery territories. 
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8.3.5. Presence and Extent of Myocardial Infarction 
In the 32 patients, 12 (38%) had no myocardial infarction (MI), 15 (47%) had subendocardial  
infarct (<50% transmurality), and in 5 (16%) patients, MI was 50-75% transmural but with 
peri-infarct ischemia. Mean MI size was 11.5 ±9.3g. At follow-up, new but limited post-
procedural MI was identified in 8/32 patients (25%). In particular, we observed septal 
perforation in 3 patients (38%) (size of new myocardial damage: 0.65g), distal embolization 
in 2 patients (25%) (0.42 g), and side-branch impairment in 3 patients (38%; 10.6 g).  
 
8.3.6. Quality of Life Questionnaire 
The total SAQ score significantly improved from 59 to 86 after recanalization (p<0.0001). 
The SAQ individual subgroup components also improved: physical limitation (Phys Lim) 
from 63 to 83 (p<0.0001), treatment satisfaction (Treat Sat) from 74 to 95 (p<0.001), and 
frequency and perception (Freq Perc) from 42 to 78 (p<0.0001) (Figure 8.6). 
 
 
Figure 8.6. Seattle Angina Questionnaire before and after revascularization. The first column 
represents the total score. The other three columns represent individual subgroup components 
of physical limitation (Phys Lim), treatment satisfaction (Treat Sat) and frequency and 
perception (Freq Perc). 
8.4 DISCUSSION 
The main findings of this study are that: 1) CMR can select patients suitable for PCI of CTO 
by demonstrating myocardial viability and the presence of inducible myocardial ischemia; 2) 
recanalization of CTO guided by CMR reduces ischemic burden and improves left ventricular 
function; 3) successful revascularization is associated with health outcome measures. To our 
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knowledge, this is the first study prospectively assessing the role of CMR in guiding the 
selection of patients with CTO for revascularization. 
 
8.4.1. CTO Recanalization and Improvement of LV Function  
Changes in left ventricular volumes, function and wall motion after successful recanalization 
of CTO have been demonstrated in small series with mixed results. Sirnes described 
improvement in EF and regional radial shortening from baseline to 6 months assessed by left 
ventricular angiography.
12
 EF improvement using left ventricular angiography was also 
reported by the Total Occlusion Study of Canada (TOSCA) investigators; this was, however, 
confined to patients with recent occlusions (<6 weeks), compared to those with longer 
duration of occlusion (>6 weeks).
13
 More recently, a significant decrease in ESV and EDV, 
without significant change in EF, was reported using cine CMR after revascularization in 
CTO patients.
14,15 
Fiocchi
 
used low-dose dobutamine CMR to predict functional recovery, and 
found improved EF and systolic wall thickening at 6 months after recanalization.
16
 Pavlovic 
demonstrated a significant reduction in EDV using gated SPECT, but no improvement in ESV 
or EF.
17
 The discrepancy in LV functional recovery after recanalization reported in these 
studies could relate to small sample size (usually 20 patients) and the different imaging 
techniques applied. We studied a larger cohort of patients with >3 months chronic total 
occlusion using CMR as a gold standard imaging technique and showed a significant 
improvement of EF with improved regional wall motion and reduction of ESV, but no 
changes in EDV.  
 
8.4.2. CTO and Myocardial Viability  
CMR can identify the presence and extent of viable but dysfunctional myocardium, and 
predict its recovery following successful revascularization.
18
 In our study, we demonstrated 
that the majority of patients with CTO in our cohort have limited or no MI, and therefore have 
the potential to improve ventricular function after successful recanalization. In selected 
patients with CTO of the LAD, Bellenger demonstrated with dobutamine CMR that the extent 
of viable myocardium in the infarct zone is related to improvements in left ventricular 
remodelling in patients undergoing late recanalization of an occluded infarct related artery.
19
 
In particular, they observed a significant relation between the number of viable myocardial 
segments in the infarct zone and the improvement in ESV and EF. Additional small studies 
have also reported that myocardial segmental wall thickening improved significantly in 
segments with no or subendocardial infarction, whereas no improvement was observed in 
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segments with almost full thickness myocardial scar.
14,15
 In our study, patients were only 
considered candidates for CTO recanalization if myocardial viability was present in a 
majority of CTO territory segments and inducible myocardial ischemia was present. The 
majority of patients (84%) in our cohort had no or limited myocardial infarction; larger 
myocardial infarction but with peri-infarct ischemia was demonstrated only in 16% of 
patients. Another factor possibly affecting viability and patient choice for CTO is the presence 
of collaterals, which were present in 70% of patients. Although controversial, the 
development of collaterals does not depend on the presence of viable myocardium.
20
 Whilst 
myocardial ischemia triggers the development of collaterals, they may not be completely 
protective against myocardial ischemia,
21
 and this was borne out in our cohort in which 
myocardial ischemia was detected despite the presence of functioning collaterals. Also, infarct 
size was predominantly limited in keeping with the evidence that in patients with acute MI, 
infarct size can be smaller up to 35% in the presence of collaterals.
22
   
 
8.4.3. CTO Recanalization and Resolution of Ischaemia 
Pavlovic demonstrated improved perfusion in the CTO territory 1 year after successful 
recanalization by 99mTc SPECT.
17
 CMR is an alternative radiation-free imaging modality 
with increased spatial resolution for monitoring the ischemic burden. In a small cohort of 17 
patients, Cheng demonstrated that PCI of CTO improved regional hyperemic myocardial 
blood flow that persisted at 6 months.
23
 Our study confirms these findings in a larger scale. 
Complete or almost complete resolution of perfusion defect (qualitative assessment) was 
coupled with an increased MPR (quantitative assessment). We also demonstrated that after 
successful recanalization, normal perfusion was restored in the treated segments to a similar 
extent as in the remote myocardium. 
 
8.4.4. CTO Recanalization and Quality of Life  
The measurement of health status is important for assessing the outcomes of patients with 
CAD. The effect of PCI on quality of life in patients with stable coronary artery disease has 
been investigated by the COURAGE trial, demonstrating a marked improvement in health 
status in patients treated with PCI versus those treated with optimal medical therapy.
24
 This, 
however, disappeared at 36 months. Quality of life was also assessed by OAT trial 
investigators that found that PCI was associated with a marginal advantage in cardiac physical 
function at 4 months, but not thereafter, and no difference in the psychological well-being 
aspect of quality of life.
25
 Our study is the first to selectively assess quality of life with the 
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Seattle questionnaire after PCI in a population with CTO. In our study, all patients underwent 
PCI guided by the presence of myocardial viability and ischemic burden by CMR, while in 
OAT and COURAGE imaging was carried out only in a subgroup of patients. These two 
aspects have not been combined in previous studies. Interestingly, the ischemic burden was 
reduced and quality of life improved also in those patients with limited symptoms (mainly in 
CCS I-II).  
 
8.4.5. Clinical Implications 
There are many economic disincentives to CTO recanalization.
26
 These procedures are 
technically challenging and require a long learning curve, longer procedural times, greater 
contrast volume use and radiation exposure, as well as more material utilization. Our study 
suggests that CMR might play a role in improving patient selection for revascularization, 
helping in directing resources to those patients most likely to benefit from the procedure with 
reduced ischemic burden, improved LV function and quality of life.   
 
8.4.6. Study Limitations 
No consensus exists with regards to the definition of CTO and in some patients the age of the 
CTO cannot be determined with confidence. This is a single centre study and the rate of 
success in CTO recanalization with anterograde and retrograde approach reflects the 
experience of a single operator. The findings of this study are hypothesis generating and 
should be confirmed in larger randomised trials using CMR to guide intervention.  
 
8.4.7. Conclusion 
CMR identifies myocardial viability and inducible myocardial ischemia in a majority of 
patients with CTO. Revascularization of these patients reduces ischemic burden, improves LV 
EF and improves health outcomes.  
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CHAPTER 9 
NOVEL PROTOCOL FOR PERFUSION IMAGING  
 
 
9.1 INTRODUCTION 
Non-invasive evaluation of myocardial perfusion with cardiovascular magnetic resonance 
(CMR) is clinically useful in patients with known or suspected coronary artery disease 
(CAD)
1,2,3,4
 and is also valuable for clinical research.
5
 Despite many comparison 
studies
6,7,8,9,10,11,12
, the perfusion protocol (pulse sequence, contrast agent dose and injection 
parameters) giving highest diagnostic confidence is not yet standardised.
13
  
Unfortunately, dark rim artefacts which mimic genuine perfusion defects remain a diagnostic 
problem. The three identified different likely sources of dark rim artefacts
4,14  
are
 
: Gibbs 
artefact
15
, cardiac motion
16
 and magnetic susceptibility effects from the transient high 
concentration of the contrast agent.   
 
Fast single-shot gradient echo (FLASH) is the most established and robust sequence but its 
coarse temporal resolution (~180ms per image without parallel RF acceleration) limits the 
acquisition of numerous imaging planes, especially during stress. The intrinsic advantage of 
hybrid echo-planar imaging (EPI) over FLASH is that it collects multiple data lines after each 
radiofrequency pulse and the smaller number of RF pulses may in some circumstances confer 
an increased contrast-noise ratio (CNR).
10
  In addition, the shorter imaging time (~75ms per 
image) makes EPI less prone to artefacts caused by cardiac motion than slower sequences. 
However, a fast multiple echo readout of EPI is required for its reliability with respect to off-
resonance errors, and this reduces its image signal-to-noise ratio (SNR) compared to balanced 
steady state free precession (SSFP) or even FLASH imaging. All first-pass CMR perfusion 
techniques suffer from suboptimal SNR, which particularly affects EPI, usually mandating the 
use of a higher dose of contrast agent. More recently, SSFP sequences have been used, but 
experience is limited.
7,9,11
 Compared with FLASH, SSFP has superior performance, providing 
higher SNR and CNR,
17
 but the longer imaging time than EPI (~125ms per image) but not 
FLASH, increases motion related dark rim artefacts. In principle, the intrinsic high SNR of 
SSFP allows the use of lower dose contrast agent however, which could reduce dark rim 
artefacts.  
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The aim of our study was therefore to compare first pass myocardial perfusion imaging using 
a hybrid-EPI sequence at full contrast dose versus SSFP at half contrast dose. 
 
9.2 METHODS 
9.2.1 Study Design and Population  
We studied 17 patients (14 men, mean age 54 ± 9 years, table 1) with known or suspected 
CAD scheduled for x-ray coronary angiography, with all patients undergoing both first-pass 
perfusion protocols. Perfusion imaging with EPI was the standard clinical investigation; 
patients were then invited to participate in the SSFP trial within a week of the initial scan. 
Patients with contraindication to CMR or adenosine were excluded. Subjects abstained from 
caffeine containing products for 24 hours prior to each study.  
All patients participating in the study had a glomerular filtration rate (GFR)> 30 
mL/min/1.73m
2
. The study was approved by the local ethics committee and each participant 
gave written informed consent.  
Patient characteristics are described in Table 9.1.  
 
 
Table 9.1 Patient characteristics. 
 
  
  
  
Age, years 56 ± 10  
Males 14 (82) 
Diabetes 3 (18) 
Hypertension 10 (59) 
Dyslipidemia 9 (53) 
Smokers 0  
Myocardial infarction 8 (47) 
Previous PCI 6 (35) 
Previous CABG 2 (17) 
 
Values are mean ± SD (%). PCI= percutaneous coronary intervention; CABG= coronary bypass graft 
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9.2.2 CMR Image Acquisition 
Patients underwent CMR in a 1.5T scanner (Avanto, Siemens) with a cardiac dedicated 12-
channel phased array receiver surface coil (6 anterior and 6 posterior coil elements). Stress 
perfusion images were acquired for 50 cycles, covering the left ventricular first-pass, after 4 
minutes of 140µg/kg of intravenous adenosine infusion. Patients held their breath as long as 
comfortable at end-expiration. Resting perfusion images were acquired >20 minutes after 
stress using identical acquisition parameters. Heart rate was monitored continuously and 
blood pressure measured preceding and 3 minutes following initiation of adenosine infusion. 
Eleven patients received Gadopentate dimeglumine (0.5mol/L, Bayer Shering) at the dose of 
0.1mmol/kg for the EPI sequence and 0.05mmol/kg for SSFP sequence. Contrast was, 
injected in the contralateral antecubital fossa to the adenosine infusion at 7mL/s with 15mL 
saline flush at 7mL/s. The last six patients enrolled in the study received 0.1mmol/Kg of 
Gadobutrol (1mol/L, Bayer Schering) for EPI and 0.05mmol/kg for SSFP, injected at 3.5mL/s 
followed by a 15mL saline flush at 7mL/s. The change of contrast agent during the study 
coincided with changes in our departmental policy because of concerns related to the 
association of nephrogenic systemic sclerosis and use of gadolinium chelates. All patients 
received the same contrast dose for the EPI and SSFP studies.  
 
Centre-out hybrid EPI (TR 5.8ms, 30º, echo train length, ETL 4, 1860Hz/pixel) acquired 2.8 x 
2.8 x 8mm voxels over typically 360x270mm FOV (adapted per patient) at TI=110-160ms for 
each of 3 fat-suppressed slices per cycle, using TSENSE (R2), typical image time 75ms 
(excluding prepulses). Linear-ordered SSFP (TR 2.6ms, 70º, 930Hz/pixel) acquired the same 
voxel size at the same TI for central k-space for each of 3 fat-suppressed slices per cycle, 
using TSENSE (R2), typical image time 125ms (Table 9.2). The slice acquisition order was 
the same in EPI and SSFP, resulting in approximately similar image timings through the 
cardiac cycle in both. To ensure consistent imaging, perfusion short-axis slice positions were 
reproduced by viewing the first study while piloting the second and using identical slice 
separation. 
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Table 9.2 Pulse sequence parameters. 
 
 Pulse Sequence 
 EPI SSFP 
Contrast dose 0.1 mmol/kg 0.05 mmol/kg 
TR (ms) 5.8 2.6 
TE (ms) 1.2 1.3 
Flip angle 30° 70° 
Read FOV (cm) 36x27 36x27 
TI (ms) 110-160 110-160 
Image data acquisition time (ms) 75 125 
Bandwidth (Hz/pixel) 1860 930 
Parallel acquisition method TSENSE TSENSE 
Effective acceleration factor (R) 2 2 
 
 
 
9.2.3 CMR Image Analysis  
All image analysis was performed offline using dedicated software (CMRtools, 
Cardiovascular Imaging Solutions, UK). Scans were anonymized and randomised; 2 blinded 
experienced observers scored them based on the AHA/ACC 16-segment model.
18
 The 
diagnostic confidence of perfusion scans was assessed subjectively (score from 0=unusable to 
4=excellent). Stress perfusion scans were scored as normal (no perfusion defect), abnormal 
(true perfusion defect) or dark-rim artefact. Dark-rim artefacts were identified based on 
transience, particularly the temporal correlation of a dark rim with blood brightness, or if the 
artefact was also clearly present at rest in segments that showed no late gadolinium 
enhancement. Other artefacts such as parallel imaging effects were not scored. A total of 544 
segments were analyzed (272 segments per sequence).  
 
9.2.4 Statistical Analysis 
Scan results were compared to coronary angiography as the gold standard for CAD, and chi-
squared was used to compare the proportion of dark-rim artefacts in the two sequences. 
Comparison of agreement between observers and scan methods was assessed by kappa 
coefficients. 
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9.3 RESULTS 
The three major coronary arteries and their first-order branches >2mm were assessed. 
Significant CAD (>50% stenosis) was detected in 6/17 patients (35%). Eleven patients had 
unobstructed coronary arteries: smooth coronary arteries (n=8) or with minor atheroma (n=3). 
There was no significant difference in the hemodynamic recordings between the two studies 
(Table 9.3). 
 
Table 9.3. Hemodynamic response during the 2 perfusion scans  
   
 EPI SSFP p 
Rest    
     Heart rate, beats/min 69 ± 11 65 ± 9 ns 
     Systolic BP, mmHg 133 ±15 131 ± 17 ns 
     Diastolic BP, mmHg 81 ±12 78± 10 ns 
    
Stress    
     Heart rate, beats/min 96 ±15 92 ± 25 ns 
     Systolic BP, mmHg 132 ± 20 135 ± 19 ns 
     Diastolic BP, mmHg 78 ±11 79 ± 14 ns 
Values are mean ± SD. BP= blood pressure. 
 
9.3.1 Agreement Between Scans 
According to Observer 1, EPI and SSFP agreed on normal perfusion in 151 segments, the 
presence of dark-rim artefacts in 8 segments and stress perfusion defects in 19 segments. 
According to Observer 2, EPI and SSFP agreed on normal perfusion in 117 segments, dark-
rim artefact in 2 segments and stress perfusion defects in 25 segments. The agreement 
between SSFP and EPI scans on the presence of normal perfusion, dark-rim artefact, genuine 
perfusion defects was 68% (k=0.25, 95% CI: 0.18-0.30, p<0.0001) for observer 1 (Table 9.4) 
and 56% (k=0.14, 95% CI: 0.09-0.20, p<0.0001) for observer 2 (Table 9.5). 
 
Table 9.4. Agreement between sequences for observer 1.   
         EPI 
SSFP 0 99 Total 
0 123 13 136 
99 56 26 82 
Total 179 39 218 
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Table 9.5. Agreement between sequences for observer 2.   
         EPI 
SSFP 0 99 Total 
0 93 11 104 
99 85 29 114 
Total 178 40 218 
 
 
9.3.2 Agreement Between Observers  
For EPI scans, Observer 1 and 2 agreed on normal perfusion in 195 segments and stress 
perfusion defects in 31 segments. There were no segments with agreed dark-rim artefact.   
For SSFP scans, observer 1 and 2 agreed on normal perfusion in 94 segments, dark-rim 
artefact in 31 segments and stress perfusion defects in 16 segments. The agreement between 
observer 1 and 2 on the presence of normal perfusion, dark-rim artefact or genuine perfusion 
defects was 86% (k=0.52, 95% CI: 0.45-0.59, p<0.0001) for EPI scans Table 9.6) and 60% 
(k=0.2, 95% CI: 0.14-0.27, p<0.0001) for the SSFP scans Table 9.7). 
 
Table 9.6. Agreement for the EPI sequence.   
            Observer 2 
Observer 1 0 99 Total 
0 163 16 179 
99 15 24 39 
Total 178 40 218 
 
 
Table 9.7. Agreement for the SSFP sequence.   
         Observer 2 
Observer 1 0 99 Total 
0 123 13 136 
99 56 26 82 
Total 179 39 218 
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9.3.3 Artefacts 
125 segments were labelled as artefact on the SSFP scan (62 segments for observer 1 and 63 
segments for observer 2). Twenty-two segments from the EPI scans were labelled as dark-rim 
artefact (17 segments for observer 1 and 5 segments for observer 2). True artefacts (compared 
against no obstructions on CA) occurred more frequently with SSFP (59 segments, 22%) than 
with EPI (14 segments, 5%) (X
2
, p<0.001) (Figure 9.1 and Figure 9.2). 
 
 
 
Figure 9.1 CMR stress perfusion images in a 60 year old female with atypical chest pain. Top 
panel shows EPI with full contrast dose and the lower panel SSFP with half dose. The large 
hypointense area in the apical septum of the SSFP scan was interpreted as genuine perfusion 
defect. However, the angiogram showed unobstructed coronary arteries.   
The corresponding apical EPI image did not show areas of hypointensity, confirming the 
occurrence of dark rim artefact in the SSFP scan.  
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Figure 9.2 Comparison of EPI and SSFP scans in a patient with agreement for the finding of 
true perfusion defect in the RCA territory, confirmed by coronary angiography. 
 
9.3.4 Diagnostic Confidence 
Observer 1 noted a significant lower diagnostic confidence for SSFP vs EPI scans (3.1 vs 3.5, 
respectively, p<0.05) (Figure 9.3). Both observers reported a similar diagnostic confidence 
for EPI scans. Image quality of the SSFP and EPI were similar for both observers. 
 
 
Figure 9.3 Observer scoring of diagnostic confidence displaying mean value and 95% 
confidence interval. EPI had a significantly higher score which represents greater diagnostic 
confidence.   
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9.4 DISCUSSION 
9.4.1 General Observations 
This study showed significant differences in the interpretation and scoring between the EPI 
and SSFP perfusion sequences. Dark rim artefacts occurred more frequently in the SSFP than 
EPI scans, even despite the use of the half-contrast dose. Only fair agreement between EPI 
and SSFP was found in normal segments, as many such segments in the latter sequence 
showed dark rim artefacts. Greater agreement between observers was achieved with EPI 
scans, compared to SSFP. Finally, although the observers were usually able to read-through 
the dark rim artefacts, the confidence ascribed to the EPI scans was significantly higher than 
for SSFP. Overall therefore, these findings favour clinical use of the EPI sequence.  
 
The three sequences available (FLASH, EPI, SSFP) for first-pass contrast agent perfusion 
imaging each has advantages and limitations. SSFP readout has the greatest SNR compared to 
FLASH and especially EPI. Although EPI is a fast sequence reducing cardiac motion artefact 
by its short imaging time, it has the lowest myocardial CNR of all three
12
 and a highly 
deleterious off-resonance “splitting” distortion,19 requiring careful attention to the scanner 
centre-frequency adjustment in the left ventricle. SSFP has greater SNR but previously has 
been reported as more prone to dark subendocardial rim artefacts
20
, the greater 
blood/myocardium contrast and the sensitivity of SSFP to field distortion by the high-dose 
bolus are suspected reasons. Thus one study of direct comparison of EPI, FLASH and SSFP 
first pass perfusion readouts, scored EPI as the best (lower number of artefact and highest 
observer confidence)
12
 despite the SSFP having greater CNR and SNR.
11
  
Dark rim artefacts are considered to have three likely causes: 
4,21
 Gibbs artefact
15
, cardiac 
motion
22
 and magnetic susceptibility of the contrast agent. The transient dark rim artefacts 
visible in the subendocardial layer can mimic a hypoperfused area and are therefore a clinical 
concern, as they can reduce observer diagnostic confidence. However, dark rim artefacts last 
only for a few heart beats, and vary temporally as the contrast bolus passes through the left 
ventricular blood pool, while a real perfusion defect tends to be visible for longer duration.
23
 
The main diagnostic problem is a mild perfusion defect which fills in quickly, as 
differentiation may then be difficult to identify in the presence of artefact. Di Bella 
demonstrated in ex-vivo (motionless hearts) that Gibbs ringing plays a major role in 
producing dark rim artefacts.
15
 It is most prominently located to the blood–myocardium 
interface perpendicular to the direction with the lowest spatial resolution (which is typically 
the phase-encoding direction). The artefacts width decreases with increasing spatial 
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resolution, as has been achieved by k-space and time (k-t) sensitivity encoding (SENSE) at 
both 1.5T and 3T.
24
  Higher concentrations of contrast agent increase the Gibbs ringing in the 
endocardial border, and the same effect is expected from a higher injection rate of the contrast 
agent.
25
 Our group and others have opted for fast (7mL/s) Gd-DTPA contrast injection rate 
that guarantees a compact concentrated contrast bolus, and consequent accurate measurement 
of the arterial input function, which is pivotal for quantitative perfusion measurements.
26,27
 
Although previous comparisons of sequence have kept the dose and injection parameters 
fixed for the sequences being compared, there is a case for allowing these to vary between 
sequences. The SSFP sequence is more likely to suffer from Gibbs ringing because of higher 
signal intensity difference between the blood pool and myocardium.  Also, Gibbs artefact is 
very dependent on the position of subendocardial wall with respect to pixels, and sub-pixel 
shifts have been advocated to explain its variability during perfusion imaging.
28
 This 
particular type of variability is eliminated by ensuring the reconstruction performs image 
interpolation by zero-filling prior to FT.  
 
Susceptibility can also cause dark (and bright) artefacts at high gadolinium concentrations.  
These artefacts are due to dephasing and signal pile-up, and are predictable for simple 
geometries oriented perpendicular to the main magnetic field. Although TE is very short 
(~1ms) for perfusion sequences, which reduces susceptibility effects, it must be remembered 
that SSFP relies on achieving steady-state free-precession over a longer period than TE. 
Susceptibility artefact may occur at the border of the myocardium and contrast-enhanced 
blood of the ventricles. However, susceptibility artefacts appear only at the peak bolus transit 
through the LV (and far more prominently around the RV/septum earlier on) and last only for 
few images in the perfusion series. Increased magnetic field distortion in the subendocardium 
during this time may cause dephasing of individual voxels, which is also dependent on the 
heart orientation in relation to B0.  However, in a typical perfusion sequence the distortion of 
the main magnetic field B0 is too weak to cause dark rim artefacts due simply to intravoxel 
dephasing; however, when added to routine off-resonance error it may conceivably cause dark 
rims in particular regions of the myocardium wall in balanced-SSFP sequences.
29
 Thus SSFP 
dark rim artefacts are likely to be reduced by using a smaller peak concentration of contrast 
agent, trading off the high SNR. 
 
All known reasons for dark-rim artefact tend to strengthen the artefact when the blood signal 
is bright compared to the myocardium. Even with half-dose contrast agent, the ratio between 
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the peak-enhancement of blood/myocardium was approximately 4 in SSFP compared to full-
dose 2.5 in EPI. The longer image acquisition time of SSFP (125ms per image) compared to 
EPI (75ms per image) was another potential factor with regard to cardiac motion which 
cannot be avoided in a multislice protocol. However, using the 
matched TI values, the SNR of half-dose SSFP appeared similar to the full-dose EPI. In 
principle, half-dose SSFP is also more likely to avoid the compression of myocardial response 
curves associated with greater myocardial longitudinal magnetisation recovery
30
  
 
In conclusion, SSFP showed lower diagnostic accuracy compared to EPI because dark-rim 
artefacts occurred more frequently even when the half-contrast dose was used. Although two 
experienced observers were usually able to correctly identify dark-rim artefacts, the use of 
SSFP in clinical practice by less experienced observers may not be ideal because of reduced 
diagnostic confidence. 
 
9.4.2 Study Limitations 
The order of the scans could not be randomly assigned, because all patients underwent the 
clinical EPI scan, followed by recruitment for the SSFP research scan. Therefore, the 
influence of the order of the sequences could not be assessed. When comparing a saturation-
recovery SSFP vs saturation recovery FLASH sequence, Fenchel demonstrated that the 
detection of perfusion defects was influenced by the order of sequences.
9
 The second 
perfusion examination missed more hypoperfused segments. Although the influence of the 
order of sequence was not assessed in the current study, our second perfusion examination 
(always the SSFP scan) tended to overestimate the number of hypoperfused segments, rather 
than missing it. Only a small percentage of patients had significant CAD. This might confirm 
the Bayesian principle dictating that many positive tests results will be false positive (rather 
than true positive) if the test is used extensively in low-risk patient population. The cohort of 
patients included in this study was limited and the findings should be confirmed in larger 
studies and in a larger cohort of patients with obstructive coronary artery disease. 
 
9.4.3 Conclusion 
At the contrast doses used in this study, SSFP perfusion imaging had more frequent dark rim 
artefacts and had lower diagnostic agreement than EPI. Although experienced observers were 
often able to correctly identify dark rim artefacts, clinical practise in less experienced centres 
may be affected by the reduced diagnostic confidence.  
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CHAPTER 10 
CONCLUSIONS 
 
CMR is an attractive non invasive imaging modality in patients with acute and chronic 
myocardial ischaemia. CMR can provide in vivo noninvasive tissue characterisation by 
identifying reversible and irreversible myocardial damage. In this thesis, I have used CMR to 
investigate a number of acute and chronic clinical conditions involving coronary artery 
disease.  
 
I investigated the impact of primary angioplasty delay on the presence and extent of 
myocardial salvage, microvascular obstruction and infarct size using T2- and T1-weighted 
imaging. I found that “time is muscle” and in particular that shorter time to reperfusion was 
associated with smaller infarct size, smaller MVO and increased salvage myocardium.  
 
Microvascular obstruction was then used as endpoint in a prospective randomised trial 
assessing the impact of a thrombectomy device as adjunctive therapy in primary PCI. I found 
that the incidence and extent of microvascular damage was significantly lower in the 
thrombectomy group compared to standard primary PCI. Subsequently, I investigated the role 
of two degrees of microvascular damage assessed by CMR in left ventricular remodelling and 
infarct healing.  
 
When applied to a selected patient cohort with CTO, CMR demonstrated to be helpful in 
identifying patient that could benefit from recanalization and to predict functional 
improvement after revascularisation, as well as improvement on quality of life. The results of 
this study could potentially impact the clinical management of these patients.   
 
Given the lack of standardisation in perfusion CMR, I sought to test a novel perfusion 
protocol. I expected to see improved image quality while reducing the occurrence of artefacts. 
However, this did not occur and the commonly used EPI sequence proved to provide greater 
diagnostic confidence.  
 
The results of this work suggest that CMR could emerge as clinical valuable technique in 
numerous clinical settings, in addition to providing surrogate endpoints for clinical trials.  
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CHAPTER 11 
SUMMARY OF ORIGINAL CONTRIBUTIONS 
 
 
 “Time is muscle”: longer time-to-reperfusion is associated with larger infarct size, 
greater microvascular damage and less myocardial salvage. These results apply to 
patients with STEMI undergoing PPCI.  
 
 The use of thrombectomy in the setting of PPCI reduces microvascular damage in 
patients with STEMI. In this study, microvascular obstruction was assessed by CMR. 
 
 CMR can detect two degrees of microvascular dysfunction: PMO is the most severe 
form, associated with larger infarct size and strongly related to LV remodelling; MVO 
of less clinical relevance because highly prevalent. 
 
 Microvascular dysfunction is a dynamic process with a peculiar time course. 
 
 Infarct shrinkage is a phenomenon occurring early (within the first month after the 
acute event) in the evolving phase of myocardial infarction, mirroring the resolution of 
microvascular dysfunction. 
 
 Echocardiography and CMR are equally valuable in serial LV volumetric evaluation 
but CMR  
 
 CMR with viability and ischeamia testing can identify patients with CTO that could 
benefit from recanalisation, as well as predicting their improvement after 
revascularization.  
 
 Stress perfusion imaging with SSPF sequence and half-dose of contrast is more prone 
to artifacts than the standard EPI sequence and full contrast dose.  
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CHAPTER 12 
FUTURE DIRECTIONS 
 
 
There are several areas of further research that have been identified. These include improving 
methods for quantification (simplified and more robust algorithm, post-processing), strategies 
to overcome artefacts, sequence development and sequence comparison. 
 
12.1 PERFUSION IMAGING 
12.1.1 Quantification 
CMR perfusion offers important advantages over other imaging modalities but its further 
progress depends on the successful dissemination of the perfusion quantification technique 
among the CMR community. Currently, perfusion quantification is not standardised, it is 
laborious and time consuming and therefore not applicable in clinical practice. Simplified 
and more robust algorithms for quantification are warranted if they were to be introduced 
in clinical practice.  
 
12.1.2 Intravascular contrast agents 
Limited data are available regarding the application of intravascular gadolinium-based 
contrast media. Intravascular contrast media yield lower signal intensity in the myocardium 
than extracellular contrast agents because of reduced exchange into the extracellular space 
during the first pass.
1
 Dose effects on peak signal enhancement have been described in 
inversion recovery EPI using intra- and extravascular gadolinium-based contrast agents.
2
 
Jerosch-Herold et al. have demonstrated that perfusion index with an intravascular contrast 
agent (MS-325) is accurately estimated if corrected by the time-to maximum upslope.
3
 
Similarly, other groups have identified advantages of intravascular agents for first-pass 
perfusion imaging.
4
 
However, the value of quantitative perfusion with intravascular contrast agent in humans with 
CAD is currently not known and further research is needed.  
 
12.1.3 Selective Tracers  
As in SPECT, an agent that could directly assess areas of ischaemia which persist after stress 
is highly desirable for CMR, so that first-pass imaging is not needed. Manganese is a 
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paramagnetic ion with pharmacokinetic properties similar to those of 99mTC-sestamibi and 
there are experimental studies with manganese-enhanced CMR.
5
 However, the cardiotoxic 
and cardio depressant effects of manganese
6
 make its clinical application not feasible at this 
time. 
 
12.1.4 High Field (3 Tesla) Scanner 
CMR perfusion at 3T offers potential advantages over 1.5T.  
Higher field strengths have the advantage of higher SNR, but not without a number of 
possible disadvantages: at 3T both B0 and B1 field inhomogeneities are increased, the T1 
relaxation time s are longer, and the T1 shortening effect of the contrast agent is reduced.  
Also, at 3.0T the susceptibility effect is greater and hence banding artefacts will be more 
prevalent. But the higher SNR can be used to improve the spatial or temporal resolution by 
applying a parallel imaging technique.  
Preliminary investigations on CMR perfusion at 3T versus 1.5 T are promising showing the 
predictable benefit of the higher SNR
7
 and improved correlation between microspheres and 
absolute myocardial blood flow by CMR.
8
 In humans, Plein demonstrated a comparable 
image quality to 1.5T when five fold k-t SENSE acceleration was used at 3T.
9
   
Diagnostic performance of CMR perfusion imaging at 3.0T versus 1.5T for detecting 
myocardial ischaemia in patients with CAD needs to be investigated.   
 
12.2 OEDEMA IMAGING  
The clinical application of oedema imaging with T2-weighted imaging is promising and 
attractive both in ischaemic and non ischaemic heart disease. However, the technique suffers 
from a variety of technical limitations, including sensitivity to myocardial motion, variation of 
surface coil intensity, high subendocardial signal from static blood and the subjective nature 
of image interpretation. To overcome some of these limitations Coil intensity correction 
algorithms have been proposed
10,11
 and the initial experience of the T2-prepared single shot 
SSFP sequence in a clinical study appears promising.
12
 More recently, a novel T2 mapping 
SSFP sequence has been advocated as a more accurate technique because overcomes most the 
aforementioned limitations, including binging the advantage of quantification.
13
 
However, direct comparison of T2-prepared SSFP and T2 mapping techniques in the clinical 
setting of patients with acute myocardial infarction need to be investigated.  
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CHAPTER 13 
APPENDIX A  
 
13.1 PERSONAL CONTRIBUTION TO THE RESEARCH  
I was appointed in October 2006 as the research fellow in perfusion CMR imaging under the 
supervision of Professor Dudley J Pennell with funding from CORDA, a charity dedicated to 
the early diagnosis and treatment of heart disease and stroke.  
 
My predecessors Dr Andrew Elkington and Dr Jonathan Lyne had previously worked in the 
technical development, sequence optimization and early clinical validation of CMR perfusion 
techniques both in normal volunteers and in patients with ischaemic heart disease.  
 
My research project had five main elements mainly based on the clinical validation of CMR 
in patients with acute and chronic myocardial ischaemia and the common theme to all studies 
is the role of CMR for the interventional cardiologist. The first study was to validate CMR 
myocardial tissue characterisation (and its parameters of reversible and irreversible 
myocardial damage) in patients with STEMI in relation to time to reperfusion. The second 
study used microvascular damage as an endpoint to assess the impact of a thrombectomy 
device as an adjunctive treatment in primary PCI. The third study investigated two different 
degrees of microvascular damage by CMR and their impact on LV remodelling and infarct 
healing. For all these three projects, I personally conceived the study designs and plan, 
contribute in part to image acquisition, performed image analysis and interpretation. Data was 
collected at the University “La Sapienza” in Rome Italy. I was assisted by Dr Emanuele 
Canali, cardiology SpR for patient recruitment in the coronary care unit and by Dr Marco 
Francone and Dr Iacobo Carbone, consultants from the radiology department, for CMR 
image acquisition and image analysis.  
 
The forth study was to validate the clinical use of CMR perfusion in a cohort of patients with 
chronic coronary occlusion whose management is controversial. I personally conceived the 
study, from its design and plan to image acquisition and data interpretation.  
I am grateful to Professor Carlo di Mario and his team in the cardiology department, Royal 
Brompton Hospital, for patient selection, and to Mr Ricardo Wage, deputy CMR 
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superintendent radiographer, and to Mrs Karen Symmonds, CMR superintendent 
radiographer, for assistance in image acquisition. I was assisted in analysing the perfusion 
images by Dr Joanna Petryka, CMR Fellow, Royal Brompton Hospital.  
 
The fifth study was to validate a new clinical CMR perfusion protocol aiming at improving 
the diagnostic performance of the technique. I personally conceived the study, designed the 
imaging protocol, granted ethical approval, recruited patients, acquired images and 
interpreted the data. I am very grateful to Dr Peter Gatehouse, senior physicist, CMR Unit, 
Royal Brompton Hospital for assistance in protocol design and to Mr Ricardo Wage for 
assistance in image acquisition. Analysis of perfusion images was provided by Dr Peter 
Gatehouse, senior physicist, and by Dr Rory O’Hanlon, CMR Research Fellow, Royal 
Brompton Hospital.  
 
 
For all projects, statistical analysis was performed by me with the assistance of Mr Michael 
Roughton, former Medical Statistician at the Royal Brompton Hospital. All papers and 
chapters were written by me under the supervision of Professor Dudley J Pennell.  
 
 
 
13.2 SUPERVISION 
This thesis was supervised by Dudley J Pennell, Professor of Cardiology at Imperial College 
London, UK, and Director of the Cardiovascular Magnetic Resonance Unit, Royal Brompton 
Hospital, London, United Kingdom. 
Professor Francesco Fedele, Professor of Cardiology at the University of Rome “La 
Sapienza”, acted as a guarantor for the work conducted in Italy.  
 
 
 
13.3 FUNDING 
CORDA- a cardiovascular research charity, provided personal support for this research 
though a fellowship from the van Geest Foundation.  
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13.4.1 PEER REVIEWED ARTICLES 
Bucciarelli-Ducci C, Gatehouse P, O'Hanlon R, Lyne J, Grasso A, Wage R, Firmin D, 
Pennell DJ. First-Pass Myocardial Perfusion Cardiovascular Magnetic Resonance: 
Comparison between Hybrid Echo Planar Imaging and Balanced Steady State Free 
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13.4.2 INVITED REVIEW 
Bucciarelli-Ducci C, Lyne JC, Gatehouse PD, Pennell DJ. Cardiovascular magnetic 
resonance myocardial perfusion: methods and applications in patients with coronary artery 
disease. SA Heart 2007; 4:4-11. 
 
13.4.3 LETTERS 
Bucciarelli-Ducci C, Pennell DJ. Low diagnostic yield of elective coronary angiography.  N 
Eng J Med 2010;363:94.   
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Circulation 2008;118:e89-92. 
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Passariello R. Utility of T2 weighted short-tau inversion recovery (STIR) sequences in 
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LIST OF ABBREVIATIONS 
 
A    
 AAR  Area At Risk 
 ACC  American College of Cardiology 
 ACS  Acute coronary syndrome 
 AHA  American Heart Association 
 AIF  Arterial input function 
 AMI  Acute myocardial infarction 
 ANOVA  Analysis of variance  
 ASNC  American Society of Nuclear Cardiology  
 AUC  Area under the curve 
 AV  Atrio-ventricular 
    
B    
 BARI  Bypass Angioplasty Revascularization Investigation 
 BOPTA  Gadobenate dimeglumine 
    
C    
 CABG  Coronary artery bypass surgery  
 CAD  Coronary artery disease 
 CBF  Coronary blood flow 
 CCS  Canadian Cardiovascular Society  
 CI  Confidence interval 
 CMR  Cardiovascular magnetic resonance 
 CNR  Contrast-to-noise ratio 
 COURAGE  Clinical Outcome Utilizing Revascularization and 
Aggressive Drug Evaluation 
 COPD  Chronic obstructive pulmonary disease 
 CT  Computed tomography 
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 CTO  Chronic total occlusion  
    
D    
 2D  2-Dimensional 
 3D  3-Dimensional 
 DTPA  Diethylenetriaminepentaacetic acid 
    
E    
 ECG  Electrocardiogragram  
 EDV  End-diastolic volume 
 EF  Ejection fraction 
 EM-PCI  Export Medtronic percutaneous coronary intervention 
 EPI  Hybrid echo planar imaging 
 ESV  End-systolic volume 
 ETL  Echo train length 
    
F    
 
18
FDG  
18
Fluorodeoxyglucose 
 FISP  Fast imaging with steady-state precession 
 FLASH  Fast low angle shot 
 FOV or FoV  Field of view 
 FT  Fourier transform 
    
G    
 G  Gauge 
 Gd  Gadolinium 
 Gd-BOPTA  Gadobenate dimeglumine 
 GE  General Electric  
 GFR  Glomerular filtration rate 
 GRE  Gradient echo 
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H    
 HASTE  Half Fourier Single shot Turbo Spin Echo 
 HLA  Horizontal long axis 
    
I    
 ICD  Implantable cardiac defibrillator 
 IRA  Infarct related artery 
 IS  Infarct size 
 IZ-WMSI  Infarct-zone wall motion score index 
    
J    
    
K    
 KeV  Kilo electron volt 
L    
 LAD  Left anterior descending (coronary artery) 
 LCx  Left circumflex (coronary artery)  
 LGE  Late gadolinium enhancement 
 LV  Left ventricular or left ventricle 
 LVEDV  Left ventricular end-diastolic volume 
 LVEF  Left ventricular ejection fraction 
 LVESV  Left ventricular end-systolic volume 
    
M    
 MACE  Major adverse cardiovascular (coronary) events 
 MBG  Myocardial blush grade 
 MBq  Megabecquerel 
 MCE  Myocardial contrast echo 
 MI  Myocardial infarction 
 MIBI  Methoxy-IsoButyl Isonitrile 
 MPR  Myocardial perfusion reserve  
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 MR  Magnetic resonance  
 MRI  Magnetic resonance imaging 
 mSv  Millisievert 
 MVO  Microvascular obstruction 
 MVO2  Myocardial oxygen consumption  
    
N    
 N  Number 
 NHLI  Nation Heart and Lung Institute 
 NICE  National Institute for Health and Clinical Excellence 
 NYHA  New York Heart Association 
 NSF  Nephrogenic systemic fibrosis 
    
    
O    
 OWR  Over the Wire  
    
P    
 P  Pressure 
 PET  Positron emission tomography 
 PMO  Persistent microvascular obstruction 
 PCI  Percutaneous coronary intervention 
 PPCI  Primary percutaneous coronary intervention 
    
Q    
    
R    
 R  Resistance 
 RCA  Right coronary artery 
 RF  Radiofrequency 
 ROI  Region of interest 
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 RV  Right ventricular or ventricle 
    
S    
 SA  Short axis 
 SAQ  Seattle Angina Questionnaire  
 SCMR  Society of Cardiovascular Magnetic Resonance  
 SD  Standard deviation 
 SENSE  Sensitivity encoding 
 SI  Signal Intensity  
 SNR  Signal-to-noise ratio 
 S-PCI  Standard percutaneous coronary intervention 
 SPECT   Single photon emission computed tomography 
 SSFP  Steady state free precession 
 STEMI  ST-segment elevation myocardial infarction 
 STIR  Short T1 inversion recovery 
    
T    
 T  Tesla 
 T1W  T1-weighted 
 T2W  T2-weighted 
 TAPAS  Thrombus Aspiration During Percutaneous Coronary 
Intervention in Acute MI 
 TE  Echo time 
 TI  Inversion time 
 TIMI  Thrombolysis In Myocardial Infarction 
 TMP  TIMI Myocardial Perfusion 
 TOSCA  Total Occlusion Study of Canada 
 TR  Repetition time 
 TSE  Turbo spin echo 
 TTC  Triphenyl-Tetrazolium Chloride 
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U    
 UK  United Kingdom 
 US  United States  
    
    
V    
 VLA  Vertical long axis  
    
W    
    
X    
    
Y    
    
Z    
    
 
 
 
 
